Skyzero9285 personal page - To The Moon

Skyzero9285

Skyzero9285

No personal profile

21Follow

1Followers

1Topic

0Badge

2022-07-12

Lets go travelling

@MaverickWealthBuilder:Dollar Index Hit 20-Year High! How to invest USD with USD?

2022-07-11

Huat ah all the way...

Twitter, DWAC, Alibaba, Uber and More: U.S. Stocks To Watch

2022-07-09

$MP Materials Corp.(MP)$Try while low but dontkeep the share,just hit and run

2022-07-07

Grab grab grab...

@CrystalRose:Grab's Leadership Equates To Its Willingness To Spend

2022-07-06

$Spectrum Pharmaceuticals(SPPI)$Gogo

2022-07-06

Material increase...

@koolgal:Semiconductor stocks performance is the key barometer for the broader market and economy. Chips are used in appliances, data centres, gaming, EVs and even artificial intelligence.Have the semiconductor stocks bottomed yet? In my humble opinion NO.With inflation at all time high, rising interest rates, the war in Ukraine, increasing oil prices, the global economy is slowing down. Hence there is lesser demand for chips.However there are still demand for chips especially in the EV industry. Elon Musk said that his gigafactories in Austin and Berlin are "burning furnaces" due to supply constraints of raw materials especially chips.Data centres are still humming along as their demand for chips continue to grow. I like

2022-07-05

All giant share here

@MaverickWealthBuilder:10 Most Watched U.S. Stocks in H12022 By Tiger Community

2022-07-04

Can try

@jayc:Advanced Micro Devices

2022-07-03

Good

@Capital_Insights:15 Institutions' H22022 Stratiges for Stocks and Bonds

2022-06-30

All in pfizer.....Stock of the year💪🏼👏🏼👏🏼👏🏼👏🏼🚀

Pfizer Files for Full FDA Approval for COVID-19 Antiviral

2022-06-30

Gogo pfizer...

Pfizer Files for Full FDA Approval for COVID-19 Antiviral

2022-06-29

Nice..

Got $1,000? 3 Buffett Stocks to Buy Now and Hold Forever

2022-06-28

Going to shine?

Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug

2022-06-28

Mai siao siao leh...

3 Reasons to Buy Novavax and 1 to Sell

2022-06-28

Research stock..

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More

2022-06-28

Take note on this annoucement ....

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial

2022-06-27

Temporary rebound?

@TechnicalHunter:Market Still in Extremely Fear: 10 Indicators to Check Bottom Reverse

2022-06-26

Great to know

Best Penny Stocks to Buy This Week? 3 to Watch as June Ends

2022-06-24

$Pfizer(PFE)$For long run..predict will reach $100 end of the year.

2022-06-24

$Grab Holdings(GRAB)$Today sure flying...$3.50if I am right

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3574635585550746","uuid":"3574635585550746","gmtCreate":1611541562158,"gmtModify":1653574435736,"name":"Skyzero9285","pinyin":"skyzero9285","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":21,"tweetSize":134,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.07","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.07","exceedPercentage":"60.23%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9078949914,"gmtCreate":1657624820338,"gmtModify":1676536035714,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Lets go travelling","listText":"Lets go travelling","text":"Lets go travelling","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9078949914","repostId":"9078997792","repostType":1,"repost":{"id":9078997792,"gmtCreate":1657611240647,"gmtModify":1676536034205,"author":{"id":"4102740236684050","authorId":"4102740236684050","name":"MaverickWealthBuilder","avatar":"https://community-static.tradeup.com/news/bbf0f514b8e5abb92266789b89f6e1e6","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4102740236684050","authorIdStr":"4102740236684050"},"themes":[],"title":"Dollar Index Hit 20-Year High! How to invest USD with USD?","htmlText":"Compare&nbsp;to&nbsp;short&nbsp;trade,&nbsp;a&nbsp;moderate&nbsp;long&nbsp;trade&nbsp;with&nbsp;ETF&nbsp;is&nbsp;more&nbsp;sustainable.Euro USD rate&nbsp;is&nbsp;about&nbsp;to&nbsp;under parity,&nbsp;which&nbsp;makes US dollar index surge&nbsp;to&nbsp;a 20-year&nbsp;high.What&nbsp;is&nbsp;the US dollar index?The US dollar index refers to the general&nbsp;international&nbsp;value of the US dollar, which is&nbsp;a&nbsp;measure of the value of the US dollar relative to&nbsp;a basket of foreign currencies. The US dollar index was&nbsp;established by the U.S. Federal Reserve in 1973 after the dissolution of the Bretton Woods Agreement. It is now maintained by ICE Data Indices,&nbsp;a&nbsp;subsdiary&nbsp;of&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/ICE\">$Intercontinental Exchange(ICE)$&lt;</a>","listText":"Compare&nbsp;to&nbsp;short&nbsp;trade,&nbsp;a&nbsp;moderate&nbsp;long&nbsp;trade&nbsp;with&nbsp;ETF&nbsp;is&nbsp;more&nbsp;sustainable.Euro USD rate&nbsp;is&nbsp;about&nbsp;to&nbsp;under parity,&nbsp;which&nbsp;makes US dollar index surge&nbsp;to&nbsp;a 20-year&nbsp;high.What&nbsp;is&nbsp;the US dollar index?The US dollar index refers to the general&nbsp;international&nbsp;value of the US dollar, which is&nbsp;a&nbsp;measure of the value of the US dollar relative to&nbsp;a basket of foreign currencies. The US dollar index was&nbsp;established by the U.S. Federal Reserve in 1973 after the dissolution of the Bretton Woods Agreement. It is now maintained by ICE Data Indices,&nbsp;a&nbsp;subsdiary&nbsp;of&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/ICE\">$Intercontinental Exchange(ICE)$&lt;</a>","text":"Compare to short trade, a moderate long trade with ETF is more sustainable.Euro USD rate is about to under parity, which makes US dollar index surge to a 20-year high.What is the US dollar index?The US dollar index refers to the general international value of the US dollar, which is a measure of the value of the US dollar relative to a basket of foreign currencies. The US dollar index was established by the U.S. Federal Reserve in 1973 after the dissolution of the Bretton Woods Agreement. It is now maintained by ICE Data Indices, a subsdiary of $Intercontinental Exchange(ICE)$<","images":[{"img":"https://community-static.tradeup.com/news/320e860482ce9a846ab28de1c78246af","width":"1757","height":"727"},{"img":"https://community-static.tradeup.com/news/20c0e433d59c125956000ae323c2f5eb","width":"369","height":"276"},{"img":"https://community-static.tradeup.com/news/2de41cfa448dff1454abff28396eea5b","width":"840","height":"470"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9078997792","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":7,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":685,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9071219695,"gmtCreate":1657536105118,"gmtModify":1676536021675,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Huat ah all the way...","listText":"Huat ah all the way...","text":"Huat ah all the way...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9071219695","repostId":"1159547646","repostType":4,"repost":{"id":"1159547646","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1657532906,"share":"https://ttm.financial/m/news/1159547646?lang=&edition=fundamental","pubTime":"2022-07-11 17:48","market":"us","language":"en","title":"Twitter, DWAC, Alibaba, Uber and More: U.S. Stocks To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=1159547646","media":"Tiger Newspress","summary":"Twitter (TWTR): Twitter has hired merger law heavyweight Wachtell, Lipton, Rosen & Katz as it races ","content":"<html><head></head><body><p><b>Twitter</b> <b>(TWTR):</b> Twitter has hired merger law heavyweight Wachtell, Lipton, Rosen &amp; Katz as it races to sue Elon Musk for moving to dump his $44 billion takeover of the company, according to people familiar with the matter. Twitter shares dropped 6.6% in premarket trading.</p><p><b>Digital World Acquisition Corp</b>.<b>(DWAC): </b>the special purpose acquisition behind the Truth Social app, surged 23.5% in premarket trading on Monday. The rally in Digital World Acquisition is attributable to the decision by Elon Musk to cancel the deal to buy Twitter. Following the development, Wedbush analyst Daniel Ives slashed the price target for Twitter from $43 to $30. This marked a back-to-back reduction following a cut from $54 to $43 just last week.</p><p><b>Hot Chinese ADRs:</b> Alibaba, JD.com, Pinduoduo, Baidu, Nio, Xpeng Motors and Li Auto fell between 3% and 5% in premarket trading.</p><p><b>Uber(UBER):</b> Uber Technologies Inc. attempted to lobby politicians and flouted laws as part of efforts to expand globally from 2013 to 2017, according to newspaper reports based on leaked documents. Uber shares lost 2.2% in premarket trading.</p><p><b>GlobalFoundries(GFS):</b> Chipmakers STMicroelectronics and GlobalFoundries announced on Monday plans to build a semiconductor factory in France, drawing on funding from the government, the latest move to boost output in the region. GlobalFoundries shares declined 3.2% while STMicroelectronics stock slightly increased by 0.7% in premarket trading.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Twitter, DWAC, Alibaba, Uber and More: U.S. Stocks To Watch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwitter, DWAC, Alibaba, Uber and More: U.S. Stocks To Watch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-07-11 17:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><b>Twitter</b> <b>(TWTR):</b> Twitter has hired merger law heavyweight Wachtell, Lipton, Rosen &amp; Katz as it races to sue Elon Musk for moving to dump his $44 billion takeover of the company, according to people familiar with the matter. Twitter shares dropped 6.6% in premarket trading.</p><p><b>Digital World Acquisition Corp</b>.<b>(DWAC): </b>the special purpose acquisition behind the Truth Social app, surged 23.5% in premarket trading on Monday. The rally in Digital World Acquisition is attributable to the decision by Elon Musk to cancel the deal to buy Twitter. Following the development, Wedbush analyst Daniel Ives slashed the price target for Twitter from $43 to $30. This marked a back-to-back reduction following a cut from $54 to $43 just last week.</p><p><b>Hot Chinese ADRs:</b> Alibaba, JD.com, Pinduoduo, Baidu, Nio, Xpeng Motors and Li Auto fell between 3% and 5% in premarket trading.</p><p><b>Uber(UBER):</b> Uber Technologies Inc. attempted to lobby politicians and flouted laws as part of efforts to expand globally from 2013 to 2017, according to newspaper reports based on leaked documents. Uber shares lost 2.2% in premarket trading.</p><p><b>GlobalFoundries(GFS):</b> Chipmakers STMicroelectronics and GlobalFoundries announced on Monday plans to build a semiconductor factory in France, drawing on funding from the government, the latest move to boost output in the region. GlobalFoundries shares declined 3.2% while STMicroelectronics stock slightly increased by 0.7% in premarket trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UBER":"优步","NIO":"蔚来","GFS":"GLOBALFOUNDRIES Inc.","BABA":"阿里巴巴","TWTR":"Twitter"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1159547646","content_text":"Twitter (TWTR): Twitter has hired merger law heavyweight Wachtell, Lipton, Rosen & Katz as it races to sue Elon Musk for moving to dump his $44 billion takeover of the company, according to people familiar with the matter. Twitter shares dropped 6.6% in premarket trading.Digital World Acquisition Corp.(DWAC): the special purpose acquisition behind the Truth Social app, surged 23.5% in premarket trading on Monday. The rally in Digital World Acquisition is attributable to the decision by Elon Musk to cancel the deal to buy Twitter. Following the development, Wedbush analyst Daniel Ives slashed the price target for Twitter from $43 to $30. This marked a back-to-back reduction following a cut from $54 to $43 just last week.Hot Chinese ADRs: Alibaba, JD.com, Pinduoduo, Baidu, Nio, Xpeng Motors and Li Auto fell between 3% and 5% in premarket trading.Uber(UBER): Uber Technologies Inc. attempted to lobby politicians and flouted laws as part of efforts to expand globally from 2013 to 2017, according to newspaper reports based on leaked documents. Uber shares lost 2.2% in premarket trading.GlobalFoundries(GFS): Chipmakers STMicroelectronics and GlobalFoundries announced on Monday plans to build a semiconductor factory in France, drawing on funding from the government, the latest move to boost output in the region. GlobalFoundries shares declined 3.2% while STMicroelectronics stock slightly increased by 0.7% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":471,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9073516441,"gmtCreate":1657374091983,"gmtModify":1676535998839,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/MP\">$MP Materials Corp.(MP)$</a>Try while low but dontkeep the share,just hit and run","listText":"<a href=\"https://ttm.financial/S/MP\">$MP Materials Corp.(MP)$</a>Try while low but dontkeep the share,just hit and run","text":"$MP Materials Corp.(MP)$Try while low but dontkeep the share,just hit and run","images":[{"img":"https://community-static.tradeup.com/news/0c2cc552bdc4f88420792f3cf33385d7","width":"1242","height":"3588"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9073516441","isVote":1,"tweetType":1,"viewCount":718,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9079617922,"gmtCreate":1657189584966,"gmtModify":1676535966229,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Grab grab grab...","listText":"Grab grab grab...","text":"Grab grab grab...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9079617922","repostId":"9079892589","repostType":1,"repost":{"id":9079892589,"gmtCreate":1657166005116,"gmtModify":1676535963108,"author":{"id":"9000000000000644","authorId":"9000000000000644","name":"CrystalRose","avatar":"https://static.tigerbbs.com/25ded438897391c2e32edc77a343fe21","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"9000000000000644","authorIdStr":"9000000000000644"},"themes":[],"title":"Grab's Leadership Equates To Its Willingness To Spend","htmlText":"We showed Grab is leading the mobility, delivery, and e-wallet segments by its willingness to spend on consumer and partner incentives. Profitability will be in sight should incentive expenditure normalize amid recovering mobility segment. Shortage of drivers/riders is expected to keep Grab's partner incentive expenditure high as overall supply declines, especially during peak hours. Consumer incentive expenditure is showing signs of normalizing and could propel Grab to profitability as revenue growth could outpace consumer incentive expenditure growth. Dollar-cost averaging into Grab can be justified on the basis of net of net cash liquidity as Grab is priced at only 3.4x 2022Q1 annualized revenue compared to UBER's 6x. IntroductionIn our last coverage on Grab","listText":"We showed Grab is leading the mobility, delivery, and e-wallet segments by its willingness to spend on consumer and partner incentives. Profitability will be in sight should incentive expenditure normalize amid recovering mobility segment. Shortage of drivers/riders is expected to keep Grab's partner incentive expenditure high as overall supply declines, especially during peak hours. Consumer incentive expenditure is showing signs of normalizing and could propel Grab to profitability as revenue growth could outpace consumer incentive expenditure growth. Dollar-cost averaging into Grab can be justified on the basis of net of net cash liquidity as Grab is priced at only 3.4x 2022Q1 annualized revenue compared to UBER's 6x. IntroductionIn our last coverage on Grab","text":"We showed Grab is leading the mobility, delivery, and e-wallet segments by its willingness to spend on consumer and partner incentives. Profitability will be in sight should incentive expenditure normalize amid recovering mobility segment. Shortage of drivers/riders is expected to keep Grab's partner incentive expenditure high as overall supply declines, especially during peak hours. Consumer incentive expenditure is showing signs of normalizing and could propel Grab to profitability as revenue growth could outpace consumer incentive expenditure growth. Dollar-cost averaging into Grab can be justified on the basis of net of net cash liquidity as Grab is priced at only 3.4x 2022Q1 annualized revenue compared to UBER's 6x. IntroductionIn our last coverage on Grab","images":[{"img":"https://community-static.tradeup.com/news/5b0f5717bca46305e446cf86eb565dfc","width":"-1","height":"-1"},{"img":"https://community-static.tradeup.com/news/5ae2ee988f44e63a60ce39274a9cf64e","width":"-1","height":"-1"},{"img":"https://community-static.tradeup.com/news/04894edaeef65f22fb67efacb08ff481","width":"-1","height":"-1"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9079892589","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":7,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":629,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9079034507,"gmtCreate":1657119116109,"gmtModify":1676535952834,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SPPI\">$Spectrum Pharmaceuticals(SPPI)$</a>Gogo","listText":"<a href=\"https://ttm.financial/S/SPPI\">$Spectrum Pharmaceuticals(SPPI)$</a>Gogo","text":"$Spectrum Pharmaceuticals(SPPI)$Gogo","images":[{"img":"https://community-static.tradeup.com/news/c6e1a5318cc67ed3c97d3860f97cb01d","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9079034507","isVote":1,"tweetType":1,"viewCount":611,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"content":"SPPI will go over $1.0…estimated $1.30","text":"SPPI will go over $1.0…estimated $1.30","html":"SPPI will go over $1.0…estimated $1.30"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9070619124,"gmtCreate":1657062009168,"gmtModify":1676535939636,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Material increase...","listText":"Material increase...","text":"Material increase...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9070619124","repostId":"9047106945","repostType":1,"repost":{"id":9047106945,"gmtCreate":1656889442788,"gmtModify":1676535908246,"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3559581955535845","authorIdStr":"3559581955535845"},"themes":[],"htmlText":"Semiconductor stocks performance is the key barometer for the broader market and economy.&nbsp; Chips are used in appliances, data centres, gaming, EVs&nbsp;and even artificial intelligence.Have the semiconductor stocks bottomed yet?&nbsp; In my humble opinion NO.With inflation at all time high, rising interest rates, the war in Ukraine, increasing oil prices, the global economy is slowing down.&nbsp; Hence there is lesser demand for chips.However there are still demand for chips especially in the EV industry.&nbsp; Elon Musk said that his gigafactories in Austin and Berlin are \"burning furnaces\" due to supply constraints of raw materials especially chips.Data centres are still humming along as their demand for chips continue to grow.&nbsp;I like&nbsp;<a href=\"https://ttm.financial/S/SMH\"></a>","listText":"Semiconductor stocks performance is the key barometer for the broader market and economy.&nbsp; Chips are used in appliances, data centres, gaming, EVs&nbsp;and even artificial intelligence.Have the semiconductor stocks bottomed yet?&nbsp; In my humble opinion NO.With inflation at all time high, rising interest rates, the war in Ukraine, increasing oil prices, the global economy is slowing down.&nbsp; Hence there is lesser demand for chips.However there are still demand for chips especially in the EV industry.&nbsp; Elon Musk said that his gigafactories in Austin and Berlin are \"burning furnaces\" due to supply constraints of raw materials especially chips.Data centres are still humming along as their demand for chips continue to grow.&nbsp;I like&nbsp;<a href=\"https://ttm.financial/S/SMH\"></a>","text":"Semiconductor stocks performance is the key barometer for the broader market and economy. Chips are used in appliances, data centres, gaming, EVs and even artificial intelligence.Have the semiconductor stocks bottomed yet? In my humble opinion NO.With inflation at all time high, rising interest rates, the war in Ukraine, increasing oil prices, the global economy is slowing down. Hence there is lesser demand for chips.However there are still demand for chips especially in the EV industry. Elon Musk said that his gigafactories in Austin and Berlin are \"burning furnaces\" due to supply constraints of raw materials especially chips.Data centres are still humming along as their demand for chips continue to grow. I like","images":[],"top":1,"highlighted":2,"essential":2,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9047106945","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":600,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9070072561,"gmtCreate":1656988579753,"gmtModify":1676535928340,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"All giant share here","listText":"All giant share here","text":"All giant share here","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9070072561","repostId":"9045454968","repostType":1,"repost":{"id":9045454968,"gmtCreate":1656646554995,"gmtModify":1676535870851,"author":{"id":"4102740236684050","authorId":"4102740236684050","name":"MaverickWealthBuilder","avatar":"https://community-static.tradeup.com/news/bbf0f514b8e5abb92266789b89f6e1e6","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4102740236684050","authorIdStr":"4102740236684050"},"themes":[],"title":"10 Most Watched U.S. Stocks in H12022 By Tiger Community","htmlText":"<a target=\"_blank\" href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a> Price&nbsp;close: 673.42 (June 30) Market cap: $697.9 billion YTD&nbsp;change:&nbsp;-36.3% PE&nbsp;Ratio (TTM): 90.7 2021 is a wonderful&nbsp;year for Elon&nbsp;Musk, successfully&nbsp;being the richest man in the world due&nbsp;to&nbsp;soaring market cap&nbsp;of Tesla, while&nbsp;in&nbsp;2022, his words aroused criticism&nbsp;to&nbsp;some&nbsp;extent,&nbsp;and&nbsp;Tesla&nbsp;also&nbsp;needs improving. Due to the tremendous&nbsp;sales amount&nbsp;of Model 3, Tesla&nbsp;posted a record 310,000 deliveries and an operating margin of 19%&nbsp;in&nbsp;Q1, leading the whole EV&nbsp;market&nbsp;booming. However, due to inflation&nbsp;and&nbsp;supply chain&nbsp;crisis, Tesla has to raise prices several times,&nbsp;At the","listText":"<a target=\"_blank\" href=\"https://laohu8.com/S/TSLA\">$Tesla Motors(TSLA)$</a> Price&nbsp;close: 673.42 (June 30) Market cap: $697.9 billion YTD&nbsp;change:&nbsp;-36.3% PE&nbsp;Ratio (TTM): 90.7 2021 is a wonderful&nbsp;year for Elon&nbsp;Musk, successfully&nbsp;being the richest man in the world due&nbsp;to&nbsp;soaring market cap&nbsp;of Tesla, while&nbsp;in&nbsp;2022, his words aroused criticism&nbsp;to&nbsp;some&nbsp;extent,&nbsp;and&nbsp;Tesla&nbsp;also&nbsp;needs improving. Due to the tremendous&nbsp;sales amount&nbsp;of Model 3, Tesla&nbsp;posted a record 310,000 deliveries and an operating margin of 19%&nbsp;in&nbsp;Q1, leading the whole EV&nbsp;market&nbsp;booming. However, due to inflation&nbsp;and&nbsp;supply chain&nbsp;crisis, Tesla has to raise prices several times,&nbsp;At the","text":"$Tesla Motors(TSLA)$ Price close: 673.42 (June 30) Market cap: $697.9 billion YTD change: -36.3% PE Ratio (TTM): 90.7 2021 is a wonderful year for Elon Musk, successfully being the richest man in the world due to soaring market cap of Tesla, while in 2022, his words aroused criticism to some extent, and Tesla also needs improving. Due to the tremendous sales amount of Model 3, Tesla posted a record 310,000 deliveries and an operating margin of 19% in Q1, leading the whole EV market booming. However, due to inflation and supply chain crisis, Tesla has to raise prices several times, At the","images":[{"img":"https://static.tigerbbs.com/ce820979223d842549667daebe749d24","width":"1200","height":"675"},{"img":"https://community-static.tradeup.com/news/304ce7fbba9b9b3789dedae545c5490e","width":"750","height":"1620"},{"img":"https://static.tigerbbs.com/50bb19d5de7403f46a338566b82e6977","width":"2880","height":"1792"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9045454968","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":11,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":476,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9047312947,"gmtCreate":1656867978489,"gmtModify":1676535906379,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Can try","listText":"Can try","text":"Can try","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9047312947","repostId":"9044433598","repostType":1,"repost":{"id":9044433598,"gmtCreate":1656807613214,"gmtModify":1676535895739,"author":{"id":"4090153192826740","authorId":"4090153192826740","name":"jayc","avatar":"https://static.tigerbbs.com/19c91ee324a75aab3e761bbbe23dc892","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4090153192826740","authorIdStr":"4090153192826740"},"themes":[],"title":"Advanced Micro Devices","htmlText":"<a href=\"https://ttm.financial/S/AMD\">$AMD(AMD)$</a>A $50,000 investment in shares of AMD at the beginning of 2012 was worth more than $1.3 million at the end of 2021. Of course, the stock has pulled back 42% so far in 2022, but investors who bought the company's shares a decade ago are still sitting on fat gains.The good part is that AMD's slide this year has made the stock attractive as far as its valuation is concerned. The stock's price-to-earnings (P/E) ratio of 31 is way lower than its five-year average earnings multiple of 105. The forward P/E of 20 points toward healthy growth in AMD's bottom line over the next year.More importantly, a closer look at the markets that AMD serves tells us that this company could grow at an impressive pace for years to come. Take the data center busin","listText":"<a href=\"https://ttm.financial/S/AMD\">$AMD(AMD)$</a>A $50,000 investment in shares of AMD at the beginning of 2012 was worth more than $1.3 million at the end of 2021. Of course, the stock has pulled back 42% so far in 2022, but investors who bought the company's shares a decade ago are still sitting on fat gains.The good part is that AMD's slide this year has made the stock attractive as far as its valuation is concerned. The stock's price-to-earnings (P/E) ratio of 31 is way lower than its five-year average earnings multiple of 105. The forward P/E of 20 points toward healthy growth in AMD's bottom line over the next year.More importantly, a closer look at the markets that AMD serves tells us that this company could grow at an impressive pace for years to come. Take the data center busin","text":"$AMD(AMD)$A $50,000 investment in shares of AMD at the beginning of 2012 was worth more than $1.3 million at the end of 2021. Of course, the stock has pulled back 42% so far in 2022, but investors who bought the company's shares a decade ago are still sitting on fat gains.The good part is that AMD's slide this year has made the stock attractive as far as its valuation is concerned. The stock's price-to-earnings (P/E) ratio of 31 is way lower than its five-year average earnings multiple of 105. The forward P/E of 20 points toward healthy growth in AMD's bottom line over the next year.More importantly, a closer look at the markets that AMD serves tells us that this company could grow at an impressive pace for years to come. Take the data center busin","images":[{"img":"https://community-static.tradeup.com/news/d9c45c072ebc4c5489da99f697e78782","width":"275","height":"183"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9044433598","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":659,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9044483558,"gmtCreate":1656808813974,"gmtModify":1676535896266,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9044483558","repostId":"9045768427","repostType":1,"repost":{"id":9045768427,"gmtCreate":1656657658892,"gmtModify":1676535872884,"author":{"id":"3527667668165440","authorId":"3527667668165440","name":"Capital_Insights","avatar":"https://static.tigerbbs.com/cfdc66fff48bb2b9e2d328ac5eb33100","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3527667668165440","authorIdStr":"3527667668165440"},"themes":[],"title":"15 Institutions' H22022 Stratiges for Stocks and Bonds","htmlText":"Key&nbsp;Takeaways: 5 Investing Bankings’ 2nd half 2022's Expectations and Trend Forecasts Top Sectors and stocks Opportunities for 2nd half of 2022 from 5 Institutions Bond Opportunities being highlighted by 6 institutions In&nbsp;The first half of 2022,&nbsp;Stocks around the world slumped as economic uncertainty surged with the war in Europe, a lockdown-induced recession in Asia's biggest economy, stubbornly high inflation, and several major central banks pursuing the most aggressive series of policy rate increases in decades.So far in this year, the <a target=\"_blank\" href=\"https://laohu8.com/S/.SPX\">$S&amp;P 500(.SPX)$</a> performed the biggest drop since 1932 (see chart below) .Research from global investment management firm T. Rowe Price: War in Ukraine and sanctions against Russia","listText":"Key&nbsp;Takeaways: 5 Investing Bankings’ 2nd half 2022's Expectations and Trend Forecasts Top Sectors and stocks Opportunities for 2nd half of 2022 from 5 Institutions Bond Opportunities being highlighted by 6 institutions In&nbsp;The first half of 2022,&nbsp;Stocks around the world slumped as economic uncertainty surged with the war in Europe, a lockdown-induced recession in Asia's biggest economy, stubbornly high inflation, and several major central banks pursuing the most aggressive series of policy rate increases in decades.So far in this year, the <a target=\"_blank\" href=\"https://laohu8.com/S/.SPX\">$S&amp;P 500(.SPX)$</a> performed the biggest drop since 1932 (see chart below) .Research from global investment management firm T. Rowe Price: War in Ukraine and sanctions against Russia","text":"Key Takeaways: 5 Investing Bankings’ 2nd half 2022's Expectations and Trend Forecasts Top Sectors and stocks Opportunities for 2nd half of 2022 from 5 Institutions Bond Opportunities being highlighted by 6 institutions In The first half of 2022, Stocks around the world slumped as economic uncertainty surged with the war in Europe, a lockdown-induced recession in Asia's biggest economy, stubbornly high inflation, and several major central banks pursuing the most aggressive series of policy rate increases in decades.So far in this year, the $S&P 500(.SPX)$ performed the biggest drop since 1932 (see chart below) .Research from global investment management firm T. Rowe Price: War in Ukraine and sanctions against Russia","images":[{"img":"https://community-static.tradeup.com/news/6ca36c2e8c0b0cbd3513d645995581ad","width":"1074","height":"660"},{"img":"https://community-static.tradeup.com/news/d4d49a8edf61d141d66869734ec29bc2","width":"1068","height":"349"},{"img":"https://community-static.tradeup.com/news/c471d9aa1479de368a5b6c5b56faf0b5","width":"731","height":"449"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9045768427","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":9,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":844,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9045174255,"gmtCreate":1656588138377,"gmtModify":1676535858645,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"All in pfizer.....Stock of the year💪🏼👏🏼👏🏼👏🏼👏🏼🚀","listText":"All in pfizer.....Stock of the year💪🏼👏🏼👏🏼👏🏼👏🏼🚀","text":"All in pfizer.....Stock of the year💪🏼👏🏼👏🏼👏🏼👏🏼🚀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9045174255","repostId":"2247475886","repostType":2,"repost":{"id":"2247475886","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1656587274,"share":"https://ttm.financial/m/news/2247475886?lang=&edition=fundamental","pubTime":"2022-06-30 19:07","market":"us","language":"en","title":"Pfizer Files for Full FDA Approval for COVID-19 Antiviral","url":"https://stock-news.laohu8.com/highlight/detail?id=2247475886","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 tr","content":"<html><head></head><body><p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.</p><p>PAXLOVID has previously been granted Emergency Use Authorization <a href=\"https://laohu8.com/S/EUA.UK\">$(EUA.UK)$</a> for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.</p><p>&#34;Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,&#34; said Pfizer Chief Executive Albert Bourla.</p><p>The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&amp;P 500  has climbed 19.9%.</p><p><img src=\"https://static.tigerbbs.com/5f5463ed1aa0fa37ef029aec1dd2eea6\" tg-width=\"842\" tg-height=\"830\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Files for Full FDA Approval for COVID-19 Antiviral</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Files for Full FDA Approval for COVID-19 Antiviral\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-06-30 19:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.</p><p>PAXLOVID has previously been granted Emergency Use Authorization <a href=\"https://laohu8.com/S/EUA.UK\">$(EUA.UK)$</a> for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.</p><p>&#34;Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,&#34; said Pfizer Chief Executive Albert Bourla.</p><p>The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&amp;P 500  has climbed 19.9%.</p><p><img src=\"https://static.tigerbbs.com/5f5463ed1aa0fa37ef029aec1dd2eea6\" tg-width=\"842\" tg-height=\"830\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4570":"地缘局势概念股","BK4017":"黄金","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4550":"红杉资本持仓","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4581":"高盛持仓","BK4007":"制药","PFE":"辉瑞","BNTX":"BioNTech SE","NGD":"New Gold"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2247475886","content_text":"Pfizer Inc. $(PFE)$ said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.PAXLOVID has previously been granted Emergency Use Authorization $(EUA.UK)$ for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.\"Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,\" said Pfizer Chief Executive Albert Bourla.The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&P 500  has climbed 19.9%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":560,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9045174898,"gmtCreate":1656588093914,"gmtModify":1676535858644,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Gogo pfizer...","listText":"Gogo pfizer...","text":"Gogo pfizer...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9045174898","repostId":"2247475886","repostType":2,"repost":{"id":"2247475886","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1656587274,"share":"https://ttm.financial/m/news/2247475886?lang=&edition=fundamental","pubTime":"2022-06-30 19:07","market":"us","language":"en","title":"Pfizer Files for Full FDA Approval for COVID-19 Antiviral","url":"https://stock-news.laohu8.com/highlight/detail?id=2247475886","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 tr","content":"<html><head></head><body><p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.</p><p>PAXLOVID has previously been granted Emergency Use Authorization <a href=\"https://laohu8.com/S/EUA.UK\">$(EUA.UK)$</a> for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.</p><p>&#34;Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,&#34; said Pfizer Chief Executive Albert Bourla.</p><p>The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&amp;P 500  has climbed 19.9%.</p><p><img src=\"https://static.tigerbbs.com/5f5463ed1aa0fa37ef029aec1dd2eea6\" tg-width=\"842\" tg-height=\"830\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Files for Full FDA Approval for COVID-19 Antiviral</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Files for Full FDA Approval for COVID-19 Antiviral\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-06-30 19:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.</p><p>PAXLOVID has previously been granted Emergency Use Authorization <a href=\"https://laohu8.com/S/EUA.UK\">$(EUA.UK)$</a> for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.</p><p>&#34;Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,&#34; said Pfizer Chief Executive Albert Bourla.</p><p>The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&amp;P 500  has climbed 19.9%.</p><p><img src=\"https://static.tigerbbs.com/5f5463ed1aa0fa37ef029aec1dd2eea6\" tg-width=\"842\" tg-height=\"830\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4570":"地缘局势概念股","BK4017":"黄金","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4550":"红杉资本持仓","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4581":"高盛持仓","BK4007":"制药","PFE":"辉瑞","BNTX":"BioNTech SE","NGD":"New Gold"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2247475886","content_text":"Pfizer Inc. $(PFE)$ said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.PAXLOVID has previously been granted Emergency Use Authorization $(EUA.UK)$ for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.\"Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,\" said Pfizer Chief Executive Albert Bourla.The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&P 500  has climbed 19.9%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9042219602,"gmtCreate":1656478391306,"gmtModify":1676535837805,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Nice..","listText":"Nice..","text":"Nice..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9042219602","repostId":"2246370707","repostType":4,"repost":{"id":"2246370707","kind":"highlight","pubTimestamp":1656474287,"share":"https://ttm.financial/m/news/2246370707?lang=&edition=fundamental","pubTime":"2022-06-29 11:44","market":"us","language":"en","title":"Got $1,000? 3 Buffett Stocks to Buy Now and Hold Forever","url":"https://stock-news.laohu8.com/highlight/detail?id=2246370707","media":"Motley Fool","summary":"These Buffett stocks look primed for a bull run, so buy them while you still can.","content":"<html><head></head><body><p>Investors from all walks of life idolize Warren Buffett for his stock-picking prowess. Buffett started investing in stocks when he was only 11, but he didn&#39;t become a billionaire until age 56, and there&#39;s been no looking back since. Buffett&#39;s net worth right now is around $97 billion.</p><p>Buffett has shown how investing in stocks for the long term can generate life-changing wealth. His company, <b>Berkshire Hathaway,</b> owns more than 50 stocks, most of which were first purchased several years ago. You too can build wealth if you start early, and buy and hold high-conviction stocks. Here are three such rock-solid Buffett stocks you can buy for as little as $1,000 and hold forever.</p><h2>This transformation should pay off</h2><p>First up is <b>Johnson &amp; Johnson</b>. Buffett hasn&#39;t traded or spoken much about J&amp;J over the years, but the fact that he first bought the healthcare stock almost 16 years ago and continues to own it bespeaks his conviction in the healthcare giant.</p><p>The easiest argument in favor of J&amp;J stock amid market volatility is its clout in healthcare, which also makes it an attractive defensive stock. To put that into context, J&amp;J has handily outperformed the market this year, and for all we know, this could just be the beginning as J&amp;J transforms itself.</p><p>J&amp;J plans to spin off its consumer health business into a separate publicly traded company within the next 18 to 24 months. That will leave it with two high-potential, fast-growing segments -- pharmaceuticals and medical devices.</p><p>In 2021, 52% of J&amp;J&#39;s sales came from pharmaceuticals that include well-known drugs for complex diseases, while medical devices brought in 27% of its sales. The remaining sales came from consumer health which, despite including iconic brands like Neutrogena, Tylenol, and Listerine, is a cyclical business and has been a laggard on J&amp;J&#39;s margins.</p><p>While J&amp;J works toward its transformation, you can sit back and enjoy a 2.5% yield backed by steady and growing dividends. Buffett loves dividends, and J&amp;J is a Dividend King that has hiked dividends every year for 60 consecutive years.</p><h2>Buffett saw promise in this stock when no one else did</h2><p>The second Buffet stock to buy -- and I&#39;ve been pounding the table on this one for several months now -- is <b>BYD</b>. The <b>S&amp;P 500</b> has shed almost 18% value so far this year, but BYD stock is up 19% so far. There&#39;s a reason why BYD is outperforming the market.</p><p>BYD has only recently caught Wall Street&#39;s attention, but Buffett spotted potential in the Chinese electric vehicle (EV) manufacturer as early as 2008. Today, China is the world&#39;s largest EV market, and BYD is a leader in the industry.</p><p>In fact, BYD sees so much potential in plug-in hybrids and all-electric vehicles that it stopped production of traditional internal combustion engine vehicles in March. BYD&#39;s sales more than doubled in May, and it now reportedly has a backlog of nearly 600,000 units, according to local Chinese media outlets. Between January and May alone, BYD sold more than 500,000 vehicles, close to the number it sold in 2021.</p><p><img src=\"https://static.tigerbbs.com/b6a011c773ed7dc5d29960e570bca71c\" tg-width=\"700\" tg-height=\"520\" referrerpolicy=\"no-referrer\"/></p><p>Aside from passenger cars, BYD also makes commercial vehicles, and even builds and sells them in the U.S. BYD is also one of the leading battery makers in China and has reportedly even struck a battery-supply deal with EV giant <b>Tesla</b>. Lithium is one of the hottest metals right now, so much so that BYD plans to buy several lithium mines in Africa to secure a long-term supply.</p><p>BYD is doing everything right in an industry with exponential growth potential, making it a no-brainer Buffett stock to own.</p><p>Also Read: <a href=\"https://ttm.financial/NW/1116401864\" target=\"_blank\">BYD’s 66% Gain Catapults Stock to Near Trillion Yuan Market Cap</a></p><h2>A no-brainer Buffett cash cow stock to buy</h2><p><b><a href=\"https://laohu8.com/S/V\">Visa</a></b> is the third and one of the smartest Buffett stocks you could buy right now and own for as long as you possibly can.</p><p>Many expected Visa&#39;s growth to pause as consumers fall back on cash after relying on online purchases and digital payments over the past couple of years when the COVID-19 pandemic raged. However, digital payments continue to displace cash. Visa processed 7.9 billion more payments transactions across debit and credit cards but 16 million fewer cash transactions (including cash access, balance access, and balance transfer transactions) in its second quarter ended March 31.</p><p>Remember, the war on cash isn&#39;t a fad but a secular trend that Visa, the industry leader, is perfectly poised to ride. And here&#39;s something else that works in its favor: Visa is not a lender but only processes payments made using its co-branded cards in return for a fee.</p><p>Such a business model is not only asset-light but free from credit risks that most financial stocks typically face. <i>And</i> it&#39;s huge: Visa processed payments and cash transactions worth $13 trillion in 2021 and had nearly 3.7 billion cards issued worldwide. It&#39;s no surprise, then, that owning shares of a cash cow with solid margins in a growing industry has turned out to be so lucrative for long-term investors. It should continue to be lucrative for those who buy this Buffett stock that&#39;s still down about 14% in the past one year and trading at a price/earnings-to-growth (PEG) ratio of 1.39 times, considerably below its five-year average PEG.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Got $1,000? 3 Buffett Stocks to Buy Now and Hold Forever</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGot $1,000? 3 Buffett Stocks to Buy Now and Hold Forever\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-29 11:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/28/got-1000-3-buffett-stocks-to-buy-now-and-hold-fore/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors from all walks of life idolize Warren Buffett for his stock-picking prowess. Buffett started investing in stocks when he was only 11, but he didn't become a billionaire until age 56, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/28/got-1000-3-buffett-stocks-to-buy-now-and-hold-fore/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"V":"Visa","002594":"比亚迪","BYDDY":"比亚迪ADR","01211":"比亚迪股份","JNJ":"强生"},"source_url":"https://www.fool.com/investing/2022/06/28/got-1000-3-buffett-stocks-to-buy-now-and-hold-fore/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2246370707","content_text":"Investors from all walks of life idolize Warren Buffett for his stock-picking prowess. Buffett started investing in stocks when he was only 11, but he didn't become a billionaire until age 56, and there's been no looking back since. Buffett's net worth right now is around $97 billion.Buffett has shown how investing in stocks for the long term can generate life-changing wealth. His company, Berkshire Hathaway, owns more than 50 stocks, most of which were first purchased several years ago. You too can build wealth if you start early, and buy and hold high-conviction stocks. Here are three such rock-solid Buffett stocks you can buy for as little as $1,000 and hold forever.This transformation should pay offFirst up is Johnson & Johnson. Buffett hasn't traded or spoken much about J&J over the years, but the fact that he first bought the healthcare stock almost 16 years ago and continues to own it bespeaks his conviction in the healthcare giant.The easiest argument in favor of J&J stock amid market volatility is its clout in healthcare, which also makes it an attractive defensive stock. To put that into context, J&J has handily outperformed the market this year, and for all we know, this could just be the beginning as J&J transforms itself.J&J plans to spin off its consumer health business into a separate publicly traded company within the next 18 to 24 months. That will leave it with two high-potential, fast-growing segments -- pharmaceuticals and medical devices.In 2021, 52% of J&J's sales came from pharmaceuticals that include well-known drugs for complex diseases, while medical devices brought in 27% of its sales. The remaining sales came from consumer health which, despite including iconic brands like Neutrogena, Tylenol, and Listerine, is a cyclical business and has been a laggard on J&J's margins.While J&J works toward its transformation, you can sit back and enjoy a 2.5% yield backed by steady and growing dividends. Buffett loves dividends, and J&J is a Dividend King that has hiked dividends every year for 60 consecutive years.Buffett saw promise in this stock when no one else didThe second Buffet stock to buy -- and I've been pounding the table on this one for several months now -- is BYD. The S&P 500 has shed almost 18% value so far this year, but BYD stock is up 19% so far. There's a reason why BYD is outperforming the market.BYD has only recently caught Wall Street's attention, but Buffett spotted potential in the Chinese electric vehicle (EV) manufacturer as early as 2008. Today, China is the world's largest EV market, and BYD is a leader in the industry.In fact, BYD sees so much potential in plug-in hybrids and all-electric vehicles that it stopped production of traditional internal combustion engine vehicles in March. BYD's sales more than doubled in May, and it now reportedly has a backlog of nearly 600,000 units, according to local Chinese media outlets. Between January and May alone, BYD sold more than 500,000 vehicles, close to the number it sold in 2021.Aside from passenger cars, BYD also makes commercial vehicles, and even builds and sells them in the U.S. BYD is also one of the leading battery makers in China and has reportedly even struck a battery-supply deal with EV giant Tesla. Lithium is one of the hottest metals right now, so much so that BYD plans to buy several lithium mines in Africa to secure a long-term supply.BYD is doing everything right in an industry with exponential growth potential, making it a no-brainer Buffett stock to own.Also Read: BYD’s 66% Gain Catapults Stock to Near Trillion Yuan Market CapA no-brainer Buffett cash cow stock to buyVisa is the third and one of the smartest Buffett stocks you could buy right now and own for as long as you possibly can.Many expected Visa's growth to pause as consumers fall back on cash after relying on online purchases and digital payments over the past couple of years when the COVID-19 pandemic raged. However, digital payments continue to displace cash. Visa processed 7.9 billion more payments transactions across debit and credit cards but 16 million fewer cash transactions (including cash access, balance access, and balance transfer transactions) in its second quarter ended March 31.Remember, the war on cash isn't a fad but a secular trend that Visa, the industry leader, is perfectly poised to ride. And here's something else that works in its favor: Visa is not a lender but only processes payments made using its co-branded cards in return for a fee.Such a business model is not only asset-light but free from credit risks that most financial stocks typically face. And it's huge: Visa processed payments and cash transactions worth $13 trillion in 2021 and had nearly 3.7 billion cards issued worldwide. It's no surprise, then, that owning shares of a cash cow with solid margins in a growing industry has turned out to be so lucrative for long-term investors. It should continue to be lucrative for those who buy this Buffett stock that's still down about 14% in the past one year and trading at a price/earnings-to-growth (PEG) ratio of 1.39 times, considerably below its five-year average PEG.","news_type":1},"isVote":1,"tweetType":1,"viewCount":297,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9042335999,"gmtCreate":1656430712111,"gmtModify":1676535827113,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Going to shine?","listText":"Going to shine?","text":"Going to shine?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9042335999","repostId":"2240220773","repostType":2,"repost":{"id":"2240220773","kind":"highlight","pubTimestamp":1654267742,"share":"https://ttm.financial/m/news/2240220773?lang=&edition=fundamental","pubTime":"2022-06-03 22:49","market":"us","language":"en","title":"Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2240220773","media":"Zacks","summary":"Aeglea BioTherapeutics, Inc. AGLE announced that it has received a Refusal to File (“RTF”) letter fr","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/AGLE\">Aeglea BioTherapeutics, Inc.</a> </strong>AGLE announced that it has received a Refusal to File (“RTF”) letter from the FDA regarding the biologics license application (“BLA”) for its lead product candidate, pegzilarginase, for the treatment of arginase 1 deficiency (ARG1-D), a devastating rare disease. Currently, there is no approved therapy for the given indication.</p>\n<p>The FDA had requested additional data to support effectiveness of pegzilarginase in the RTF letter. The regulatory body has also requested additional information relating to Chemistry Manufacturing and Controls. However, no issue related to safety was raised in the RTF letter.</p>\n<p>Aeglea is considering requesting a Type A meeting with the FDA to clarify and respond to the items mentioned in the letter.</p>\n<p>Shares of Aeglea were down 51.3% on Thursday following the announcement of the news. The stock has plunged 84.6% so far this year compared with the industry’s decrease of 24.3%.</p>\n<p><img height=\"361\" src=\"https://s.yimg.com/uu/api/res/1.2/tTYKxQ342_imzQXMZILG7A--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/zacks.com/21ad984290b5720cc98a38b8073642f3\" width=\"619\"/><br/><span>Image Source: Zacks Investment Research</span><br/></p>\n<p>In April 2022, Aeglea submitted the BLA to the FDA, seeking approval of pegzilarginase for the treatment of ARG1-D. The company had requested the FDA to grant priority review to the BLA.</p>\n<p>The BLA filling was based on data from several clinical studies, including the phase III PEACE study, an ongoing long-term extension study, a phase I/II study, as well as an open-label extension study that evaluated pegzilarginase for treating ARG1-D.</p>\n<p>Back then, the FDA had already given a feedback to Aeglea, conveying its disagreement with the substantial evidence regarding the effectiveness of pegzilarginase.</p>\n<p>Aeglea's commercialization partner in Europe and the Middle East, Immedica Pharma AB, plans to submit marketing authorization application for pegzilarginase to the European Medicines Agency later in 2022.</p>\n<p>Aeglea has no approved product in its portfolio at the moment. Therefore, the successful development of pegzilarginase, along with other pipeline candidates, remains a key focus for the company.</p>\n<h3>Zacks Rank &amp; Stocks to Consider</h3>\n<p>Aeglea currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the biotech sector are <strong>Leap Therapeutics, Inc.</strong> LPTX, <strong><a href=\"https://laohu8.com/S/AVXL\">Anavex Life Sciences Corp.</a></strong> AVXL and <strong>Precision BioSciences, Inc.</strong> DTIL, all carrying the same Zacks Rank #2 at present. You can see <strong>the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here</strong>.</p>\n<p>The Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.</p>\n<p>Earnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.</p>\n<p>Anavex Life Sciences’ loss per share estimates narrowed 6.6% for 2022 and 4.3% for 2023 in the past 60 days.</p>\n<p>Earnings of Anavex Life Sciences have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AVXL delivered an earnings surprise of 0.48%, on average.</p>\n<p>Precision BioSciences’ loss per share estimates narrowed 21.7% for 2022 and 31.4% for 2023 in the past 60 days.</p>\n<p>Earnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.</p>\n<br/>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n<br/> \n<br/>\nAnavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report\n<br/> \n<br/>\nAeglea BioTherapeutics, Inc. (AGLE) : Free Stock Analysis Report\n<br/> \n<br/>\nLeap Therapeutics, Inc. (LPTX) : Free Stock Analysis Report\n<br/> \n<br/>\nPrecision BioSciences, Inc. (DTIL) : Free Stock Analysis Report\n<br/> \n<br/>\nTo read this article on Zacks.com click here.\n<br/> \n<br/>\nZacks Investment Research\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/>\n<br/></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-03 22:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/aeglea-agle-down-rtf-letter-144902800.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aeglea BioTherapeutics, Inc. AGLE announced that it has received a Refusal to File (“RTF”) letter from the FDA regarding the biologics license application (“BLA”) for its lead product candidate, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/aeglea-agle-down-rtf-letter-144902800.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/wJfB72kiLfyM59IxzSnTjQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","relate_stocks":{"AVXL":"Anavex Life Sciences Corp.","LPTX":"Leap Therapeutics Inc","BK4139":"生物科技","DTIL":"Precision Biosciences Inc"},"source_url":"https://finance.yahoo.com/news/aeglea-agle-down-rtf-letter-144902800.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2240220773","content_text":"Aeglea BioTherapeutics, Inc. AGLE announced that it has received a Refusal to File (“RTF”) letter from the FDA regarding the biologics license application (“BLA”) for its lead product candidate, pegzilarginase, for the treatment of arginase 1 deficiency (ARG1-D), a devastating rare disease. Currently, there is no approved therapy for the given indication.\nThe FDA had requested additional data to support effectiveness of pegzilarginase in the RTF letter. The regulatory body has also requested additional information relating to Chemistry Manufacturing and Controls. However, no issue related to safety was raised in the RTF letter.\nAeglea is considering requesting a Type A meeting with the FDA to clarify and respond to the items mentioned in the letter.\nShares of Aeglea were down 51.3% on Thursday following the announcement of the news. The stock has plunged 84.6% so far this year compared with the industry’s decrease of 24.3%.\nImage Source: Zacks Investment Research\nIn April 2022, Aeglea submitted the BLA to the FDA, seeking approval of pegzilarginase for the treatment of ARG1-D. The company had requested the FDA to grant priority review to the BLA.\nThe BLA filling was based on data from several clinical studies, including the phase III PEACE study, an ongoing long-term extension study, a phase I/II study, as well as an open-label extension study that evaluated pegzilarginase for treating ARG1-D.\nBack then, the FDA had already given a feedback to Aeglea, conveying its disagreement with the substantial evidence regarding the effectiveness of pegzilarginase.\nAeglea's commercialization partner in Europe and the Middle East, Immedica Pharma AB, plans to submit marketing authorization application for pegzilarginase to the European Medicines Agency later in 2022.\nAeglea has no approved product in its portfolio at the moment. Therefore, the successful development of pegzilarginase, along with other pipeline candidates, remains a key focus for the company.\nZacks Rank & Stocks to Consider\nAeglea currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the biotech sector are Leap Therapeutics, Inc. LPTX, Anavex Life Sciences Corp. AVXL and Precision BioSciences, Inc. DTIL, all carrying the same Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nThe Zacks Consensus Estimate for Leap Therapeutics’ loss per share has narrowed 11.1% for 2022 and 5.9% for 2023 in the past 60 days.\nEarnings of Leap Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. LPTX delivered an earnings surprise of 1.92%, on average.\nAnavex Life Sciences’ loss per share estimates narrowed 6.6% for 2022 and 4.3% for 2023 in the past 60 days.\nEarnings of Anavex Life Sciences have surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions. AVXL delivered an earnings surprise of 0.48%, on average.\nPrecision BioSciences’ loss per share estimates narrowed 21.7% for 2022 and 31.4% for 2023 in the past 60 days.\nEarnings of Precision BioSciences have surpassed estimates in each of the trailing four quarters. DTIL delivered an earnings surprise of 76.15%, on average.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n \n\nAnavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report\n \n\nAeglea BioTherapeutics, Inc. (AGLE) : Free Stock Analysis Report\n \n\nLeap Therapeutics, Inc. (LPTX) : Free Stock Analysis Report\n \n\nPrecision BioSciences, Inc. (DTIL) : Free Stock Analysis Report\n \n\nTo read this article on Zacks.com click here.\n \n\nZacks Investment Research","news_type":1},"isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9046789440,"gmtCreate":1656385546280,"gmtModify":1676535819712,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Mai siao siao leh...","listText":"Mai siao siao leh...","text":"Mai siao siao leh...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9046789440","repostId":"2246803790","repostType":4,"repost":{"id":"2246803790","kind":"highlight","pubTimestamp":1656382573,"share":"https://ttm.financial/m/news/2246803790?lang=&edition=fundamental","pubTime":"2022-06-28 10:16","market":"us","language":"en","title":"3 Reasons to Buy Novavax and 1 to Sell","url":"https://stock-news.laohu8.com/highlight/detail?id=2246803790","media":"Motley Fool","summary":"What does the future hold for this COVID-19 vaccination stock?","content":"<html><head></head><body><p><b>Novavax</b> is a pandemic stock. That&#39;s why it soared in 2020-21 when the world faced the worst pandemic since the influenza outbreak of 1918. When COVID-19 hit, this vaccine biotech made an almost impossible run, from a low of $4 a share all the way to $330.</p><p>Now it&#39;s down to $50, and the company&#39;s market cap is under $4 billion. Is it a buy at these prices? Here are three arguments for buying Novavax stock and one reason for why you might want to avoid these shares.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a59fcd638ddc65fc898da7b619b04516\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"/><span>Image source: Getty Images.</span></p><h2>Green Flag #1: Huge revenue in 2022 plus profits!</h2><p>In the first quarter, Novavax reported its first profitable quarter as a public company, with $200 million in profits off of $700 million in sales. That&#39;s a huge step up for a biotech, which has been unprofitable since it hit the public markets way back in the 20th century (1995 to be exact).</p><p>Novavax is a scrappy underdog that has survived for almost three decades without making any money. When Stan Erck arrived at the CEO slot in 2011, the company turned its focus toward vaccines to thwart pandemics. So if you&#39;re worried about severe acute respiratory syndrome (SARS), Novavax has discovered a potential vaccine for that. The biotech also has vaccine candidates in its pipeline for Ebola, malaria, Middle East respiratory syndrome (MERS), and influenza.</p><p>None of those drugs have been approved yet (Novavax is still waiting for its first FDA approval), but all of this scientific research gave the small biotech a big advantage when it came to combating the new coronavirus that hit the world two years ago. Based on its research, Novavax was awarded a massive $399 million check from the Bill Gates-funded Coalition for Epidemic Preparedness Innovations (CEPI). It&#39;s still the largest grant CEPI has ever made.</p><p>Novavax got an even bigger check from the U.S. government when Operation Warp Speed (OWS) pre-ordered 100 million doses of the company&#39;s COVID-19 vaccine and paid $1.6 billion in advance. Multiple governments around the world followed suit. So far, Novavax has received orders for 2 billion doses of its COVID-19 vaccine. Management estimates it will make over $4 billion in revenue in 2022 and maybe as much as $5 billion.</p><h2>Green Flag #2: The stock is cheap, and the opportunity massive</h2><p>At the end of Q1, Novavax reported $1.6 billion in cash. So right now, the stock is trading at less than three times cash. Its forward price-to-earnings (P/E) ratio is 1.6, and its price-to-sales (P/S) ratio is 1.8. This is incredibly cheap given how fast revenue is escalating. In Q1, the biotech delivered 42 million doses of the COVID vaccine to the European Union (EU), Canada, South Korea, Australia, New Zealand, and Indonesia.</p><p>While 42 million is a lot, Novavax&#39;s massive roll-out has just begun. The company anticipates an Emergency Use Authorization (EUA) from American regulators this month. A few weeks ago, the FDA&#39;s advisory committee voted 21-0 that Novavax&#39;s vaccine should be available to the people of the United States. If and when the FDA follows the advice of its advisory committee, Novavax will be allowed to start shipping 110 million doses of vaccine in the U.S.</p><p>While the stock market is waiting for the FDA&#39;s decision, most of Novavax&#39;s market opportunity is actually abroad. The company has already received authorizations to ship its vaccines to over 170 countries. This is huge for Novavax as the biotech has advance-purchase agreements for up to 430 million doses, or 10 times what it delivered in Q1.</p><h2>Green Flag #3: At least $7 billion in near-term revenue</h2><p>If 42 million doses brought in $700 million in Q1, what will 430 million doses bring in? And note that these contracts are in many of the same places that were responsible for the Q1 revenue (EU, Canada, Australia, and New Zealand).</p><p>While Novavax keeps its pricing data secret, these deals were made when the pandemic was at its worst. If the price points are similar, the company might pull in $7 billion from these contracts alone (some of this revenue will likely spill over into 2023). So management&#39;s estimate of $4 billion to $5 billion in revenues for 2022 seems very doable.</p><p>What&#39;s remarkable is that this $7 billion does not include <i>any</i> revenue from the 110 million doses in the U.S.; nor does it include the 1.1 billion doses that Novavax is distributing to COVID-19 Vaccines Global Access (COVAX) as part of its CEPI obligations, nor another 400 million doses the company is distributing as part of licensing agreements in Asia. So to my mind, this back-of-the-envelope $7 billion calculation is a floor -- not a ceiling.</p><h2>Red Flag: Can Novavax deliver 2 billion doses?</h2><p>The big question for Novavax is not in regard to its science -- some observers call its vaccine best-in-class -- but rather the manufacturing issues which have dogged the tiny biotech. Novavax has signed multiple contracts with third-party sites to manufacture its COVID vaccine. So far, however, the only site that has been approved by regulators is the Serum Institute of India (the largest vaccine manufacturer in the world by volume). Some of the other manufacturing sites have been hampered by purity issues.</p><p>It&#39;s these manufacturing difficulties that have caused a year-long delay in getting this vaccine to market in the U.S. Novavax&#39;s share price hit $330 in the days after the company released its amazing phase 3 data for its COVID vaccine in early 2021.  But after all the delays, the stock has seen a massive price drop to $50 a share, while <b>Pfizer </b>and <b>Moderna</b> have vaccinated most of the country.</p><p>Nonetheless, I&#39;m very bullish that Novavax will solve its manufacturing issues. The Serum Institute can and will produce a billion doses of the vaccine. (That&#39;s the manufacturer Novavax has relied on to get its EUAs around the world). And now additional manufacturing sites are approaching readiness. In April, the biotech submitted data from another highly regarded manufacturer, SK Bioscience, to European health authorities. And in Q2, Novavax will file data from its own manufacturing site in the Czech Republic. That state-of-the-art facility will ultimately manufacture another one billion doses a year for Novavax.</p><h2>What is the future for Novavax?</h2><p>The market, with its short-term dynamics, seems to think that COVID-19 is over. While I wish this were the case, I&#39;m afraid it&#39;s highly unlikely. Since COVID mutates like flu viruses, many of us may well need to be vaccinated annually. COVID hospitalizations spiked dramatically in the winters of 2020 and 2021, so that is likely to happen this year too. Like the flu, the worst cases of COVID seem to be seasonal.</p><p>In that regard, Novavax is in the lead in finding a flu/COVID combo vaccine. The company has already started clinical trials and will advance its candidate into a phase 2 trial later this year. Over the next year or two, I expect Novavax revenue to spike a lot higher. But the real gains will happen if and when Novavax is first to market with its COVID/flu combo shot.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Reasons to Buy Novavax and 1 to Sell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Reasons to Buy Novavax and 1 to Sell\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-28 10:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/27/3-reasons-to-buy-novavax-and-1-to-sell/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novavax is a pandemic stock. That's why it soared in 2020-21 when the world faced the worst pandemic since the influenza outbreak of 1918. When COVID-19 hit, this vaccine biotech made an almost ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/27/3-reasons-to-buy-novavax-and-1-to-sell/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2022/06/27/3-reasons-to-buy-novavax-and-1-to-sell/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2246803790","content_text":"Novavax is a pandemic stock. That's why it soared in 2020-21 when the world faced the worst pandemic since the influenza outbreak of 1918. When COVID-19 hit, this vaccine biotech made an almost impossible run, from a low of $4 a share all the way to $330.Now it's down to $50, and the company's market cap is under $4 billion. Is it a buy at these prices? Here are three arguments for buying Novavax stock and one reason for why you might want to avoid these shares.Image source: Getty Images.Green Flag #1: Huge revenue in 2022 plus profits!In the first quarter, Novavax reported its first profitable quarter as a public company, with $200 million in profits off of $700 million in sales. That's a huge step up for a biotech, which has been unprofitable since it hit the public markets way back in the 20th century (1995 to be exact).Novavax is a scrappy underdog that has survived for almost three decades without making any money. When Stan Erck arrived at the CEO slot in 2011, the company turned its focus toward vaccines to thwart pandemics. So if you're worried about severe acute respiratory syndrome (SARS), Novavax has discovered a potential vaccine for that. The biotech also has vaccine candidates in its pipeline for Ebola, malaria, Middle East respiratory syndrome (MERS), and influenza.None of those drugs have been approved yet (Novavax is still waiting for its first FDA approval), but all of this scientific research gave the small biotech a big advantage when it came to combating the new coronavirus that hit the world two years ago. Based on its research, Novavax was awarded a massive $399 million check from the Bill Gates-funded Coalition for Epidemic Preparedness Innovations (CEPI). It's still the largest grant CEPI has ever made.Novavax got an even bigger check from the U.S. government when Operation Warp Speed (OWS) pre-ordered 100 million doses of the company's COVID-19 vaccine and paid $1.6 billion in advance. Multiple governments around the world followed suit. So far, Novavax has received orders for 2 billion doses of its COVID-19 vaccine. Management estimates it will make over $4 billion in revenue in 2022 and maybe as much as $5 billion.Green Flag #2: The stock is cheap, and the opportunity massiveAt the end of Q1, Novavax reported $1.6 billion in cash. So right now, the stock is trading at less than three times cash. Its forward price-to-earnings (P/E) ratio is 1.6, and its price-to-sales (P/S) ratio is 1.8. This is incredibly cheap given how fast revenue is escalating. In Q1, the biotech delivered 42 million doses of the COVID vaccine to the European Union (EU), Canada, South Korea, Australia, New Zealand, and Indonesia.While 42 million is a lot, Novavax's massive roll-out has just begun. The company anticipates an Emergency Use Authorization (EUA) from American regulators this month. A few weeks ago, the FDA's advisory committee voted 21-0 that Novavax's vaccine should be available to the people of the United States. If and when the FDA follows the advice of its advisory committee, Novavax will be allowed to start shipping 110 million doses of vaccine in the U.S.While the stock market is waiting for the FDA's decision, most of Novavax's market opportunity is actually abroad. The company has already received authorizations to ship its vaccines to over 170 countries. This is huge for Novavax as the biotech has advance-purchase agreements for up to 430 million doses, or 10 times what it delivered in Q1.Green Flag #3: At least $7 billion in near-term revenueIf 42 million doses brought in $700 million in Q1, what will 430 million doses bring in? And note that these contracts are in many of the same places that were responsible for the Q1 revenue (EU, Canada, Australia, and New Zealand).While Novavax keeps its pricing data secret, these deals were made when the pandemic was at its worst. If the price points are similar, the company might pull in $7 billion from these contracts alone (some of this revenue will likely spill over into 2023). So management's estimate of $4 billion to $5 billion in revenues for 2022 seems very doable.What's remarkable is that this $7 billion does not include any revenue from the 110 million doses in the U.S.; nor does it include the 1.1 billion doses that Novavax is distributing to COVID-19 Vaccines Global Access (COVAX) as part of its CEPI obligations, nor another 400 million doses the company is distributing as part of licensing agreements in Asia. So to my mind, this back-of-the-envelope $7 billion calculation is a floor -- not a ceiling.Red Flag: Can Novavax deliver 2 billion doses?The big question for Novavax is not in regard to its science -- some observers call its vaccine best-in-class -- but rather the manufacturing issues which have dogged the tiny biotech. Novavax has signed multiple contracts with third-party sites to manufacture its COVID vaccine. So far, however, the only site that has been approved by regulators is the Serum Institute of India (the largest vaccine manufacturer in the world by volume). Some of the other manufacturing sites have been hampered by purity issues.It's these manufacturing difficulties that have caused a year-long delay in getting this vaccine to market in the U.S. Novavax's share price hit $330 in the days after the company released its amazing phase 3 data for its COVID vaccine in early 2021.  But after all the delays, the stock has seen a massive price drop to $50 a share, while Pfizer and Moderna have vaccinated most of the country.Nonetheless, I'm very bullish that Novavax will solve its manufacturing issues. The Serum Institute can and will produce a billion doses of the vaccine. (That's the manufacturer Novavax has relied on to get its EUAs around the world). And now additional manufacturing sites are approaching readiness. In April, the biotech submitted data from another highly regarded manufacturer, SK Bioscience, to European health authorities. And in Q2, Novavax will file data from its own manufacturing site in the Czech Republic. That state-of-the-art facility will ultimately manufacture another one billion doses a year for Novavax.What is the future for Novavax?The market, with its short-term dynamics, seems to think that COVID-19 is over. While I wish this were the case, I'm afraid it's highly unlikely. Since COVID mutates like flu viruses, many of us may well need to be vaccinated annually. COVID hospitalizations spiked dramatically in the winters of 2020 and 2021, so that is likely to happen this year too. Like the flu, the worst cases of COVID seem to be seasonal.In that regard, Novavax is in the lead in finding a flu/COVID combo vaccine. The company has already started clinical trials and will advance its candidate into a phase 2 trial later this year. Over the next year or two, I expect Novavax revenue to spike a lot higher. But the real gains will happen if and when Novavax is first to market with its COVID/flu combo shot.","news_type":1},"isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9046298463,"gmtCreate":1656348405852,"gmtModify":1676535810940,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Research stock..","listText":"Research stock..","text":"Research stock..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9046298463","repostId":"2234978196","repostType":2,"repost":{"id":"2234978196","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1652359374,"share":"https://ttm.financial/m/news/2234978196?lang=&edition=fundamental","pubTime":"2022-05-12 20:42","market":"hk","language":"en","title":"The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More","url":"https://stock-news.laohu8.com/highlight/detail?id=2234978196","media":"Benzinga","summary":"Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:","content":"<html><body><p>Here's a roundup of top developments in the biotech space over the last 24 hours:</p>\n<h1>Stocks In Focus</h1>\n<h1>BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology</h1>\n<p><strong>BridgeBio Pharma Inc</strong> (NASDAQ:BBIO) has announced an exclusive license with <strong>Bristol Myers Squibb Co</strong> (NYSE:BMY) to develop and commercialize BBP-398 in oncology. </p>\n<p>BridgeBio will receive an upfront payment of $90 million, up to $815 million in milestone payments and tiered royalties in the low- to mid-teens. </p>\n<p>BridgeBio will retain the option to acquire higher royalties in the U.S. in connection with funding a portion of development costs upon the initiation of registrational studies.</p>\n<p>BBIO shares are up 6.53% at $5.55 during the premarket session on the last check Thursday.</p>\n<h1>FDA Green Lights Lava Therapeutics' Blood Cancer Trial</h1>\n<p>The FDA has signed off <strong>LAVA Therapeutics N.V's </strong>(NASDAQ:LVTX) investigational new drug (IND) application for LAVA-051, its lead product candidate for relapsed or refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML).</p>\n<p>The Phase 1/2a trial currently includes patients with relapsed or refractory CLL and MM. AML patients will be included later in the study. </p>\n<p>Shares are rising 4.38% at $3.81 during the premarket session.</p>\n<h1>Stealth BioTherapeutics' Elamipretide Receives Orphan Drug Tag For Duchenne Muscular Dystrophy</h1>\n<p>The FDA has granted an orphan drug tag to <strong>Stealth BioTherapeutics Corp's</strong> (NASDAQ:MITO) elamipretide for Duchenne muscular dystrophy. </p>\n<p>FDA's Division of Neurology I has granted the company's request for a pre-IND meeting to discuss a development path for elamipretide in combination with products within the approved therapeutic class of exon-skipping phosphorodiamidate morpholino oligomers.</p>\n<p>Shares are up 47.3% at 28 cents during the premarket session. </p>\n<h1>Acorda Therapeutics Inks Distribution Pact For Parkinson's Drug In Latin America</h1>\n<p><strong>Acorda Therapeutics Inc</strong> (NASDAQ:ACOR) and <strong>Biopas Laboratories</strong> have entered into distribution and supply agreements to commercialize Inbrija in Latin America. </p>\n<p>Inbrija is indicated in the U.S. for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor.</p>\n<p>Under the terms of the agreements, Acorda will receive a double-digit, tiered percentage of the selling price of Inbrija in Latin America in exchange for the supply of the product. </p>\n<p>Acorda will also receive sales-based milestones.</p>\n<h1>Salarius Shares Surge After Pre-IND Meeting For Its Cancer Candidate </h1>\n<p><strong><a href=\"https://laohu8.com/S/SLRX\">Salarius Pharmaceuticals Inc</a></strong> (NASDAQ:SLRX) has completed its pre-IND meeting process with the FDA for SP-3164, a targeted protein degrader inducing selective elimination of cancer-causing proteins. </p>\n<p>Salarius is developing SP-3164 as a potential treatment for hematological cancers and solid tumors.</p>\n<p>Salarius said it obtained valuable FDA input through the pre-IND meeting process that clarified preclinical, clinical, and other regulatory matters for preparing and submitting an IND. </p>\n<p>Salarius plans to submit an IND in 2023 and initiate the first clinical trial.</p>\n<p>Shares are surging 56.3% at 25 cents during the premarket session.</p>\n<p><strong><em>Related:</em></strong><em> </em><em>Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates</em></p>\n<h1>Lannett, Areva Pharma Ink US Distribution Pact For Leukemia Med</h1>\n<p><strong>Lannett Company Inc</strong> (NYSE:LCI) entered into an agreement with <strong>Areva Pharmaceuticals</strong> to be the exclusive the U.S. distributor of fludarabine phosphate for Injection, USP, 50 mg/2mL, single-dose vials.</p>\n<p>Fludarabine phosphate injection is indicated for B-cell chronic lymphocytic leukemia patients who have not responded to or whose disease has progressed during treatment.</p>\n<p>The product generated annual sales of $4.9 million. According to <a href=\"https://laohu8.com/S/IQV\">IQVIA</a>, the current market value is believed to be higher due to the recent market disruptions.</p>\n<p>Under the agreement, Lannett will receive a share of the profits. Other financial terms were not disclosed.</p>\n<h1>MediWound Posts Promising EscharEx Data For Chronic Wounds</h1>\n<p><strong>MediWound Ltd</strong> (NASDAQ:MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers. </p>\n<p>The study met its primary and secondary endpoints and wound closure safety measurements. </p>\n<p>The study demonstrated that patients treated with EscharEx had a statistically significant higher incidence of complete debridement during the 14-day measurement period within up to eight applications than gel vehicle (EscharEx: 63%) vs. gel vehicle: 30%. </p>\n<p>Shares are up 10% at $1.98 during the premarket session.</p>\n<h1><a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> Kickstarts Phase 2 Trial Of Nanobody Sonelokimab In Chronic Skin Disorder</h1>\n<p><strong>MoonLake Immunotherapeutics AG</strong> (NASDAQ:MLTX) has randomized and dosed the first patient in its Phase 2 trial of sonelokimab for moderate-to-severe hidradenitis suppurativa, a chronic skin condition.</p>\n<p>The MIRA trial will evaluate the efficacy and safety of different doses of sonelokimab, compared with placebo, with adalimumab as an active control reference arm in over 200 patients.</p>\n<h3>IPOs</h3>\n<p><strong>Intrinsic Medicine Inc </strong>(NASDAQ:INRX) has filed with the SEC regarding an initial public offering of 4.12 million shares.</p>\n<p>The company expects to price the offering between $5 and $7 per share.</p>\n<h3>Offerings</h3>\n<p><strong><a href=\"https://laohu8.com/S/PTN\">Palatin Technologies Inc</a></strong> (NYSE:PTN) will sell 8.1 million shares of its Series B and 900,000 shares of its Series C convertible redeemable preferred stock for gross proceeds of $15 million.</p>\n<p>Each share of Series B and Series C preferred stock has a purchase price of $1.67 and is convertible at an initial conversion price of 45 cents per share. </p>\n<p>Shares are slipping 2.79% at 32 cents during premarket trading.</p>\n<h3>On The Radar</h3>\n<h3>Stock Split</h3>\n<p><strong><a href=\"https://laohu8.com/S/RMTI\">Rockwell Medical</a> Inc</strong> (NASDAQ:RMTI) has approved a 1-for-11 reverse split, effective Friday at 12:01 a.m. eastern time.</p>\n<h3>Earnings</h3>\n<p>The earnings list presented is not comprehensive. Click here to access Benzinga's earnings calendar for the complete schedule.</p>\n<p><strong><a href=\"https://laohu8.com/S/XFOR\">X4 Pharmaceuticals Inc</a></strong> (NASDAQ:XFOR): Before Market Open.</p>\n<p><strong><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> Inc</strong> (NASDAQ:DARE): Before Market Open.</p>\n<p><strong>Matinas BioPharma Holdings Inc</strong> (NYSE:MTNB): Before Market Open.</p>\n<p><strong>Orchard Therapeutics <a href=\"https://laohu8.com/S/PLC\">PLC</a></strong> (NASDAQ:ORTX): Before Market Open.</p>\n<p><strong>Altimmune Inc</strong> (NASDAQ:ALT): Before Market Open.</p>\n<p><strong><a href=\"https://laohu8.com/S/SCYX\">SCYNEXIS Inc</a></strong> (NASDAQ:SCYX): Before Market Open.</p>\n<p><strong><a href=\"https://laohu8.com/S/ZEAL\">Zealand Pharma A/S</a></strong> (NASDAQ:ZEAL): Before Market Open.</p>\n<p><strong>Veru Inc</strong> (NASDAQ:VERU): Before Market Open.</p>\n<p><strong>Brickell Biotech Inc</strong> (NASDAQ:BBI): After Market Close.</p>\n<p><strong><a href=\"https://laohu8.com/S/SPPI\">Spectrum Pharmaceuticals</a> Inc</strong> (NASDAQ:SPPI): After Market Close.</p>\n<p><strong><a href=\"https://laohu8.com/S/RGLS\">Regulus Therapeutics Inc</a></strong> (NASDAQ:RGLS): After Market Close.</p>\n<p><strong>Ibio Inc</strong> (NYSE:IBIO): After Market Close.</p>\n<p><strong>Salarius Pharmaceuticals Inc</strong> (NASDAQ:SLRX): After Market Close.</p>\n<p><strong>CymaBay Therapeutics Inc</strong> (NASDAQ:CBAY): After Market Close.</p>\n<p><strong><a href=\"https://laohu8.com/S/MRNS\">Marinus Pharmaceuticals</a> Inc</strong> (NASDAQ:MRNS): After Market Close.</p>\n<p><strong>OpGen Inc</strong> (NASDAQ:OPGN): After Market Close.</p>\n<p><strong><a href=\"https://laohu8.com/S/LCTX\">Lineage Cell Therapeutics Inc</a></strong> (NYSE:LCTX): After Market Close.</p>\n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-05-12 20:42</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Here's a roundup of top developments in the biotech space over the last 24 hours:</p>\n<h1>Stocks In Focus</h1>\n<h1>BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology</h1>\n<p><strong>BridgeBio Pharma Inc</strong> (NASDAQ:BBIO) has announced an exclusive license with <strong>Bristol Myers Squibb Co</strong> (NYSE:BMY) to develop and commercialize BBP-398 in oncology. </p>\n<p>BridgeBio will receive an upfront payment of $90 million, up to $815 million in milestone payments and tiered royalties in the low- to mid-teens. </p>\n<p>BridgeBio will retain the option to acquire higher royalties in the U.S. in connection with funding a portion of development costs upon the initiation of registrational studies.</p>\n<p>BBIO shares are up 6.53% at $5.55 during the premarket session on the last check Thursday.</p>\n<h1>FDA Green Lights Lava Therapeutics' Blood Cancer Trial</h1>\n<p>The FDA has signed off <strong>LAVA Therapeutics N.V's </strong>(NASDAQ:LVTX) investigational new drug (IND) application for LAVA-051, its lead product candidate for relapsed or refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML).</p>\n<p>The Phase 1/2a trial currently includes patients with relapsed or refractory CLL and MM. AML patients will be included later in the study. </p>\n<p>Shares are rising 4.38% at $3.81 during the premarket session.</p>\n<h1>Stealth BioTherapeutics' Elamipretide Receives Orphan Drug Tag For Duchenne Muscular Dystrophy</h1>\n<p>The FDA has granted an orphan drug tag to <strong>Stealth BioTherapeutics Corp's</strong> (NASDAQ:MITO) elamipretide for Duchenne muscular dystrophy. </p>\n<p>FDA's Division of Neurology I has granted the company's request for a pre-IND meeting to discuss a development path for elamipretide in combination with products within the approved therapeutic class of exon-skipping phosphorodiamidate morpholino oligomers.</p>\n<p>Shares are up 47.3% at 28 cents during the premarket session. </p>\n<h1>Acorda Therapeutics Inks Distribution Pact For Parkinson's Drug In Latin America</h1>\n<p><strong>Acorda Therapeutics Inc</strong> (NASDAQ:ACOR) and <strong>Biopas Laboratories</strong> have entered into distribution and supply agreements to commercialize Inbrija in Latin America. </p>\n<p>Inbrija is indicated in the U.S. for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor.</p>\n<p>Under the terms of the agreements, Acorda will receive a double-digit, tiered percentage of the selling price of Inbrija in Latin America in exchange for the supply of the product. </p>\n<p>Acorda will also receive sales-based milestones.</p>\n<h1>Salarius Shares Surge After Pre-IND Meeting For Its Cancer Candidate </h1>\n<p><strong><a href=\"https://laohu8.com/S/SLRX\">Salarius Pharmaceuticals Inc</a></strong> (NASDAQ:SLRX) has completed its pre-IND meeting process with the FDA for SP-3164, a targeted protein degrader inducing selective elimination of cancer-causing proteins. </p>\n<p>Salarius is developing SP-3164 as a potential treatment for hematological cancers and solid tumors.</p>\n<p>Salarius said it obtained valuable FDA input through the pre-IND meeting process that clarified preclinical, clinical, and other regulatory matters for preparing and submitting an IND. </p>\n<p>Salarius plans to submit an IND in 2023 and initiate the first clinical trial.</p>\n<p>Shares are surging 56.3% at 25 cents during the premarket session.</p>\n<p><strong><em>Related:</em></strong><em> </em><em>Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates</em></p>\n<h1>Lannett, Areva Pharma Ink US Distribution Pact For Leukemia Med</h1>\n<p><strong>Lannett Company Inc</strong> (NYSE:LCI) entered into an agreement with <strong>Areva Pharmaceuticals</strong> to be the exclusive the U.S. distributor of fludarabine phosphate for Injection, USP, 50 mg/2mL, single-dose vials.</p>\n<p>Fludarabine phosphate injection is indicated for B-cell chronic lymphocytic leukemia patients who have not responded to or whose disease has progressed during treatment.</p>\n<p>The product generated annual sales of $4.9 million. According to <a href=\"https://laohu8.com/S/IQV\">IQVIA</a>, the current market value is believed to be higher due to the recent market disruptions.</p>\n<p>Under the agreement, Lannett will receive a share of the profits. Other financial terms were not disclosed.</p>\n<h1>MediWound Posts Promising EscharEx Data For Chronic Wounds</h1>\n<p><strong>MediWound Ltd</strong> (NASDAQ:MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers. </p>\n<p>The study met its primary and secondary endpoints and wound closure safety measurements. </p>\n<p>The study demonstrated that patients treated with EscharEx had a statistically significant higher incidence of complete debridement during the 14-day measurement period within up to eight applications than gel vehicle (EscharEx: 63%) vs. gel vehicle: 30%. </p>\n<p>Shares are up 10% at $1.98 during the premarket session.</p>\n<h1><a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> Kickstarts Phase 2 Trial Of Nanobody Sonelokimab In Chronic Skin Disorder</h1>\n<p><strong>MoonLake Immunotherapeutics AG</strong> (NASDAQ:MLTX) has randomized and dosed the first patient in its Phase 2 trial of sonelokimab for moderate-to-severe hidradenitis suppurativa, a chronic skin condition.</p>\n<p>The MIRA trial will evaluate the efficacy and safety of different doses of sonelokimab, compared with placebo, with adalimumab as an active control reference arm in over 200 patients.</p>\n<h3>IPOs</h3>\n<p><strong>Intrinsic Medicine Inc </strong>(NASDAQ:INRX) has filed with the SEC regarding an initial public offering of 4.12 million shares.</p>\n<p>The company expects to price the offering between $5 and $7 per share.</p>\n<h3>Offerings</h3>\n<p><strong><a href=\"https://laohu8.com/S/PTN\">Palatin Technologies Inc</a></strong> (NYSE:PTN) will sell 8.1 million shares of its Series B and 900,000 shares of its Series C convertible redeemable preferred stock for gross proceeds of $15 million.</p>\n<p>Each share of Series B and Series C preferred stock has a purchase price of $1.67 and is convertible at an initial conversion price of 45 cents per share. </p>\n<p>Shares are slipping 2.79% at 32 cents during premarket trading.</p>\n<h3>On The Radar</h3>\n<h3>Stock Split</h3>\n<p><strong><a href=\"https://laohu8.com/S/RMTI\">Rockwell Medical</a> Inc</strong> (NASDAQ:RMTI) has approved a 1-for-11 reverse split, effective Friday at 12:01 a.m. eastern time.</p>\n<h3>Earnings</h3>\n<p>The earnings list presented is not comprehensive. Click here to access Benzinga's earnings calendar for the complete schedule.</p>\n<p><strong><a href=\"https://laohu8.com/S/XFOR\">X4 Pharmaceuticals Inc</a></strong> (NASDAQ:XFOR): Before Market Open.</p>\n<p><strong><a href=\"https://laohu8.com/S/DARE\">Dare Bioscience</a> Inc</strong> (NASDAQ:DARE): Before Market Open.</p>\n<p><strong>Matinas BioPharma Holdings Inc</strong> (NYSE:MTNB): Before Market Open.</p>\n<p><strong>Orchard Therapeutics <a href=\"https://laohu8.com/S/PLC\">PLC</a></strong> (NASDAQ:ORTX): Before Market Open.</p>\n<p><strong>Altimmune Inc</strong> (NASDAQ:ALT): Before Market Open.</p>\n<p><strong><a href=\"https://laohu8.com/S/SCYX\">SCYNEXIS Inc</a></strong> (NASDAQ:SCYX): Before Market Open.</p>\n<p><strong><a href=\"https://laohu8.com/S/ZEAL\">Zealand Pharma A/S</a></strong> (NASDAQ:ZEAL): Before Market Open.</p>\n<p><strong>Veru Inc</strong> (NASDAQ:VERU): Before Market Open.</p>\n<p><strong>Brickell Biotech Inc</strong> (NASDAQ:BBI): After Market Close.</p>\n<p><strong><a href=\"https://laohu8.com/S/SPPI\">Spectrum Pharmaceuticals</a> Inc</strong> (NASDAQ:SPPI): After Market Close.</p>\n<p><strong><a href=\"https://laohu8.com/S/RGLS\">Regulus Therapeutics Inc</a></strong> (NASDAQ:RGLS): After Market Close.</p>\n<p><strong>Ibio Inc</strong> (NYSE:IBIO): After Market Close.</p>\n<p><strong>Salarius Pharmaceuticals Inc</strong> (NASDAQ:SLRX): After Market Close.</p>\n<p><strong>CymaBay Therapeutics Inc</strong> (NASDAQ:CBAY): After Market Close.</p>\n<p><strong><a href=\"https://laohu8.com/S/MRNS\">Marinus Pharmaceuticals</a> Inc</strong> (NASDAQ:MRNS): After Market Close.</p>\n<p><strong>OpGen Inc</strong> (NASDAQ:OPGN): After Market Close.</p>\n<p><strong><a href=\"https://laohu8.com/S/LCTX\">Lineage Cell Therapeutics Inc</a></strong> (NYSE:LCTX): After Market Close.</p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SCYX":"SCYNEXIS Inc","VERU":"Veru Inc.","RMTI":"Rockwell Medical","XFOR":"X4制药","SPPI":"Spectrum Pharmaceuticals","MRNS":"Marinus Pharmaceuticals","ALT":"Altimmune, Inc.","MYE":"Myers Industries Inc","MTNB":"Matinas BioPharma Holdings, Inc","RGLS":"Regulus Therapeutics Inc","PTN":"Palatin Technologies Inc","IBB":"生物科技指数ETF-iShares Nasdaq","LCTX":"Lineage Cell Therapeutics Inc","BMY":"施贵宝","IBIO":"iBio Inc.","ZEAL":"Zealand Pharma A/S","SLRX":"Salarius Pharmaceuticals Inc","ORTX":"Orchard Therapeutics Plc","DARE":"Dare Bioscience","BK4126":"金属与玻璃容器","LVTX":"LAVA Therapeutics N.V.","MLTX":"MoonLake Immunotherapeutics","BBIO":"BridgeBio Pharma, Inc.","CBAY":"CymaBay Therapeutics Inc.","OPGN":"OpGen, Inc.","MITO":"Stealth Biotherapeutics Corp","MDWD":"MediWound Ltd.","ACOR":"阿索尔达生物制药公司"},"source_url":"https://www.benzinga.com/general/biotech/22/05/27161064/the-daily-biotech-pulse-bristol-myers-bridgebio-ink-oncology-pact-fda-nod-for-lava-therapeutics-b","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2234978196","content_text":"Here's a roundup of top developments in the biotech space over the last 24 hours:\nStocks In Focus\nBridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology\nBridgeBio Pharma Inc (NASDAQ:BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE:BMY) to develop and commercialize BBP-398 in oncology. \nBridgeBio will receive an upfront payment of $90 million, up to $815 million in milestone payments and tiered royalties in the low- to mid-teens. \nBridgeBio will retain the option to acquire higher royalties in the U.S. in connection with funding a portion of development costs upon the initiation of registrational studies.\nBBIO shares are up 6.53% at $5.55 during the premarket session on the last check Thursday.\nFDA Green Lights Lava Therapeutics' Blood Cancer Trial\nThe FDA has signed off LAVA Therapeutics N.V's (NASDAQ:LVTX) investigational new drug (IND) application for LAVA-051, its lead product candidate for relapsed or refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML).\nThe Phase 1/2a trial currently includes patients with relapsed or refractory CLL and MM. AML patients will be included later in the study. \nShares are rising 4.38% at $3.81 during the premarket session.\nStealth BioTherapeutics' Elamipretide Receives Orphan Drug Tag For Duchenne Muscular Dystrophy\nThe FDA has granted an orphan drug tag to Stealth BioTherapeutics Corp's (NASDAQ:MITO) elamipretide for Duchenne muscular dystrophy. \nFDA's Division of Neurology I has granted the company's request for a pre-IND meeting to discuss a development path for elamipretide in combination with products within the approved therapeutic class of exon-skipping phosphorodiamidate morpholino oligomers.\nShares are up 47.3% at 28 cents during the premarket session. \nAcorda Therapeutics Inks Distribution Pact For Parkinson's Drug In Latin America\nAcorda Therapeutics Inc (NASDAQ:ACOR) and Biopas Laboratories have entered into distribution and supply agreements to commercialize Inbrija in Latin America. \nInbrija is indicated in the U.S. for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor.\nUnder the terms of the agreements, Acorda will receive a double-digit, tiered percentage of the selling price of Inbrija in Latin America in exchange for the supply of the product. \nAcorda will also receive sales-based milestones.\nSalarius Shares Surge After Pre-IND Meeting For Its Cancer Candidate \nSalarius Pharmaceuticals Inc (NASDAQ:SLRX) has completed its pre-IND meeting process with the FDA for SP-3164, a targeted protein degrader inducing selective elimination of cancer-causing proteins. \nSalarius is developing SP-3164 as a potential treatment for hematological cancers and solid tumors.\nSalarius said it obtained valuable FDA input through the pre-IND meeting process that clarified preclinical, clinical, and other regulatory matters for preparing and submitting an IND. \nSalarius plans to submit an IND in 2023 and initiate the first clinical trial.\nShares are surging 56.3% at 25 cents during the premarket session.\nRelated: Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates\nLannett, Areva Pharma Ink US Distribution Pact For Leukemia Med\nLannett Company Inc (NYSE:LCI) entered into an agreement with Areva Pharmaceuticals to be the exclusive the U.S. distributor of fludarabine phosphate for Injection, USP, 50 mg/2mL, single-dose vials.\nFludarabine phosphate injection is indicated for B-cell chronic lymphocytic leukemia patients who have not responded to or whose disease has progressed during treatment.\nThe product generated annual sales of $4.9 million. According to IQVIA, the current market value is believed to be higher due to the recent market disruptions.\nUnder the agreement, Lannett will receive a share of the profits. Other financial terms were not disclosed.\nMediWound Posts Promising EscharEx Data For Chronic Wounds\nMediWound Ltd (NASDAQ:MDWD) has announced results from its U.S. Phase 2 clinical study of EscharEx for the debridement of venous leg ulcers. \nThe study met its primary and secondary endpoints and wound closure safety measurements. \nThe study demonstrated that patients treated with EscharEx had a statistically significant higher incidence of complete debridement during the 14-day measurement period within up to eight applications than gel vehicle (EscharEx: 63%) vs. gel vehicle: 30%. \nShares are up 10% at $1.98 during the premarket session.\nMoonLake Immunotherapeutics Kickstarts Phase 2 Trial Of Nanobody Sonelokimab In Chronic Skin Disorder\nMoonLake Immunotherapeutics AG (NASDAQ:MLTX) has randomized and dosed the first patient in its Phase 2 trial of sonelokimab for moderate-to-severe hidradenitis suppurativa, a chronic skin condition.\nThe MIRA trial will evaluate the efficacy and safety of different doses of sonelokimab, compared with placebo, with adalimumab as an active control reference arm in over 200 patients.\nIPOs\nIntrinsic Medicine Inc (NASDAQ:INRX) has filed with the SEC regarding an initial public offering of 4.12 million shares.\nThe company expects to price the offering between $5 and $7 per share.\nOfferings\nPalatin Technologies Inc (NYSE:PTN) will sell 8.1 million shares of its Series B and 900,000 shares of its Series C convertible redeemable preferred stock for gross proceeds of $15 million.\nEach share of Series B and Series C preferred stock has a purchase price of $1.67 and is convertible at an initial conversion price of 45 cents per share. \nShares are slipping 2.79% at 32 cents during premarket trading.\nOn The Radar\nStock Split\nRockwell Medical Inc (NASDAQ:RMTI) has approved a 1-for-11 reverse split, effective Friday at 12:01 a.m. eastern time.\nEarnings\nThe earnings list presented is not comprehensive. Click here to access Benzinga's earnings calendar for the complete schedule.\nX4 Pharmaceuticals Inc (NASDAQ:XFOR): Before Market Open.\nDare Bioscience Inc (NASDAQ:DARE): Before Market Open.\nMatinas BioPharma Holdings Inc (NYSE:MTNB): Before Market Open.\nOrchard Therapeutics PLC (NASDAQ:ORTX): Before Market Open.\nAltimmune Inc (NASDAQ:ALT): Before Market Open.\nSCYNEXIS Inc (NASDAQ:SCYX): Before Market Open.\nZealand Pharma A/S (NASDAQ:ZEAL): Before Market Open.\nVeru Inc (NASDAQ:VERU): Before Market Open.\nBrickell Biotech Inc (NASDAQ:BBI): After Market Close.\nSpectrum Pharmaceuticals Inc (NASDAQ:SPPI): After Market Close.\nRegulus Therapeutics Inc (NASDAQ:RGLS): After Market Close.\nIbio Inc (NYSE:IBIO): After Market Close.\nSalarius Pharmaceuticals Inc (NASDAQ:SLRX): After Market Close.\nCymaBay Therapeutics Inc (NASDAQ:CBAY): After Market Close.\nMarinus Pharmaceuticals Inc (NASDAQ:MRNS): After Market Close.\nOpGen Inc (NASDAQ:OPGN): After Market Close.\nLineage Cell Therapeutics Inc (NYSE:LCTX): After Market Close.","news_type":1},"isVote":1,"tweetType":1,"viewCount":226,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9046290909,"gmtCreate":1656347399401,"gmtModify":1676535810846,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Take note on this annoucement ....","listText":"Take note on this annoucement ....","text":"Take note on this annoucement ....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9046290909","repostId":"2245051233","repostType":2,"repost":{"id":"2245051233","kind":"highlight","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1655816632,"share":"https://ttm.financial/m/news/2245051233?lang=&edition=fundamental","pubTime":"2022-06-21 21:03","market":"hk","language":"en","title":"The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2245051233","media":"Benzinga","summary":"Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:","content":"<html><body><p>Here's a roundup of top developments in the biotech space over the last 24 hours:</p>\n<h1>Stocks In Focus</h1>\n<h1>FDA AdComm Gives Thumbs Down To Acadia's Pimavanserin</h1>\n<p>A panel of the FDA's outside experts voted 9-3 that <strong>Acadia Pharmaceuticals Inc's</strong> (NASDAQ:ACAD) pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis.</p>\n<p>The drug, Nuplazid, is already indicated for Parkinson's-related psychosis.</p>\n<p>Acadia tried and failed last year to get another FDA approval for Alzheimer's psychosis. </p>\n<p>Shares are down 32.29% at $13.25 during the premarket session.</p>\n<h1>AstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial</h1>\n<p><strong>AstraZeneca plc</strong> (NASDAQ:AZN) and partner <strong>Ionis Pharmaceuticals Inc</strong> (NASDAQ:IONS) announced a positive interim analysis of eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).</p>\n<p>In Phase 3 NEURO-TTRansform study, eplontersen met the main goals.</p>\n<p>Eplontersen also showed significantly improved patient-reported quality of life versus the historical placebo group.</p>\n<h1>Pharma Giant Pfizer Buys 8% Stake In Valneva</h1>\n<p><strong>Pfizer Inc</strong> (NYSE:PFE) will invest €90.5 million ($95 million) for an 8.1% stake in <strong><a href=\"https://laohu8.com/S/VNVLF\">Valneva SE</a></strong> (NASDAQ:VALN), as the companies updated the terms of agreement for Lyme disease vaccine candidate VLA15.</p>\n<p>Under the revised deal, Valneva will now fund 40% of the remaining shared development costs, compared to 30% before.</p>\n<p>Pfizer will pay Valneva tiered royalties ranging from 14% to 22%. In addition, the royalties will be complemented by up to $100 million in milestones payable to Valneva based on cumulative sales.</p>\n<p>VALN shares are up 85% at $25.40 during the premarket session.</p>\n<h1>Recursion Pharma Starts Late-Stage Brain Cancer Trial Of REC-2282 </h1>\n<p><strong>Recursion Pharmaceuticals Inc</strong> (NASDAQ:RXRX) initiated Phase 2/3 POPLAR-NF2 trial of REC-2282 for progressive neurofibromatosis type 2-mutated meningiomas, tumors that form on the membrane that covers the brain and spinal cord.</p>\n<p>The trial is designed to investigate the safety, efficacy, and pharmacokinetics of REC-2282. </p>\n<p>The study is expected to enroll approximately 90 participants.</p>\n<h1>Hepion Pharma's Liver Cancer Candidate Secures Orphan Drug Tag</h1>\n<p>The FDA has granted Orphan Drug Designation to <strong>Hepion Pharmaceuticals Inc's</strong> (NASDAQ:HEPA) rencofilstat, a liver-targeting, orally-administered, novel cyclophilin inhibitor for hepatocellular carcinoma.</p>\n<p>\"In addition to two Phase 2 studies in patients with NASH, we remain on track to initiate patient enrollment in a Phase 2a study of rencofilstat in HCC in the third quarter of 2022,\" said Robert Foster, Hepion's CEO.</p>\n<h1>Iktos, Zealand Pharma Ink AI Technology Pact For Peptide Drug Design</h1>\n<p><strong>Iktos</strong>, a specialized Artificial Intelligence company for new drug design, announced a research collaboration with <strong><a href=\"https://laohu8.com/S/ZEAL\">Zealand Pharma A/S</a></strong> (NASDAQ:ZEAL) to co-develop generative and predictive AI technologies for peptide drug design.</p>\n<p>Iktos' AI technology, based on a comprehensive data-driven chemical structure generation technology, automatically designs virtual novel molecules with all the characteristics of a successful drug molecule. </p>\n<h1>XBiotech Concludes Phase 1 Portion of Pancreatic Cancer Study</h1>\n<p><strong>XBiotech Inc</strong> (NASDAQ:XBIT) completed the Phase 1 portion of its 1-BETTER study, a Phase 1/2 to evaluate its anti-cancer drug Natrunix in combination with chemotherapy for pancreatic cancer. </p>\n<p>Enrollment in the Phase 2 portion is commencing immediately.</p>\n<p>Key endpoints in the Phase 2 portion will be progression-free survival, overall survival, and time-to-treatment-failure. </p>\n<p>The Phase 2 portion is enrolling 60 subjects.</p>\n<h1>Midatech Pharma's Pediatric Brain Cancer Candidate Gets Orphan Drug Status In Europe</h1>\n<p>The European Medicines Agency has granted orphan drug designation to <strong><a href=\"https://laohu8.com/S/MTP\">Midatech Pharma PLC</a>'s</strong> (NASDAQ:MTP) MTX110 for glioma.</p>\n<p>Midatech has been developing MTX110 for recurrent glioblastoma in adult patients and diffuse intrinsic pontine glioma and medulloblastoma in pediatric patients.</p>\n<h1>Edgewise's Dystrophy Candidate Lowers Muscle Damage Biomarkers</h1>\n<p><strong>Edgewise Therapeutics Inc</strong> (NASDAQ:EWTX) announced 2-month interim results from the ARCH study of EDG-5506 in adults with Becker Muscular Dystrophy. </p>\n<p>EDG-5506 at 10 mg showed a significant decrease in key biomarkers of muscle damage. Notably, creatine kinase and fast skeletal muscle troponin I were reduced by an average of 30% and 68%, respectively.</p>\n<p>All patients have subsequently been dose-escalated to 15 mg daily as per protocol.</p>\n<h3>Clinical Readouts/Presentations</h3>\n<p><strong>Krystal Biotech Inc</strong> (NASDAQ:KRYS): Phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), topical gene therapy for dystrophic epidermolysis bullosa at the Society for Investigative Dermatology 2022 Annual Meeting.</p>\n<p><strong>Aura Biosciences Inc</strong> (NASDAQ:AURA): Final safety and efficacy data from phase 1b/2 trial of AU-011 for choroidal melanoma via intravitreal administration at the International Society of Ocular Oncology.</p>\n<h3>On The Radar</h3>\n<h3>Earnings</h3>\n<p><strong><a href=\"https://laohu8.com/S/ACST\">Acasti Pharma</a> Inc</strong> (NASDAQ:ACST): Before the market open.</p>\n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-06-21 21:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Here's a roundup of top developments in the biotech space over the last 24 hours:</p>\n<h1>Stocks In Focus</h1>\n<h1>FDA AdComm Gives Thumbs Down To Acadia's Pimavanserin</h1>\n<p>A panel of the FDA's outside experts voted 9-3 that <strong>Acadia Pharmaceuticals Inc's</strong> (NASDAQ:ACAD) pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis.</p>\n<p>The drug, Nuplazid, is already indicated for Parkinson's-related psychosis.</p>\n<p>Acadia tried and failed last year to get another FDA approval for Alzheimer's psychosis. </p>\n<p>Shares are down 32.29% at $13.25 during the premarket session.</p>\n<h1>AstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial</h1>\n<p><strong>AstraZeneca plc</strong> (NASDAQ:AZN) and partner <strong>Ionis Pharmaceuticals Inc</strong> (NASDAQ:IONS) announced a positive interim analysis of eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).</p>\n<p>In Phase 3 NEURO-TTRansform study, eplontersen met the main goals.</p>\n<p>Eplontersen also showed significantly improved patient-reported quality of life versus the historical placebo group.</p>\n<h1>Pharma Giant Pfizer Buys 8% Stake In Valneva</h1>\n<p><strong>Pfizer Inc</strong> (NYSE:PFE) will invest €90.5 million ($95 million) for an 8.1% stake in <strong><a href=\"https://laohu8.com/S/VNVLF\">Valneva SE</a></strong> (NASDAQ:VALN), as the companies updated the terms of agreement for Lyme disease vaccine candidate VLA15.</p>\n<p>Under the revised deal, Valneva will now fund 40% of the remaining shared development costs, compared to 30% before.</p>\n<p>Pfizer will pay Valneva tiered royalties ranging from 14% to 22%. In addition, the royalties will be complemented by up to $100 million in milestones payable to Valneva based on cumulative sales.</p>\n<p>VALN shares are up 85% at $25.40 during the premarket session.</p>\n<h1>Recursion Pharma Starts Late-Stage Brain Cancer Trial Of REC-2282 </h1>\n<p><strong>Recursion Pharmaceuticals Inc</strong> (NASDAQ:RXRX) initiated Phase 2/3 POPLAR-NF2 trial of REC-2282 for progressive neurofibromatosis type 2-mutated meningiomas, tumors that form on the membrane that covers the brain and spinal cord.</p>\n<p>The trial is designed to investigate the safety, efficacy, and pharmacokinetics of REC-2282. </p>\n<p>The study is expected to enroll approximately 90 participants.</p>\n<h1>Hepion Pharma's Liver Cancer Candidate Secures Orphan Drug Tag</h1>\n<p>The FDA has granted Orphan Drug Designation to <strong>Hepion Pharmaceuticals Inc's</strong> (NASDAQ:HEPA) rencofilstat, a liver-targeting, orally-administered, novel cyclophilin inhibitor for hepatocellular carcinoma.</p>\n<p>\"In addition to two Phase 2 studies in patients with NASH, we remain on track to initiate patient enrollment in a Phase 2a study of rencofilstat in HCC in the third quarter of 2022,\" said Robert Foster, Hepion's CEO.</p>\n<h1>Iktos, Zealand Pharma Ink AI Technology Pact For Peptide Drug Design</h1>\n<p><strong>Iktos</strong>, a specialized Artificial Intelligence company for new drug design, announced a research collaboration with <strong><a href=\"https://laohu8.com/S/ZEAL\">Zealand Pharma A/S</a></strong> (NASDAQ:ZEAL) to co-develop generative and predictive AI technologies for peptide drug design.</p>\n<p>Iktos' AI technology, based on a comprehensive data-driven chemical structure generation technology, automatically designs virtual novel molecules with all the characteristics of a successful drug molecule. </p>\n<h1>XBiotech Concludes Phase 1 Portion of Pancreatic Cancer Study</h1>\n<p><strong>XBiotech Inc</strong> (NASDAQ:XBIT) completed the Phase 1 portion of its 1-BETTER study, a Phase 1/2 to evaluate its anti-cancer drug Natrunix in combination with chemotherapy for pancreatic cancer. </p>\n<p>Enrollment in the Phase 2 portion is commencing immediately.</p>\n<p>Key endpoints in the Phase 2 portion will be progression-free survival, overall survival, and time-to-treatment-failure. </p>\n<p>The Phase 2 portion is enrolling 60 subjects.</p>\n<h1>Midatech Pharma's Pediatric Brain Cancer Candidate Gets Orphan Drug Status In Europe</h1>\n<p>The European Medicines Agency has granted orphan drug designation to <strong><a href=\"https://laohu8.com/S/MTP\">Midatech Pharma PLC</a>'s</strong> (NASDAQ:MTP) MTX110 for glioma.</p>\n<p>Midatech has been developing MTX110 for recurrent glioblastoma in adult patients and diffuse intrinsic pontine glioma and medulloblastoma in pediatric patients.</p>\n<h1>Edgewise's Dystrophy Candidate Lowers Muscle Damage Biomarkers</h1>\n<p><strong>Edgewise Therapeutics Inc</strong> (NASDAQ:EWTX) announced 2-month interim results from the ARCH study of EDG-5506 in adults with Becker Muscular Dystrophy. </p>\n<p>EDG-5506 at 10 mg showed a significant decrease in key biomarkers of muscle damage. Notably, creatine kinase and fast skeletal muscle troponin I were reduced by an average of 30% and 68%, respectively.</p>\n<p>All patients have subsequently been dose-escalated to 15 mg daily as per protocol.</p>\n<h3>Clinical Readouts/Presentations</h3>\n<p><strong>Krystal Biotech Inc</strong> (NASDAQ:KRYS): Phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), topical gene therapy for dystrophic epidermolysis bullosa at the Society for Investigative Dermatology 2022 Annual Meeting.</p>\n<p><strong>Aura Biosciences Inc</strong> (NASDAQ:AURA): Final safety and efficacy data from phase 1b/2 trial of AU-011 for choroidal melanoma via intravitreal administration at the International Society of Ocular Oncology.</p>\n<h3>On The Radar</h3>\n<h3>Earnings</h3>\n<p><strong><a href=\"https://laohu8.com/S/ACST\">Acasti Pharma</a> Inc</strong> (NASDAQ:ACST): Before the market open.</p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AURA":"Aura Biosciences, Inc.","BK4581":"高盛持仓","AKR":"阿卡迪亚房地产信托","BK4534":"瑞士信贷持仓","RXRX":"Recursion Pharmaceuticals, Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","VALN":"Valneva SE","BK4007":"制药","ACAD":"阿卡迪亚","BK4080":"零售业房地产投资信托","AZN":"阿斯利康","ZEAL":"Zealand Pharma A/S","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","HEPA":"Hepion Pharmaceuticals, Inc.","XBIT":"XBiotech Inc.","PFE":"辉瑞","KRYS":"Krystal Biotech Inc.","IBB":"生物科技指数ETF-iShares Nasdaq","EWTX":"Edgewise Therapeutics, Inc.","IONS":"Ionis Pharmaceuticals, Inc"},"source_url":"https://www.benzinga.com/general/biotech/22/06/27792486/the-daily-biotech-pulse-thumbs-down-for-acadias-pimavanserin-pfizer-buys-stake-in-valneva-astraze","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2245051233","content_text":"Here's a roundup of top developments in the biotech space over the last 24 hours:\nStocks In Focus\nFDA AdComm Gives Thumbs Down To Acadia's Pimavanserin\nA panel of the FDA's outside experts voted 9-3 that Acadia Pharmaceuticals Inc's (NASDAQ:ACAD) pimavanserin doesn't appear to be effective at treating patients with Alzheimer's-related psychosis.\nThe drug, Nuplazid, is already indicated for Parkinson's-related psychosis.\nAcadia tried and failed last year to get another FDA approval for Alzheimer's psychosis. \nShares are down 32.29% at $13.25 during the premarket session.\nAstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial\nAstraZeneca plc (NASDAQ:AZN) and partner Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced a positive interim analysis of eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).\nIn Phase 3 NEURO-TTRansform study, eplontersen met the main goals.\nEplontersen also showed significantly improved patient-reported quality of life versus the historical placebo group.\nPharma Giant Pfizer Buys 8% Stake In Valneva\nPfizer Inc (NYSE:PFE) will invest €90.5 million ($95 million) for an 8.1% stake in Valneva SE (NASDAQ:VALN), as the companies updated the terms of agreement for Lyme disease vaccine candidate VLA15.\nUnder the revised deal, Valneva will now fund 40% of the remaining shared development costs, compared to 30% before.\nPfizer will pay Valneva tiered royalties ranging from 14% to 22%. In addition, the royalties will be complemented by up to $100 million in milestones payable to Valneva based on cumulative sales.\nVALN shares are up 85% at $25.40 during the premarket session.\nRecursion Pharma Starts Late-Stage Brain Cancer Trial Of REC-2282 \nRecursion Pharmaceuticals Inc (NASDAQ:RXRX) initiated Phase 2/3 POPLAR-NF2 trial of REC-2282 for progressive neurofibromatosis type 2-mutated meningiomas, tumors that form on the membrane that covers the brain and spinal cord.\nThe trial is designed to investigate the safety, efficacy, and pharmacokinetics of REC-2282. \nThe study is expected to enroll approximately 90 participants.\nHepion Pharma's Liver Cancer Candidate Secures Orphan Drug Tag\nThe FDA has granted Orphan Drug Designation to Hepion Pharmaceuticals Inc's (NASDAQ:HEPA) rencofilstat, a liver-targeting, orally-administered, novel cyclophilin inhibitor for hepatocellular carcinoma.\n\"In addition to two Phase 2 studies in patients with NASH, we remain on track to initiate patient enrollment in a Phase 2a study of rencofilstat in HCC in the third quarter of 2022,\" said Robert Foster, Hepion's CEO.\nIktos, Zealand Pharma Ink AI Technology Pact For Peptide Drug Design\nIktos, a specialized Artificial Intelligence company for new drug design, announced a research collaboration with Zealand Pharma A/S (NASDAQ:ZEAL) to co-develop generative and predictive AI technologies for peptide drug design.\nIktos' AI technology, based on a comprehensive data-driven chemical structure generation technology, automatically designs virtual novel molecules with all the characteristics of a successful drug molecule. \nXBiotech Concludes Phase 1 Portion of Pancreatic Cancer Study\nXBiotech Inc (NASDAQ:XBIT) completed the Phase 1 portion of its 1-BETTER study, a Phase 1/2 to evaluate its anti-cancer drug Natrunix in combination with chemotherapy for pancreatic cancer. \nEnrollment in the Phase 2 portion is commencing immediately.\nKey endpoints in the Phase 2 portion will be progression-free survival, overall survival, and time-to-treatment-failure. \nThe Phase 2 portion is enrolling 60 subjects.\nMidatech Pharma's Pediatric Brain Cancer Candidate Gets Orphan Drug Status In Europe\nThe European Medicines Agency has granted orphan drug designation to Midatech Pharma PLC's (NASDAQ:MTP) MTX110 for glioma.\nMidatech has been developing MTX110 for recurrent glioblastoma in adult patients and diffuse intrinsic pontine glioma and medulloblastoma in pediatric patients.\nEdgewise's Dystrophy Candidate Lowers Muscle Damage Biomarkers\nEdgewise Therapeutics Inc (NASDAQ:EWTX) announced 2-month interim results from the ARCH study of EDG-5506 in adults with Becker Muscular Dystrophy. \nEDG-5506 at 10 mg showed a significant decrease in key biomarkers of muscle damage. Notably, creatine kinase and fast skeletal muscle troponin I were reduced by an average of 30% and 68%, respectively.\nAll patients have subsequently been dose-escalated to 15 mg daily as per protocol.\nClinical Readouts/Presentations\nKrystal Biotech Inc (NASDAQ:KRYS): Phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), topical gene therapy for dystrophic epidermolysis bullosa at the Society for Investigative Dermatology 2022 Annual Meeting.\nAura Biosciences Inc (NASDAQ:AURA): Final safety and efficacy data from phase 1b/2 trial of AU-011 for choroidal melanoma via intravitreal administration at the International Society of Ocular Oncology.\nOn The Radar\nEarnings\nAcasti Pharma Inc (NASDAQ:ACST): Before the market open.","news_type":1},"isVote":1,"tweetType":1,"viewCount":349,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9048728924,"gmtCreate":1656265327968,"gmtModify":1676535794397,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Temporary rebound?","listText":"Temporary rebound?","text":"Temporary rebound?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048728924","repostId":"9043148558","repostType":1,"repost":{"id":9043148558,"gmtCreate":1655896321516,"gmtModify":1676535727543,"author":{"id":"3448793367875557","authorId":"3448793367875557","name":"TechnicalHunter","avatar":"https://static.tigerbbs.com/20616c062c392e47ee8fc9107f46437d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3448793367875557","authorIdStr":"3448793367875557"},"themes":[],"title":"Market Still in Extremely Fear: 10 Indicators to Check Bottom Reverse","htmlText":"Wednesday's rise of US stocks seemed to make people forget the suffering of the bear market.&nbsp;<a href=\"https://laohu8.com/S/.DJI\">$DJIA(.DJI)$</a> ,<a href=\"https://laohu8.com/S/.IXIC\">$NASDAQ(.IXIC)$</a> ,<a href=\"https://laohu8.com/S/.SPX\">$S&amp;P 500(.SPX)$</a>.Various indexes rose, with clean green energy ranking the first&nbsp;rise&nbsp;for 3,52%.Meanwhile, the&nbsp;CBOE Volatility Index VIX also rose 3.51% to 31.According to the CNN' Fear and Greed Index, the current market sentiment is Extreme Fear.This&nbsp;may&nbsp;indicates&nbsp;that&nbsp;the market is still very pessimistic, and the US stock market seems to have not hit the bottom under the expectation of depression and inflation.Yesterday, I shared two indicators to confirm a bottom：","listText":"Wednesday's rise of US stocks seemed to make people forget the suffering of the bear market.&nbsp;<a href=\"https://laohu8.com/S/.DJI\">$DJIA(.DJI)$</a> ,<a href=\"https://laohu8.com/S/.IXIC\">$NASDAQ(.IXIC)$</a> ,<a href=\"https://laohu8.com/S/.SPX\">$S&amp;P 500(.SPX)$</a>.Various indexes rose, with clean green energy ranking the first&nbsp;rise&nbsp;for 3,52%.Meanwhile, the&nbsp;CBOE Volatility Index VIX also rose 3.51% to 31.According to the CNN' Fear and Greed Index, the current market sentiment is Extreme Fear.This&nbsp;may&nbsp;indicates&nbsp;that&nbsp;the market is still very pessimistic, and the US stock market seems to have not hit the bottom under the expectation of depression and inflation.Yesterday, I shared two indicators to confirm a bottom：","text":"Wednesday's rise of US stocks seemed to make people forget the suffering of the bear market. $DJIA(.DJI)$ ,$NASDAQ(.IXIC)$ ,$S&P 500(.SPX)$.Various indexes rose, with clean green energy ranking the first rise for 3,52%.Meanwhile, the CBOE Volatility Index VIX also rose 3.51% to 31.According to the CNN' Fear and Greed Index, the current market sentiment is Extreme Fear.This may indicates that the market is still very pessimistic, and the US stock market seems to have not hit the bottom under the expectation of depression and inflation.Yesterday, I shared two indicators to confirm a bottom：","images":[{"img":"https://community-static.tradeup.com/news/4af4e811ad58ad89109caf1c27062945","width":"1266","height":"614"},{"img":"https://community-static.tradeup.com/news/41ab286d3d014c9ef6dfa81b6f06761a","width":"643","height":"424"},{"img":"https://community-static.tradeup.com/news/e2573233433d5fdd69318ba55bfeecc0","width":"1170","height":"750"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9043148558","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":5,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":294,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9048660093,"gmtCreate":1656204784312,"gmtModify":1676535783561,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Great to know","listText":"Great to know","text":"Great to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9048660093","repostId":"2245253007","repostType":2,"repost":{"id":"2245253007","kind":"highlight","pubTimestamp":1655833200,"share":"https://ttm.financial/m/news/2245253007?lang=&edition=fundamental","pubTime":"2022-06-22 01:40","market":"us","language":"en","title":"Best Penny Stocks to Buy This Week? 3 to Watch as June Ends","url":"https://stock-news.laohu8.com/highlight/detail?id=2245253007","media":"StreetInsider","summary":"3 Penny Stocks to Add to Your End of June Watchlist Finding penny stocks that are worth buying right","content":"<html><body><div>\n<p><b>3 Penny Stocks to Add to Your End of June Watchlist </b></p><p>Finding penny stocks that are worth buying right now can be challenging. With so much volatility in the stock market, investors need to have a thorough understanding of exactly what is going on. This is the best and only way that traders can have a heightened chance of making money with penny stocks. </p><p>Despite today being highly bullish for penny stocks and blue chips, we continue to see extremely high volatility. In addition to all of this, investors have to consider what is going on at large, and then use that in their trading strategies. Today is a perfect example of just how volatile the stock market is. </p><p><strong>[Read More]</strong> 3 Hot Penny Stocks To Watch After Big News This Week</p><p>With the S&amp;P 500 jumping by over 2% during trading today represents the large jumps that investors can use to profit. In addition to all of this, many investors believe that we could be entering into a recession given the official bear market that we are witnessing right now. Regardless, it all comes down to knowing how and where to find value with penny stocks. So, with this in mind, let's take a look at three that could be worth watching right now. </p><p><b>3 Penny Stocks to Watch Right Now </b></p><ol><li><a href=\"https://laohu8.com/S/CLVS\">Clovis Oncology</a> Inc. (NASDAQ: CLVS) </li><li><a href=\"https://laohu8.com/S/MULN\">Mullen Automotive</a> Inc. (NASDAQ: MULN)</li><li>Blacksky Technology Inc. (NYSE: BKSY)</li></ol><p><b>Clovis Oncology Inc. (NASDAQ: CLVS) </b></p><p>One of the largest gainers on June 21st and in quite some time is CLVS stock. At midday, shares of CLVS stock had shot up by a staggering 67%. This is a major gain and <a href=\"https://laohu8.com/S/AONE.U\">one</a> that adds to its five day gain of 122%. So, why are shares of CLVS stock exploding right now? The main reason comes as the company announced positive results from its interim phase 1/2 clinical trial on June 14th. </p><p>While this was around a week ago, it is still causing a lasting positive effect, especially considering the bullishness in the stock market right now. The drug in question is FAP-2286, which showed no adverse side effects causing withdrawal from the study. Currently, Clovis has an approved product known as Rubraca, which is a therapy for certain cancers including ovarian and prostate, but, the company has not yet seen a financial benefit from this. </p><p>But, the recent volatility in the biotech sector has been a major boost for CLVS stock, leading to its recent bullish uptick. Now, keep in mind that CLVS is highly volatile and continues to show just how much it can fluctuate. But, if you're looking for a penny stock that is making large moves, CLVS could be worth adding to your penny stocks watchlist. </p><div><figure><img height=\"450\" sizes=\"(max-width: 688px) 100vw, 688px\" src=\"https://pennystocks.com/wp-content/uploads/2022/06/Penny_Stocks_to_Watch_Clovis-Oncology-CLVS-Stock-Chart-2.jpg\" srcset=\"https://pennystocks.com/wp-content/uploads/2022/06/Penny_Stocks_to_Watch_Clovis-Oncology-CLVS-Stock-Chart-2.jpg 688w, https://pennystocks.com/wp-content/uploads/2022/06/Penny_Stocks_to_Watch_Clovis-Oncology-CLVS-Stock-Chart-2-300x196.jpg 300w\" width=\"688\"/></figure></div><p><b>Mereo BioPharma Group (NASDAQ: MREO)</b></p><p>Another big gainer on June 21st is MREO stock. At midday, shares of MREO stock had shot up by over 12%. While this is not as large of a gain as CLVS, it is still impressive and worth considering. And, in the past five days, we've seen shares of MREO stock shoot up by an explosive 149%. For that reason, today's uptick is likely the result of continued momentum following exciting news from last week. </p><p><strong>[Read More]</strong> Biotech Penny Stocks Investing Guide</p><p>The biggest news came on June 20th when the company announced that AstraZeneca could be interest in acquiring it. The company stated that AstraZeneca could accept the bid at $5 per share, which would bring it to a total price of $500 million. </p><p>While there is nothing set in stone, Mereo already has a partnership with AstraZeneca, where the former received exclusive global worldwide rights to alvelestat, which is a rare-disease candidate. So, although this deal is still very much in the works, it could be worth watching for the future. With this in mind, do you think MREO is worth adding to your list of penny stocks to buy. </p><div><figure><img height=\"450\" sizes=\"(max-width: 688px) 100vw, 688px\" src=\"https://pennystocks.com/wp-content/uploads/2022/06/Penny_Stocks_to_Watch_Mereo-BioPharma-MREO-Stock-Chart.jpg\" srcset=\"https://pennystocks.com/wp-content/uploads/2022/06/Penny_Stocks_to_Watch_Mereo-BioPharma-MREO-Stock-Chart.jpg 688w, https://pennystocks.com/wp-content/uploads/2022/06/Penny_Stocks_to_Watch_Mereo-BioPharma-MREO-Stock-Chart-300x196.jpg 300w\" width=\"688\"/></figure></div><p><b>Blacksky Technology Inc. (NYSE: BKSY) </b></p><p>With over 20% in gains on June 21st, BKSY stock is another penny stock that is seeing heightened popularity right now. And in the past five days, shares of BKSY stock have shot up by over 26%. If this seem like a lot, in the last month, we've seen BKSY stock climb by a very exciting, 93%.</p><p> So, in this time we have covered it many times. The main reason for its gain today comes as the company made an exciting announcement on June 21st that it was awarded a five-year joint artificial intelligence center contract for AI data readiness. </p><blockquote><p>\"With demonstrated AI expertise in space-based dynamic monitoring, this agreement will open even more doors for BlackSky to contribute its unique value to the diverse national security challenges faced by the wider DoD community. </p><p>From automatically tasking satellites to the low-latency delivery and analysis of high-frequency geospatial imagery and non-imagery data, our unique, data-rich platform brings a strong source of core AI-enabled end-to-end capabilities to the DoD's mission sets\"</p><cite>The Chief Innovation Officer for BlackSky, Patrick O'Neil</cite></blockquote><p>With this very exciting news considered, will BKSY be on your buy list today or not?</p><div><figure><img height=\"450\" sizes=\"(max-width: 688px) 100vw, 688px\" src=\"https://pennystocks.com/wp-content/uploads/2022/06/Penny_Stocks_to_Watch_Blacksky-BKSY-Stock-Chart.jpg\" srcset=\"https://pennystocks.com/wp-content/uploads/2022/06/Penny_Stocks_to_Watch_Blacksky-BKSY-Stock-Chart.jpg 688w, https://pennystocks.com/wp-content/uploads/2022/06/Penny_Stocks_to_Watch_Blacksky-BKSY-Stock-Chart-300x196.jpg 300w\" width=\"688\"/></figure></div><p><b>Which Penny Stocks Are on Your Watchlist Right Now?</b></p><p>Finding the best penny stocks to buy in 2022 is not easy. But, with careful research and a firm trading strategy, making a profit with small caps can be much easier than previously imagined. </p><p><strong>[Read More]</strong> 3 Tips and Tricks for Buying Penny Stocks in June</p><p>As mentioned earlier, right now, we have a sizable amount of volatility in the stock market. This means that traders need to stay on their toes and understand how to take advantage with every day's news. Considering all of this, which penny stocks are on your watchlist right now?</p><pre><code>[reblex id='29520']</code></pre>\n<img height=\"1\" src=\"https://prt.comtex.com/prt.php?ContentID=409015772&amp;SourceID=2685&amp;EndPointID=4090&amp;DateTime=2022-06-21T13:36:16&amp;Headline=Best%2520Penny%2520Stocks%2520to%2520Buy%2520This%2520Week?%25203%2520to%2520Watch%2520as%2520June%2520Ends\" width=\"865\"/><p>COMTEX_409015772/2685/2022-06-21T13:36:16</p> </div></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Best Penny Stocks to Buy This Week? 3 to Watch as June Ends</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBest Penny Stocks to Buy This Week? 3 to Watch as June Ends\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-22 01:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20237132><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3 Penny Stocks to Add to Your End of June Watchlist Finding penny stocks that are worth buying right now can be challenging. With so much volatility in the stock market, investors need to have a ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20237132\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4167":"医疗保健技术","HCTI":"Healthcare Triangle, Inc.","BK4123":"调查和咨询服务","CLVS":"Clovis Oncology","BKSY":"BlackSky Technology Inc.","BK4505":"高瓴资本持仓","TERN":"Terns Pharmaceuticals, Inc.","MREO":"Mereo Biopharma Group Plc","BK4209":"餐馆","BK4099":"汽车制造商","BK4183":"个人用品","CRCT":"Cricut, Inc.","FWRG":"First Watch Restaurant Group, Inc.","OLPX":"Olaplex Holdings, Inc.","BK4539":"次新股","MULN":"Mullen Automotive","BK4191":"家用电器","BK4139":"生物科技","BK4007":"制药"},"source_url":"https://www.streetinsider.com/dr/news.php?id=20237132","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2245253007","content_text":"3 Penny Stocks to Add to Your End of June Watchlist Finding penny stocks that are worth buying right now can be challenging. With so much volatility in the stock market, investors need to have a thorough understanding of exactly what is going on. This is the best and only way that traders can have a heightened chance of making money with penny stocks. Despite today being highly bullish for penny stocks and blue chips, we continue to see extremely high volatility. In addition to all of this, investors have to consider what is going on at large, and then use that in their trading strategies. Today is a perfect example of just how volatile the stock market is. [Read More] 3 Hot Penny Stocks To Watch After Big News This WeekWith the S&P 500 jumping by over 2% during trading today represents the large jumps that investors can use to profit. In addition to all of this, many investors believe that we could be entering into a recession given the official bear market that we are witnessing right now. Regardless, it all comes down to knowing how and where to find value with penny stocks. So, with this in mind, let's take a look at three that could be worth watching right now. 3 Penny Stocks to Watch Right Now Clovis Oncology Inc. (NASDAQ: CLVS) Mullen Automotive Inc. (NASDAQ: MULN)Blacksky Technology Inc. (NYSE: BKSY)Clovis Oncology Inc. (NASDAQ: CLVS) One of the largest gainers on June 21st and in quite some time is CLVS stock. At midday, shares of CLVS stock had shot up by a staggering 67%. This is a major gain and one that adds to its five day gain of 122%. So, why are shares of CLVS stock exploding right now? The main reason comes as the company announced positive results from its interim phase 1/2 clinical trial on June 14th. While this was around a week ago, it is still causing a lasting positive effect, especially considering the bullishness in the stock market right now. The drug in question is FAP-2286, which showed no adverse side effects causing withdrawal from the study. Currently, Clovis has an approved product known as Rubraca, which is a therapy for certain cancers including ovarian and prostate, but, the company has not yet seen a financial benefit from this. But, the recent volatility in the biotech sector has been a major boost for CLVS stock, leading to its recent bullish uptick. Now, keep in mind that CLVS is highly volatile and continues to show just how much it can fluctuate. But, if you're looking for a penny stock that is making large moves, CLVS could be worth adding to your penny stocks watchlist. Mereo BioPharma Group (NASDAQ: MREO)Another big gainer on June 21st is MREO stock. At midday, shares of MREO stock had shot up by over 12%. While this is not as large of a gain as CLVS, it is still impressive and worth considering. And, in the past five days, we've seen shares of MREO stock shoot up by an explosive 149%. For that reason, today's uptick is likely the result of continued momentum following exciting news from last week. [Read More] Biotech Penny Stocks Investing GuideThe biggest news came on June 20th when the company announced that AstraZeneca could be interest in acquiring it. The company stated that AstraZeneca could accept the bid at $5 per share, which would bring it to a total price of $500 million. While there is nothing set in stone, Mereo already has a partnership with AstraZeneca, where the former received exclusive global worldwide rights to alvelestat, which is a rare-disease candidate. So, although this deal is still very much in the works, it could be worth watching for the future. With this in mind, do you think MREO is worth adding to your list of penny stocks to buy. Blacksky Technology Inc. (NYSE: BKSY) With over 20% in gains on June 21st, BKSY stock is another penny stock that is seeing heightened popularity right now. And in the past five days, shares of BKSY stock have shot up by over 26%. If this seem like a lot, in the last month, we've seen BKSY stock climb by a very exciting, 93%. So, in this time we have covered it many times. The main reason for its gain today comes as the company made an exciting announcement on June 21st that it was awarded a five-year joint artificial intelligence center contract for AI data readiness. \"With demonstrated AI expertise in space-based dynamic monitoring, this agreement will open even more doors for BlackSky to contribute its unique value to the diverse national security challenges faced by the wider DoD community. From automatically tasking satellites to the low-latency delivery and analysis of high-frequency geospatial imagery and non-imagery data, our unique, data-rich platform brings a strong source of core AI-enabled end-to-end capabilities to the DoD's mission sets\"The Chief Innovation Officer for BlackSky, Patrick O'NeilWith this very exciting news considered, will BKSY be on your buy list today or not?Which Penny Stocks Are on Your Watchlist Right Now?Finding the best penny stocks to buy in 2022 is not easy. But, with careful research and a firm trading strategy, making a profit with small caps can be much easier than previously imagined. [Read More] 3 Tips and Tricks for Buying Penny Stocks in JuneAs mentioned earlier, right now, we have a sizable amount of volatility in the stock market. This means that traders need to stay on their toes and understand how to take advantage with every day's news. Considering all of this, which penny stocks are on your watchlist right now?[reblex id='29520']\nCOMTEX_409015772/2685/2022-06-21T13:36:16","news_type":1},"isVote":1,"tweetType":1,"viewCount":425,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9041529782,"gmtCreate":1656077216446,"gmtModify":1676535763271,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a>For long run..predict will reach $100 end of the year.","listText":"<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a>For long run..predict will reach $100 end of the year.","text":"$Pfizer(PFE)$For long run..predict will reach $100 end of the year.","images":[{"img":"https://community-static.tradeup.com/news/e0ee129e64fa9efd9910cb6dc909cec1","width":"1242","height":"3104"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9041529782","isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9041520405,"gmtCreate":1656077062807,"gmtModify":1676535763248,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GRAB\">$Grab Holdings(GRAB)$</a>Today sure flying...$3.50if I am right","listText":"<a href=\"https://ttm.financial/S/GRAB\">$Grab Holdings(GRAB)$</a>Today sure flying...$3.50if I am right","text":"$Grab Holdings(GRAB)$Today sure flying...$3.50if I am right","images":[{"img":"https://community-static.tradeup.com/news/bbbb08cbc9a9e24d569c0b69dfa86db5","width":"1242","height":"2834"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9041520405","isVote":1,"tweetType":1,"viewCount":314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":9020073036,"gmtCreate":1652544693625,"gmtModify":1676535118868,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"If the battery got the quality to help sustain the company.Why not we pump in and hold it for a long term invest?","listText":"If the battery got the quality to help sustain the company.Why not we pump in and hold it for a long term invest?","text":"If the battery got the quality to help sustain the company.Why not we pump in and hold it for a long term invest?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9020073036","repostId":"1103124585","repostType":4,"repost":{"id":"1103124585","kind":"news","pubTimestamp":1652489489,"share":"https://ttm.financial/m/news/1103124585?lang=&edition=fundamental","pubTime":"2022-05-14 08:51","market":"us","language":"en","title":"Did Rivian Just Spark a Huge Comeback for Electric Vehicle Stocks?","url":"https://stock-news.laohu8.com/highlight/detail?id=1103124585","media":"investorplace","summary":"They caught fire, paced by better-than-expected business updates from EV makers Lordstown Motors (Na","content":"<html><head></head><body><p>They caught fire, paced by better-than-expected business updates from EV makers Lordstown Motors (Nasdaq:RIDE) and Rivian (Nasdaq:RIVN). Most electric vehicle stocks popped more than 10% yesterday, with Lordstown rallying 50% and Rivian surging 21%.</p><p>To be sure, these huge rallies come on the heels of some major declines across the whole EV sector. Still, sales of electric vehicles across the globe continue to roar higher, and many of these companies are growing rapidly. This is all leading investors to ask: Is this the start of a major EV stock comeback?</p><p>We think it could be. Here’s why.</p><h2>Rivian and Lordstown Reestablish Confidence in Electric Vehicle Stocks</h2><p>EV stocks didn’t drop because electric vehicles stopped selling. Sales of electric vehicles in the U.S. in the first quarter of 2022 rose 60% year-over-year:</p><p>Yet EV stocks dropped big in early 2022. Amid persistent supply chain disruptions and parts shortages, investors lost confidence in major EV players’ ability to hit production targets.</p><p>But that confidence was reestablished yesterday, partly because of a positive business update from Lordstown. But it was mostly thanks to a great quarterly earnings report from Rivian.</p><p>Late Tuesday night, Lordstown said that it had closed the sales of one of its manufacturing facilities to Foxconn. The sale injects $230 million onto Lordstown’s balance sheets. That’s critical — Lordstown was on the cusp of running out of cash. But with this new capital infusion, the company now has enough liquidity to commence commercial production in quarter three.</p><p>In other words, Lordstown will hit its 2022 delivery targets — confidence reestablished.</p><p>Meanwhile, Rivian provided an excellent business update on Tuesday afternoon as well. The company said that despite huge supply chain challenges, it’s on track to hits its 25,000-vehicle production target for 2022. Pre-orders are also ramping nicely, with the latest number at 90,000 reservations.</p><p>In other words, Rivian will hit its 2022 delivery targets — confidence reestablished.</p><p>This confidence boost at two EV manufacturing startups was good enough to light a fire under the entire industry.</p><p>We don’t think that fire is going to die out anytime soon. We see electric vehicle stocks soaring from here into the end of the year.</p><h2>EV Stocks Are Wiped Out and Due for a Big Rebound</h2><p>Persistent supply chain concerns and fears about waning auto demand in a slowing economy have plagued the EV industry. And as such, electric vehicle stocks have been crushed so far in 2022.</p><p>Now, though, they’re completely washed out — and due for a big rebound rally.</p><p>Rivian, for example, was trading at 1X book value and 3X forward sales heading into its earnings report. That’s wild. This is a company that’s projected to grow sales by more than 3,000% this year, 250% in 2023, 110% the year after and 55% the year after that. And it was trading for just 1X book value and 3X forward sales!</p><p>Talk about a bargain.</p><p>But, as many seasoned investors will tell you, just because a stock is a bargain doesn’t mean it’s a buy. Cheap stocks can stay cheap for a long time. You need a catalyst to bring them back to life.</p><p>Well, yesterday, we got that catalyst.</p><p>EV makers — Rivian, in particular — are on track to hit 2022 targets, despite all the macroeconomic headwinds.</p><p>This confirmation catalyst converged on dirt-cheap valuations across the sector and sparked some huge rallies in EV stocks.</p><p>These rallies have some major runway ahead.</p><p>Indeed, we think Rivian stock can more than double from current levels in a hurry. But Rivian isn’t even our favorite stock to buy for this huge EV comeback.</p><h2>The Final Word on Electric Vehicle Stocks</h2><p>We believe that the company with the best battery technology is going to win the electric vehicle arms race.</p><p>After all, the quality of the battery determines everything about an EV. It dictates how far it can drive, how long it can last, how quickly it can recharge. The battery even affects how fast it can go.</p><p>When it comes to EVs, the battery is everything. Therefore, the company that makes the best EV battery will make the best EV — and sell the most. And ultimately, it will emerge the winner of the electric vehicle arms race.</p><p>Rivian makes a great battery. That’s why RIVN is a great EV stock to buy.</p><p>But Rivian doesn’t make the best battery.</p><p>Instead, that title is reserved for another tiny EV maker — one that could de-throne Tesla. And that company is the best EV stock to buy today.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Did Rivian Just Spark a Huge Comeback for Electric Vehicle Stocks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDid Rivian Just Spark a Huge Comeback for Electric Vehicle Stocks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-14 08:51 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/hypergrowthinvesting/2022/05/did-rivian-just-spark-a-huge-comeback-for-electric-vehicle-stocks/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>They caught fire, paced by better-than-expected business updates from EV makers Lordstown Motors (Nasdaq:RIDE) and Rivian (Nasdaq:RIVN). Most electric vehicle stocks popped more than 10% yesterday, ...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2022/05/did-rivian-just-spark-a-huge-comeback-for-electric-vehicle-stocks/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIVN":"Rivian Automotive, Inc."},"source_url":"https://investorplace.com/hypergrowthinvesting/2022/05/did-rivian-just-spark-a-huge-comeback-for-electric-vehicle-stocks/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103124585","content_text":"They caught fire, paced by better-than-expected business updates from EV makers Lordstown Motors (Nasdaq:RIDE) and Rivian (Nasdaq:RIVN). Most electric vehicle stocks popped more than 10% yesterday, with Lordstown rallying 50% and Rivian surging 21%.To be sure, these huge rallies come on the heels of some major declines across the whole EV sector. Still, sales of electric vehicles across the globe continue to roar higher, and many of these companies are growing rapidly. This is all leading investors to ask: Is this the start of a major EV stock comeback?We think it could be. Here’s why.Rivian and Lordstown Reestablish Confidence in Electric Vehicle StocksEV stocks didn’t drop because electric vehicles stopped selling. Sales of electric vehicles in the U.S. in the first quarter of 2022 rose 60% year-over-year:Yet EV stocks dropped big in early 2022. Amid persistent supply chain disruptions and parts shortages, investors lost confidence in major EV players’ ability to hit production targets.But that confidence was reestablished yesterday, partly because of a positive business update from Lordstown. But it was mostly thanks to a great quarterly earnings report from Rivian.Late Tuesday night, Lordstown said that it had closed the sales of one of its manufacturing facilities to Foxconn. The sale injects $230 million onto Lordstown’s balance sheets. That’s critical — Lordstown was on the cusp of running out of cash. But with this new capital infusion, the company now has enough liquidity to commence commercial production in quarter three.In other words, Lordstown will hit its 2022 delivery targets — confidence reestablished.Meanwhile, Rivian provided an excellent business update on Tuesday afternoon as well. The company said that despite huge supply chain challenges, it’s on track to hits its 25,000-vehicle production target for 2022. Pre-orders are also ramping nicely, with the latest number at 90,000 reservations.In other words, Rivian will hit its 2022 delivery targets — confidence reestablished.This confidence boost at two EV manufacturing startups was good enough to light a fire under the entire industry.We don’t think that fire is going to die out anytime soon. We see electric vehicle stocks soaring from here into the end of the year.EV Stocks Are Wiped Out and Due for a Big ReboundPersistent supply chain concerns and fears about waning auto demand in a slowing economy have plagued the EV industry. And as such, electric vehicle stocks have been crushed so far in 2022.Now, though, they’re completely washed out — and due for a big rebound rally.Rivian, for example, was trading at 1X book value and 3X forward sales heading into its earnings report. That’s wild. This is a company that’s projected to grow sales by more than 3,000% this year, 250% in 2023, 110% the year after and 55% the year after that. And it was trading for just 1X book value and 3X forward sales!Talk about a bargain.But, as many seasoned investors will tell you, just because a stock is a bargain doesn’t mean it’s a buy. Cheap stocks can stay cheap for a long time. You need a catalyst to bring them back to life.Well, yesterday, we got that catalyst.EV makers — Rivian, in particular — are on track to hit 2022 targets, despite all the macroeconomic headwinds.This confirmation catalyst converged on dirt-cheap valuations across the sector and sparked some huge rallies in EV stocks.These rallies have some major runway ahead.Indeed, we think Rivian stock can more than double from current levels in a hurry. But Rivian isn’t even our favorite stock to buy for this huge EV comeback.The Final Word on Electric Vehicle StocksWe believe that the company with the best battery technology is going to win the electric vehicle arms race.After all, the quality of the battery determines everything about an EV. It dictates how far it can drive, how long it can last, how quickly it can recharge. The battery even affects how fast it can go.When it comes to EVs, the battery is everything. Therefore, the company that makes the best EV battery will make the best EV — and sell the most. And ultimately, it will emerge the winner of the electric vehicle arms race.Rivian makes a great battery. That’s why RIVN is a great EV stock to buy.But Rivian doesn’t make the best battery.Instead, that title is reserved for another tiny EV maker — one that could de-throne Tesla. And that company is the best EV stock to buy today.","news_type":1},"isVote":1,"tweetType":1,"viewCount":187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9023805486,"gmtCreate":1652888237845,"gmtModify":1676535182072,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Its true..Everybody having higher cost of living.While company are incresing pay to employee,the cost also increase.","listText":"Its true..Everybody having higher cost of living.While company are incresing pay to employee,the cost also increase.","text":"Its true..Everybody having higher cost of living.While company are incresing pay to employee,the cost also increase.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9023805486","repostId":"1144253627","repostType":4,"repost":{"id":"1144253627","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1652880775,"share":"https://ttm.financial/m/news/1144253627?lang=&edition=fundamental","pubTime":"2022-05-18 21:32","market":"us","language":"en","title":"Dow Drops 300 Points, Its First Decline in 4 Days As Companies Warn of Rising Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=1144253627","media":"Tiger Newspress","summary":"U.S. stock futures fell on Wednesday morning after another major retailer warned of rising cost pressures, confirming the fears over inflation that have sent major benchmarks to big losses so far this","content":"<html><head></head><body><p>U.S. stock futures fell on Wednesday morning after another major retailer warned of rising cost pressures, confirming the fears over inflation that have sent major benchmarks to big losses so far this year.</p><p>Futures for the Dow Jones Industrial Average shed 281 points, or 0.9%, with the average set for its first loss in four days. S&amp;P 500 futures traded 1.2% lower, while Nasdaq 100 futures slipped 1.5%.</p><p>Those losses come after a disappointing earnings report from Target. Shares tumbled more than 24% in premarket trading Wednesday after Targetreported first-quarter earnings that were much lower than Wall Street estimatedbecause of higher costs for fuel and compensation. The retailer also saw lower-than-expected sales for discretionary merchandise like TVs.</p><p>Target’s report comes right after Walmart on Tuesday posted earnings that fell short of expectations as it toocited higher fuel and labor costs. Walmart shares ended Tuesday lower by 11%. They were down another 2% in premarket trading Wednesday.</p><p>“Any company that relies on households and discretionary purchases will likely suffer this quarter because a lot of discretionary income has been funneled to food and energy prices,” said Jack Ablin, founding partner of Cresset Capital.</p><p>Other retailers took a hit on the back of Target’s quarterly earnings miss, with the SPDR S&amp;P Retail ETF slipping more than 4% in Wednesday premarket trading. Best Buy’s stock price dropped more than 6% in premarket trading, Dollar General’s fell more than 6% in premarket trading and Dollar Tree’s declined more than 5% in premarket trading.</p><p>Lowe’s shares fell more than 2% in premarket trading aftermissing sales expectations in its first quarter reportas shoppers bought fewer supplies for outdoor projects.</p><p>More notable decliners in retail included shares of Macy’s, which dropped 7% in premarket trading, and shares of Kohl’s, which fell more than 5% in premarket trading.</p><p>Wednesday’s market reversal comes after shares had been mounting a comeback off the year’s lows. OnTuesday, the Dow rose 431 points, or 1.3%, while the S&amp;P 500 gained 2% and the Nasdaq Composite climbed nearly 2.8%.</p><p>The Dow has declined for seven straight weeks, but stocks have stabilized over the last three trading sessions. Last week, the S&amp;P 500 fell to the brink of a bear market — or 20% below its record high — but the index has now gained 4% since Thursday’s close.</p><p>Despite the recent comeback, the S&amp;P 500 is down 14% for the year, while the Nasdaq Composite is off by 23%.</p><p>Gas prices have steadily marched higher, contributing to inflationary pressures seen across the economy. The national average for a gallon of regular gasoline hit a record $4.567 on Wednesday, according to AAA. Prices are 48 cents more than a month ago, and $1.52 more than what consumers paid last year.</p><p>Every single state is now averaging above $4 per gallon, with some states paying much more. In California, the statewide average has crossed $6.</p><p>The yield on the benchmark 10-year Treasury note topped 3% on Wednesday morning as investors weighed the prospects of tighter monetary policy.</p><p>Stocks and other risk assets have been pressured by inflation and the Federal Reserve’s attempt to tamp down price increases through rate hikes, which has led to concerns about a potential recession. Fed Chair Jerome Powell said at a Wall Street Journal conference on Tuesday that “there won’t be any hesitation” about raising rates until inflation is under control.</p><p>However, some recent economic data, including the jobs report andretail sales datafrom April, still show the U.S. economy growing.</p><p>“There’s a big difference between corrections in the equity markets and outright bear markets,” said Matt Stucky, a senior portfolio manager at Northwestern Mutual Wealth Management. “The difference being bear markets are almost always sort of associated with some kind of recessionary macroeconomic environment, or at least an inevitable one in the forecast horizon over the next six-to-12 months. For us, as we sit here today, we just don’t see that.”</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow Drops 300 Points, Its First Decline in 4 Days As Companies Warn of Rising Costs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow Drops 300 Points, Its First Decline in 4 Days As Companies Warn of Rising Costs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-05-18 21:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>U.S. stock futures fell on Wednesday morning after another major retailer warned of rising cost pressures, confirming the fears over inflation that have sent major benchmarks to big losses so far this year.</p><p>Futures for the Dow Jones Industrial Average shed 281 points, or 0.9%, with the average set for its first loss in four days. S&amp;P 500 futures traded 1.2% lower, while Nasdaq 100 futures slipped 1.5%.</p><p>Those losses come after a disappointing earnings report from Target. Shares tumbled more than 24% in premarket trading Wednesday after Targetreported first-quarter earnings that were much lower than Wall Street estimatedbecause of higher costs for fuel and compensation. The retailer also saw lower-than-expected sales for discretionary merchandise like TVs.</p><p>Target’s report comes right after Walmart on Tuesday posted earnings that fell short of expectations as it toocited higher fuel and labor costs. Walmart shares ended Tuesday lower by 11%. They were down another 2% in premarket trading Wednesday.</p><p>“Any company that relies on households and discretionary purchases will likely suffer this quarter because a lot of discretionary income has been funneled to food and energy prices,” said Jack Ablin, founding partner of Cresset Capital.</p><p>Other retailers took a hit on the back of Target’s quarterly earnings miss, with the SPDR S&amp;P Retail ETF slipping more than 4% in Wednesday premarket trading. Best Buy’s stock price dropped more than 6% in premarket trading, Dollar General’s fell more than 6% in premarket trading and Dollar Tree’s declined more than 5% in premarket trading.</p><p>Lowe’s shares fell more than 2% in premarket trading aftermissing sales expectations in its first quarter reportas shoppers bought fewer supplies for outdoor projects.</p><p>More notable decliners in retail included shares of Macy’s, which dropped 7% in premarket trading, and shares of Kohl’s, which fell more than 5% in premarket trading.</p><p>Wednesday’s market reversal comes after shares had been mounting a comeback off the year’s lows. OnTuesday, the Dow rose 431 points, or 1.3%, while the S&amp;P 500 gained 2% and the Nasdaq Composite climbed nearly 2.8%.</p><p>The Dow has declined for seven straight weeks, but stocks have stabilized over the last three trading sessions. Last week, the S&amp;P 500 fell to the brink of a bear market — or 20% below its record high — but the index has now gained 4% since Thursday’s close.</p><p>Despite the recent comeback, the S&amp;P 500 is down 14% for the year, while the Nasdaq Composite is off by 23%.</p><p>Gas prices have steadily marched higher, contributing to inflationary pressures seen across the economy. The national average for a gallon of regular gasoline hit a record $4.567 on Wednesday, according to AAA. Prices are 48 cents more than a month ago, and $1.52 more than what consumers paid last year.</p><p>Every single state is now averaging above $4 per gallon, with some states paying much more. In California, the statewide average has crossed $6.</p><p>The yield on the benchmark 10-year Treasury note topped 3% on Wednesday morning as investors weighed the prospects of tighter monetary policy.</p><p>Stocks and other risk assets have been pressured by inflation and the Federal Reserve’s attempt to tamp down price increases through rate hikes, which has led to concerns about a potential recession. Fed Chair Jerome Powell said at a Wall Street Journal conference on Tuesday that “there won’t be any hesitation” about raising rates until inflation is under control.</p><p>However, some recent economic data, including the jobs report andretail sales datafrom April, still show the U.S. economy growing.</p><p>“There’s a big difference between corrections in the equity markets and outright bear markets,” said Matt Stucky, a senior portfolio manager at Northwestern Mutual Wealth Management. “The difference being bear markets are almost always sort of associated with some kind of recessionary macroeconomic environment, or at least an inevitable one in the forecast horizon over the next six-to-12 months. For us, as we sit here today, we just don’t see that.”</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144253627","content_text":"U.S. stock futures fell on Wednesday morning after another major retailer warned of rising cost pressures, confirming the fears over inflation that have sent major benchmarks to big losses so far this year.Futures for the Dow Jones Industrial Average shed 281 points, or 0.9%, with the average set for its first loss in four days. S&P 500 futures traded 1.2% lower, while Nasdaq 100 futures slipped 1.5%.Those losses come after a disappointing earnings report from Target. Shares tumbled more than 24% in premarket trading Wednesday after Targetreported first-quarter earnings that were much lower than Wall Street estimatedbecause of higher costs for fuel and compensation. The retailer also saw lower-than-expected sales for discretionary merchandise like TVs.Target’s report comes right after Walmart on Tuesday posted earnings that fell short of expectations as it toocited higher fuel and labor costs. Walmart shares ended Tuesday lower by 11%. They were down another 2% in premarket trading Wednesday.“Any company that relies on households and discretionary purchases will likely suffer this quarter because a lot of discretionary income has been funneled to food and energy prices,” said Jack Ablin, founding partner of Cresset Capital.Other retailers took a hit on the back of Target’s quarterly earnings miss, with the SPDR S&P Retail ETF slipping more than 4% in Wednesday premarket trading. Best Buy’s stock price dropped more than 6% in premarket trading, Dollar General’s fell more than 6% in premarket trading and Dollar Tree’s declined more than 5% in premarket trading.Lowe’s shares fell more than 2% in premarket trading aftermissing sales expectations in its first quarter reportas shoppers bought fewer supplies for outdoor projects.More notable decliners in retail included shares of Macy’s, which dropped 7% in premarket trading, and shares of Kohl’s, which fell more than 5% in premarket trading.Wednesday’s market reversal comes after shares had been mounting a comeback off the year’s lows. OnTuesday, the Dow rose 431 points, or 1.3%, while the S&P 500 gained 2% and the Nasdaq Composite climbed nearly 2.8%.The Dow has declined for seven straight weeks, but stocks have stabilized over the last three trading sessions. Last week, the S&P 500 fell to the brink of a bear market — or 20% below its record high — but the index has now gained 4% since Thursday’s close.Despite the recent comeback, the S&P 500 is down 14% for the year, while the Nasdaq Composite is off by 23%.Gas prices have steadily marched higher, contributing to inflationary pressures seen across the economy. The national average for a gallon of regular gasoline hit a record $4.567 on Wednesday, according to AAA. Prices are 48 cents more than a month ago, and $1.52 more than what consumers paid last year.Every single state is now averaging above $4 per gallon, with some states paying much more. In California, the statewide average has crossed $6.The yield on the benchmark 10-year Treasury note topped 3% on Wednesday morning as investors weighed the prospects of tighter monetary policy.Stocks and other risk assets have been pressured by inflation and the Federal Reserve’s attempt to tamp down price increases through rate hikes, which has led to concerns about a potential recession. Fed Chair Jerome Powell said at a Wall Street Journal conference on Tuesday that “there won’t be any hesitation” about raising rates until inflation is under control.However, some recent economic data, including the jobs report andretail sales datafrom April, still show the U.S. economy growing.“There’s a big difference between corrections in the equity markets and outright bear markets,” said Matt Stucky, a senior portfolio manager at Northwestern Mutual Wealth Management. “The difference being bear markets are almost always sort of associated with some kind of recessionary macroeconomic environment, or at least an inevitable one in the forecast horizon over the next six-to-12 months. For us, as we sit here today, we just don’t see that.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9049247990,"gmtCreate":1655808762611,"gmtModify":1676535708903,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GRAB\">$Grab Holdings(GRAB)$</a>Grab it tonite..Let go at $3.0","listText":"<a href=\"https://ttm.financial/S/GRAB\">$Grab Holdings(GRAB)$</a>Grab it tonite..Let go at $3.0","text":"$Grab Holdings(GRAB)$Grab it tonite..Let go at $3.0","images":[{"img":"https://community-static.tradeup.com/news/fa1b786c7bc6351ddbca9f2219fbd73c","width":"1242","height":"2924"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9049247990","isVote":1,"tweetType":1,"viewCount":181,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"content":"Gogo grab $3.00","text":"Gogo grab $3.00","html":"Gogo grab $3.00"}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9050227887,"gmtCreate":1654212007249,"gmtModify":1676535412001,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/OPEN\">$Opendoor Technologies Inc(OPEN)$</a>wow!!!","listText":"<a href=\"https://ttm.financial/S/OPEN\">$Opendoor Technologies Inc(OPEN)$</a>wow!!!","text":"$Opendoor Technologies Inc(OPEN)$wow!!!","images":[{"img":"https://community-static.tradeup.com/news/07b6b23a60a1f74aa4f9d9ff3330e865","width":"1242","height":"1968"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9050227887","isVote":1,"tweetType":1,"viewCount":277,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9028268902,"gmtCreate":1653235336406,"gmtModify":1676535244306,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Actually $3 or lower can be quite good for invesment.Just throw some $ earning from other shares to hope maybe got miracle will happen?.Please dont throw your hard earning $ to here because it will make you get heartattack.Hopefully will improve and see the + and green sign soon.","listText":"Actually $3 or lower can be quite good for invesment.Just throw some $ earning from other shares to hope maybe got miracle will happen?.Please dont throw your hard earning $ to here because it will make you get heartattack.Hopefully will improve and see the + and green sign soon.","text":"Actually $3 or lower can be quite good for invesment.Just throw some $ earning from other shares to hope maybe got miracle will happen?.Please dont throw your hard earning $ to here because it will make you get heartattack.Hopefully will improve and see the + and green sign soon.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9028268902","repostId":"2237804740","repostType":4,"repost":{"id":"2237804740","kind":"highlight","pubTimestamp":1653186784,"share":"https://ttm.financial/m/news/2237804740?lang=&edition=fundamental","pubTime":"2022-05-22 10:33","market":"us","language":"en","title":"Upgrading Grab To Buy After Solid Quarter, But Shares Remain Very Risky","url":"https://stock-news.laohu8.com/highlight/detail?id=2237804740","media":"seekingalpha","summary":"SummaryFor Grab, the most recent financial quarter was a mostly positive one, and shares reacted by ","content":"<html><head></head><body><p><b>Summary</b></p><ul><li>For Grab, the most recent financial quarter was a mostly positive one, and shares reacted by going up in price.</li><li>There are signs that high growth is returning and that some steps toward becoming profitable are being taken.</li><li>The company is being more prudent with the use of incentives, and EBITDA margins are moving in the right direction.</li><li>The delivery segment showed impressive growth, and the finance segment is proving to be one of the most promising businesses for the company.</li><li>That said, the company is still burning significant amounts of cash, and it will have to further improve margins and profitability if it wants to remain a going concern.</li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bf4369272cc8b01316e1557985846203\" tg-width=\"750\" tg-height=\"500\" width=\"100%\" height=\"auto\"/><span>whitebalance.oatt/E+ via Getty Images</span></p><p><i>This article was written by WideAlpha.</i></p><p>Grab (NASDAQ:GRAB) reported a very solid first quarter of 2022, with GMV up 32%. Particularly impressive was the deliveries segment, which saw growth of 50%, significantly above expectations. We had recently upgraded the shares to &#34;Hold&#34; based on the attractive valuation, but we&#39;re now upgrading the shares again given that profitability now looks more attainable in the medium term.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5cfaef7da7b5f4bd43db70fd365c2e6e\" tg-width=\"640\" tg-height=\"358\" width=\"100%\" height=\"auto\"/><span>Grab Investor Presentation</span></p><p>These results surpassed the previously given outlook by a good margin. For example, deliveries GMV has been guided to be between $2.4B and $2.5B and it was actually $2.56B. Mobility GMV has been guided to between $0.75B and $0.80B, and the actual result was $0.83B. But the <a href=\"https://laohu8.com/S/AONE.U\">one</a> that gave the biggest surprise was financial services total payment volume, which has been guided to be between $3.1B and $3.2B, and the actual result was significantly higher at $3.6B.</p><p>All these point to recovering growth, which is all fine and good, but we&#39;re still concerned with profitability. Here the company managed to make some improvements as well by reducing incentives as a proportion of GMV. Adjusted EBITDA margins as a proportion of GMV improved sequentially from -6.8% to -6%. Much of this improvement came from reduced losses in the deliveries segment. This is very encouraging, but it remains to be seen if the company can actually turn profitable before it runs out of funds.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a51e5f7af20f7049c56fce95c7641130\" tg-width=\"640\" tg-height=\"358\" width=\"100%\" height=\"auto\"/><span>Grab Investor Presentation</span></p><p>What makes us more optimistic about the company is the growth it&#39;s seeing in its financial services segment. We believe this is the part of the company that has the better chance of reaching solid profitability first, and maybe subsidize the rest of the company until they too become profitable. Year over year the company saw 5x growth in buy now pay later, and 3x growth in loans disbursed.</p><p>Even better, when its customers make use of Grab&#39;s financial services, they spend more and their retention on the platform improves.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/556608a22e6efd02a8162f618c3a70b3\" tg-width=\"640\" tg-height=\"358\" width=\"100%\" height=\"auto\"/><span>Grab Investor Presentation</span></p><p><b>Liquidity</b></p><p>The company reported that as of March 31, 2022, it had net cash liquidity of $5.97B, which should be enough to finance losses for a few more quarters. The investment case for Grab is that it will reach enough scale, and improve margins enough, to reach at least positive operating cash flow before its liquidity runs dry.</p><p>As of Dec. 31, 2021, the company had net cash liquidity of $6.79B. This means that in just one quarter its liquidity went down ~$800 million. At this pace it would mean the company has a runway of approximately eight quarters, but if Grab makes incremental improvements to its margins this could last a little longer. In any case, time of the essence for Grab to show that it has a sustainable business model, especially now with investors more focused on profits and less enthusiastic about unprofitable growth.</p><p><b>Valuation</b></p><p>It&#39;s difficult to value Grab, since it does not yet have positive earnings or even EBITDA, and it&#39;s difficult to do a credible discounted cash flow model when it&#39;s difficult to tell what its profit margins can be in the future. What is clear is that this is a company growing at a very fast pace, and that it is one of Asia&#39;s &#34;Super Apps.&#34; Based on this we believe that if the company finds a way to become profitable, that it can become a very valuable company. With a market cap of ~$12 B, there&#39;s room for the valuation to expand if the company proves it can become profitable.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ce4e62cfe0f52a079d8e30bdbb594793\" tg-width=\"635\" tg-height=\"417\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p>At least the company is no longer trading at an unrealistic multiple of revenues. Its EV/revenues multiple reached a high of more than 40x, but has since gone down to ~9x, and the forward EV/revenues stands at only ~5x. This tells us that investors are being a lot more realistic, and balancing the growth of the company with the profitability challenges, to come up with a valuation that leaves more room for error. Still, we would like to remind everyone that even if the risk/reward is a lot more attractive now that the company is seeing profitability improvements and that the valuation is a lot more reasonable, that this is still a company that could go bankrupt if it does not turn profitable in the next few quarters. We estimate the runway it has to become profitable at around eight quarters, but it could be more or less depending on how operating cash flow trends from here. There&#39;s also the possibility that the company will try to do another capital raise to extend its runway if it gets too close to running out of cash.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bef0947c2c077a4dc099088530669bd1\" tg-width=\"635\" tg-height=\"433\" width=\"100%\" height=\"auto\"/><span>Data by YCharts</span></p><p><b>Outlook for 2022</b></p><p>For fiscal year 2022, Grab is guiding for revenue between $1.2B and $1.3B, and GMV growth of between 30% and 35%. This guidance is reassuring that growth is returning to the business, so the remaining concern is profitability. While we&#39;re seeing some green shoots there the company still has a lot to do to become sustainably profitable.</p><p><b>ESG</b></p><p>We would like to add a quick note saying that we&#39;re positively surprised by Grab&#39;s sustainability efforts. It&#39;s pledging to become carbon neutral as a platform by 2040, it is looking to expand the proportion of women in leadership roles to 40% by 2030, and it&#39;s seeking to double the number of economically marginalized individuals earning an income on Grab by 2025. These are very laudable goals and we hope the company manages to reach them.</p><p><b>Risks</b></p><p>While the risk/reward has improved to the point that we now rate the company a &#34;Buy,&#34; we would like to remind our readers that this is a speculative investment that could easily end up in bankruptcy. It seems bears have come to the same conclusion that the risk/reward has improve, given that the short interest is not that significant at ~5.4%.</p><p>The Altman Z-score is negative, which is a red flag, and is reflective of the profitability challenges the company has. It will have to optimize its business model to reach margins that let it operate profitability if it wants to eventually go out of business.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b9a705f6d4f513634c0b5128d6154cf2\" tg-width=\"381\" tg-height=\"191\" width=\"100%\" height=\"auto\"/><span>Seeking Alpha</span></p><p><b>Conclusion</b></p><p>The most recent quarter was mostly a positive one, and shares reacted by going up in price. There are signs that high growth is returning, and that some steps toward becoming profitable are being taken. The company is being more prudent with the use of incentives, and EBITDA margins are moving in the right direction. The delivery segment showed impressive growth, and the finance segment is proving to be one of the most promising businesses for the company. That said, the company is still burning significant amounts of cash, and it will have to further improve margins and profitability if it wants to remain a going concern. Overall, we rate shares a &#34;buy&#34; given the positive risk/reward, but pointing out that risk is significant and that an investment in the company can easily result in total loss.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Upgrading Grab To Buy After Solid Quarter, But Shares Remain Very Risky</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpgrading Grab To Buy After Solid Quarter, But Shares Remain Very Risky\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-22 10:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4513446-grab-a-buy-after-solid-earnings><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryFor Grab, the most recent financial quarter was a mostly positive one, and shares reacted by going up in price.There are signs that high growth is returning and that some steps toward becoming ...</p>\n\n<a href=\"https://seekingalpha.com/article/4513446-grab-a-buy-after-solid-earnings\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/article/4513446-grab-a-buy-after-solid-earnings","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2237804740","content_text":"SummaryFor Grab, the most recent financial quarter was a mostly positive one, and shares reacted by going up in price.There are signs that high growth is returning and that some steps toward becoming profitable are being taken.The company is being more prudent with the use of incentives, and EBITDA margins are moving in the right direction.The delivery segment showed impressive growth, and the finance segment is proving to be one of the most promising businesses for the company.That said, the company is still burning significant amounts of cash, and it will have to further improve margins and profitability if it wants to remain a going concern.whitebalance.oatt/E+ via Getty ImagesThis article was written by WideAlpha.Grab (NASDAQ:GRAB) reported a very solid first quarter of 2022, with GMV up 32%. Particularly impressive was the deliveries segment, which saw growth of 50%, significantly above expectations. We had recently upgraded the shares to \"Hold\" based on the attractive valuation, but we're now upgrading the shares again given that profitability now looks more attainable in the medium term.Grab Investor PresentationThese results surpassed the previously given outlook by a good margin. For example, deliveries GMV has been guided to be between $2.4B and $2.5B and it was actually $2.56B. Mobility GMV has been guided to between $0.75B and $0.80B, and the actual result was $0.83B. But the one that gave the biggest surprise was financial services total payment volume, which has been guided to be between $3.1B and $3.2B, and the actual result was significantly higher at $3.6B.All these point to recovering growth, which is all fine and good, but we're still concerned with profitability. Here the company managed to make some improvements as well by reducing incentives as a proportion of GMV. Adjusted EBITDA margins as a proportion of GMV improved sequentially from -6.8% to -6%. Much of this improvement came from reduced losses in the deliveries segment. This is very encouraging, but it remains to be seen if the company can actually turn profitable before it runs out of funds.Grab Investor PresentationWhat makes us more optimistic about the company is the growth it's seeing in its financial services segment. We believe this is the part of the company that has the better chance of reaching solid profitability first, and maybe subsidize the rest of the company until they too become profitable. Year over year the company saw 5x growth in buy now pay later, and 3x growth in loans disbursed.Even better, when its customers make use of Grab's financial services, they spend more and their retention on the platform improves.Grab Investor PresentationLiquidityThe company reported that as of March 31, 2022, it had net cash liquidity of $5.97B, which should be enough to finance losses for a few more quarters. The investment case for Grab is that it will reach enough scale, and improve margins enough, to reach at least positive operating cash flow before its liquidity runs dry.As of Dec. 31, 2021, the company had net cash liquidity of $6.79B. This means that in just one quarter its liquidity went down ~$800 million. At this pace it would mean the company has a runway of approximately eight quarters, but if Grab makes incremental improvements to its margins this could last a little longer. In any case, time of the essence for Grab to show that it has a sustainable business model, especially now with investors more focused on profits and less enthusiastic about unprofitable growth.ValuationIt's difficult to value Grab, since it does not yet have positive earnings or even EBITDA, and it's difficult to do a credible discounted cash flow model when it's difficult to tell what its profit margins can be in the future. What is clear is that this is a company growing at a very fast pace, and that it is one of Asia's \"Super Apps.\" Based on this we believe that if the company finds a way to become profitable, that it can become a very valuable company. With a market cap of ~$12 B, there's room for the valuation to expand if the company proves it can become profitable.Data by YChartsAt least the company is no longer trading at an unrealistic multiple of revenues. Its EV/revenues multiple reached a high of more than 40x, but has since gone down to ~9x, and the forward EV/revenues stands at only ~5x. This tells us that investors are being a lot more realistic, and balancing the growth of the company with the profitability challenges, to come up with a valuation that leaves more room for error. Still, we would like to remind everyone that even if the risk/reward is a lot more attractive now that the company is seeing profitability improvements and that the valuation is a lot more reasonable, that this is still a company that could go bankrupt if it does not turn profitable in the next few quarters. We estimate the runway it has to become profitable at around eight quarters, but it could be more or less depending on how operating cash flow trends from here. There's also the possibility that the company will try to do another capital raise to extend its runway if it gets too close to running out of cash.Data by YChartsOutlook for 2022For fiscal year 2022, Grab is guiding for revenue between $1.2B and $1.3B, and GMV growth of between 30% and 35%. This guidance is reassuring that growth is returning to the business, so the remaining concern is profitability. While we're seeing some green shoots there the company still has a lot to do to become sustainably profitable.ESGWe would like to add a quick note saying that we're positively surprised by Grab's sustainability efforts. It's pledging to become carbon neutral as a platform by 2040, it is looking to expand the proportion of women in leadership roles to 40% by 2030, and it's seeking to double the number of economically marginalized individuals earning an income on Grab by 2025. These are very laudable goals and we hope the company manages to reach them.RisksWhile the risk/reward has improved to the point that we now rate the company a \"Buy,\" we would like to remind our readers that this is a speculative investment that could easily end up in bankruptcy. It seems bears have come to the same conclusion that the risk/reward has improve, given that the short interest is not that significant at ~5.4%.The Altman Z-score is negative, which is a red flag, and is reflective of the profitability challenges the company has. It will have to optimize its business model to reach margins that let it operate profitability if it wants to eventually go out of business.Seeking AlphaConclusionThe most recent quarter was mostly a positive one, and shares reacted by going up in price. There are signs that high growth is returning, and that some steps toward becoming profitable are being taken. The company is being more prudent with the use of incentives, and EBITDA margins are moving in the right direction. The delivery segment showed impressive growth, and the finance segment is proving to be one of the most promising businesses for the company. That said, the company is still burning significant amounts of cash, and it will have to further improve margins and profitability if it wants to remain a going concern. Overall, we rate shares a \"buy\" given the positive risk/reward, but pointing out that risk is significant and that an investment in the company can easily result in total loss.","news_type":1},"isVote":1,"tweetType":1,"viewCount":81,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4092376851552610","authorId":"4092376851552610","name":"Tall Guy","avatar":"https://community-static.tradeup.com/news/5e11acf97134ffdcfb93cea9aabffca0","crmLevel":3,"crmLevelSwitch":0,"idStr":"4092376851552610","authorIdStr":"4092376851552610"},"content":"at 3 bucks I think it's a gd buy too. just buy some to get a small pie when it rises.","text":"at 3 bucks I think it's a gd buy too. just buy some to get a small pie when it rises.","html":"at 3 bucks I think it's a gd buy too. just buy some to get a small pie when it rises."}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9052100037,"gmtCreate":1655132258729,"gmtModify":1676535567479,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Avoid everything until thursday...","listText":"Avoid everything until thursday...","text":"Avoid everything until thursday...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9052100037","repostId":"2243656683","repostType":4,"repost":{"id":"2243656683","kind":"highlight","pubTimestamp":1655134408,"share":"https://ttm.financial/m/news/2243656683?lang=&edition=fundamental","pubTime":"2022-06-13 23:33","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2243656683","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>My &#34;three stocks to avoid&#34; column last week was a mixed bag. The three stocks I thought were going to move lower for the week -- <b>Hooker Furnishings</b>, <b>Stitch Fix</b>, and <b>ChargePoint</b> -- finished up 1%, down 28%, and down 1%, respectively, averaging out to a 9.3% decline.</p><p>The <b>S&amp;P 500</b> experienced a 5.1% slide, and the investments I figured would fare worse did lose to the market. I was right. I have been correct in 24 of the past 34 weeks.</p><p>Where do I go to next? I see <b>Oracle</b>, <b>Beyond Air</b>, and <b><a href=\"https://laohu8.com/S/BLNK\">Blink Charging</a></b> as stocks you may want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2>Oracle</h2><p>Time hasn&#39;t been kind to <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the titans of enterprise software. The heady growth and Larry Ellison&#39;s cockiness appear to be in short supply over the past decade, and we won&#39;t have to wait long to get fresh financials. Oracle reports its fiscal fourth-quarter results shortly after Monday&#39;s market close.</p><p>Growth has slowed at Oracle. Analysts see revenue climbing 4% for the quarter and the entire fiscal year. That&#39;s not a fluke. It should be the 11th consecutive fiscal year in which revenue fails to grow by at least 5%. And that&#39;s not the only thing that seems to be unimpressive at Oracle. The same company that routinely managed expectations to deliver market-thumping bottom-line results proved mortal last time. It missed Wall Street&#39;s profit target, and analysts are bracing for a year-over-year decline in this week&#39;s report.</p><h2>Beyond Air</h2><p>A much smaller but still potentially problematic company reporting earnings this week is Beyond Air. The clinical-stage medical-device company is pinning its hopes on a successful rollout of LungFit, a treatment device for persistent pulmonary hypertension of the newborn (or PPHN, for short). It ran into some regulatory delays last year, missing its goal of a commercial launch in 2021.</p><p>Clinical studies have been largely positive, but Beyond Air is running into a few obstacles. It created a chief medical officer position six months ago, and it&#39;s already on its second executive in that role. It has also posted larger-than-expected losses in its last three quarters, a bad omen heading into Thursday&#39;s financial update. Beyond Air still has a cash-rich balance sheet, but like most early stage biopharmaceutical companies, it&#39;s burning through a lot of dough. It may have to raise money at the worst possible time with the market under pressure.</p><h2>Blink Charging</h2><p>There&#39;s no denying that electric vehicles are the future, but investors hungry for pick-and-shovel plays may be short-circuiting their prospects by betting on the third-party companies specializing in charging stations. This remains a cutthroat niche, and it&#39;s too soon to predict winners.</p><p>Blink Charging shares have fallen 75% since peaking early last year, but the stock is still trading at a stiff 24 times trailing revenue. Analysts don&#39;t see Blink Charging turning a profit until 2026, and by then we&#39;ll probably be looking at a much different landscape when it comes to the leaders of fast-charging stations. A lot can and will happen in the next four years. Did you think the largest maker of electric cars would be announcing layoffs of its salaried staff this year? Blue skies are looking a little gray, and just because you see lightning doesn&#39;t mean third-party charging kiosks will ever be profitable.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Oracle, Beyond Air, or Blink Charging this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-13 23:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/13/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>My \"three stocks to avoid\" column last week was a mixed bag. The three stocks I thought were going to move lower for the week -- Hooker Furnishings, Stitch Fix, and ChargePoint -- finished up 1%, down...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/13/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BLNK":"Blink Charging","XAIR":"BEYOND AIR INC","ORCL":"甲骨文"},"source_url":"https://www.fool.com/investing/2022/06/13/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2243656683","content_text":"My \"three stocks to avoid\" column last week was a mixed bag. The three stocks I thought were going to move lower for the week -- Hooker Furnishings, Stitch Fix, and ChargePoint -- finished up 1%, down 28%, and down 1%, respectively, averaging out to a 9.3% decline.The S&P 500 experienced a 5.1% slide, and the investments I figured would fare worse did lose to the market. I was right. I have been correct in 24 of the past 34 weeks.Where do I go to next? I see Oracle, Beyond Air, and Blink Charging as stocks you may want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.OracleTime hasn't been kind to one of the titans of enterprise software. The heady growth and Larry Ellison's cockiness appear to be in short supply over the past decade, and we won't have to wait long to get fresh financials. Oracle reports its fiscal fourth-quarter results shortly after Monday's market close.Growth has slowed at Oracle. Analysts see revenue climbing 4% for the quarter and the entire fiscal year. That's not a fluke. It should be the 11th consecutive fiscal year in which revenue fails to grow by at least 5%. And that's not the only thing that seems to be unimpressive at Oracle. The same company that routinely managed expectations to deliver market-thumping bottom-line results proved mortal last time. It missed Wall Street's profit target, and analysts are bracing for a year-over-year decline in this week's report.Beyond AirA much smaller but still potentially problematic company reporting earnings this week is Beyond Air. The clinical-stage medical-device company is pinning its hopes on a successful rollout of LungFit, a treatment device for persistent pulmonary hypertension of the newborn (or PPHN, for short). It ran into some regulatory delays last year, missing its goal of a commercial launch in 2021.Clinical studies have been largely positive, but Beyond Air is running into a few obstacles. It created a chief medical officer position six months ago, and it's already on its second executive in that role. It has also posted larger-than-expected losses in its last three quarters, a bad omen heading into Thursday's financial update. Beyond Air still has a cash-rich balance sheet, but like most early stage biopharmaceutical companies, it's burning through a lot of dough. It may have to raise money at the worst possible time with the market under pressure.Blink ChargingThere's no denying that electric vehicles are the future, but investors hungry for pick-and-shovel plays may be short-circuiting their prospects by betting on the third-party companies specializing in charging stations. This remains a cutthroat niche, and it's too soon to predict winners.Blink Charging shares have fallen 75% since peaking early last year, but the stock is still trading at a stiff 24 times trailing revenue. Analysts don't see Blink Charging turning a profit until 2026, and by then we'll probably be looking at a much different landscape when it comes to the leaders of fast-charging stations. A lot can and will happen in the next four years. Did you think the largest maker of electric cars would be announcing layoffs of its salaried staff this year? Blue skies are looking a little gray, and just because you see lightning doesn't mean third-party charging kiosks will ever be profitable.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Oracle, Beyond Air, or Blink Charging this week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":137,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9028401515,"gmtCreate":1653265181437,"gmtModify":1676535248721,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9028401515","repostId":"1171500400","repostType":4,"repost":{"id":"1171500400","kind":"news","pubTimestamp":1653263894,"share":"https://ttm.financial/m/news/1171500400?lang=&edition=fundamental","pubTime":"2022-05-23 07:58","market":"sg","language":"en","title":"Singapore Stock Market Expected To Be Rangebound On Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1171500400","media":"RTTNews","summary":"The Singapore stock market bounced higher again on Friday, one day after halting the three-day winni","content":"<html><head></head><body><p>The Singapore stock market bounced higher again on Friday, one day after halting the three-day winning streak in which it had improved more than 60 points or 1.9 percent. The Straits Times Index now rests just above the 3,240-point plateau and it&#39;s likely to see little movement on Monday.</p><p>The global forecast for the Asian markets is flat to slightly higher, with support from oil stocks capped by weakness from tech shares. The European markets were slightly higher and the U.S. bourses were mixed and little changed and the Asian markets figure to split the difference.</p><p>The STI finished sharply higher on Friday following gains from the financial shares, property stocks and industrial issues.</p><p>For the day, the index spiked 49.87 points or 1.56 percent to finish at 3,240.58 after trading between 3,210.75 and 3,246.13. Volume was 1.81 billion shares worth 1.54 billion Singapore dollars. There were 340 gainers and 170 decliners.</p><p>Among the actives, Ascendas REIT added 0.74 percent, while CapitaLand Integrated Commercial Trust perked 0.45 percent, CapitaLand Investment accelerated 2.62 percent, City Developments strengthened 2.25 percent, Comfort DelGro rose 0.68 percent, DBS Group collected 1.00 percent, Genting Singapore rallied 2.60 percent, Hongkong Land jumped 2.34 percent, Keppel Corp increased 0.89 percent, Mapletree Industrial Trust was up 0.41 percent, Oversea-Chinese Banking Corporation gathered 1.03 percent, SATS soared 3.40 percent, SembCorp Industries improved 1.41 percent, Singapore Exchange climbed 2.07 percent, Singapore Technologies Engineering advanced 2.00 percent, Thai Beverage gained 0.71 percent, United Overseas Bank spiked 3.19 percent, Wilmar International surged 4.13 percent, Yangzijiang Financial skyrocketed 8.97 percent and Yangzijiang Shipbuilding, Mapletree Commercial Trust, Mapletree Logistics Trust, SingTel and Frasers Logistics were unchanged.</p><p>Wall Street offers little guidance as the major averages opened higher on Friday, quickly plummeted into the red before rallying to finish mixed and little changed.</p><p>The Dow added 8.77 points or 0.03 percent to finish at 31,261.90, while the NASDAQ fell 33.88 points or 0.30 percent to close at 11,354.62 and the S&amp;P 500 rose 0.57 points or 0.01 percent to end at 3,901.36.</p><p>For the week, the NASDAQ dove 3.8 percent, the S&amp;P sank 3 percent and the Dow lost 2.9 percent.</p><p>The extended volatility on Wall Street came as traders continued to debate when the markets will reach a bottom following recent weakness.</p><p>The S&amp;P 500 was down more than 20 percent from January&#39;s record closing high, which is seen as signaling a bear market.</p><p>Crude oil futures settled higher on Friday, lifted by the proposed ban on Russian oil by the EU and the relaxation of Covid lockdowns in China. West Texas Intermediate Crude oil futures for July added $0.39 or 0.4 percent at $110.28 a barrel.</p><p>Closer to home, Singapore will see April data for consumer prices later today; in March, overall inflation was up 1.2 percent on month and 5.4 percent on year, while core CPI rose an annual 2.9 percent.</p></body></html>","source":"lsy1626938412129","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Stock Market Expected To Be Rangebound On Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Stock Market Expected To Be Rangebound On Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-23 07:58 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.rttnews.com/3285836/singapore-stock-market-expected-to-be-rangebound-on-monday.aspx?type=acom><strong>RTTNews</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Singapore stock market bounced higher again on Friday, one day after halting the three-day winning streak in which it had improved more than 60 points or 1.9 percent. The Straits Times Index now ...</p>\n\n<a href=\"https://www.rttnews.com/3285836/singapore-stock-market-expected-to-be-rangebound-on-monday.aspx?type=acom\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.rttnews.com/3285836/singapore-stock-market-expected-to-be-rangebound-on-monday.aspx?type=acom","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171500400","content_text":"The Singapore stock market bounced higher again on Friday, one day after halting the three-day winning streak in which it had improved more than 60 points or 1.9 percent. The Straits Times Index now rests just above the 3,240-point plateau and it's likely to see little movement on Monday.The global forecast for the Asian markets is flat to slightly higher, with support from oil stocks capped by weakness from tech shares. The European markets were slightly higher and the U.S. bourses were mixed and little changed and the Asian markets figure to split the difference.The STI finished sharply higher on Friday following gains from the financial shares, property stocks and industrial issues.For the day, the index spiked 49.87 points or 1.56 percent to finish at 3,240.58 after trading between 3,210.75 and 3,246.13. Volume was 1.81 billion shares worth 1.54 billion Singapore dollars. There were 340 gainers and 170 decliners.Among the actives, Ascendas REIT added 0.74 percent, while CapitaLand Integrated Commercial Trust perked 0.45 percent, CapitaLand Investment accelerated 2.62 percent, City Developments strengthened 2.25 percent, Comfort DelGro rose 0.68 percent, DBS Group collected 1.00 percent, Genting Singapore rallied 2.60 percent, Hongkong Land jumped 2.34 percent, Keppel Corp increased 0.89 percent, Mapletree Industrial Trust was up 0.41 percent, Oversea-Chinese Banking Corporation gathered 1.03 percent, SATS soared 3.40 percent, SembCorp Industries improved 1.41 percent, Singapore Exchange climbed 2.07 percent, Singapore Technologies Engineering advanced 2.00 percent, Thai Beverage gained 0.71 percent, United Overseas Bank spiked 3.19 percent, Wilmar International surged 4.13 percent, Yangzijiang Financial skyrocketed 8.97 percent and Yangzijiang Shipbuilding, Mapletree Commercial Trust, Mapletree Logistics Trust, SingTel and Frasers Logistics were unchanged.Wall Street offers little guidance as the major averages opened higher on Friday, quickly plummeted into the red before rallying to finish mixed and little changed.The Dow added 8.77 points or 0.03 percent to finish at 31,261.90, while the NASDAQ fell 33.88 points or 0.30 percent to close at 11,354.62 and the S&P 500 rose 0.57 points or 0.01 percent to end at 3,901.36.For the week, the NASDAQ dove 3.8 percent, the S&P sank 3 percent and the Dow lost 2.9 percent.The extended volatility on Wall Street came as traders continued to debate when the markets will reach a bottom following recent weakness.The S&P 500 was down more than 20 percent from January's record closing high, which is seen as signaling a bear market.Crude oil futures settled higher on Friday, lifted by the proposed ban on Russian oil by the EU and the relaxation of Covid lockdowns in China. West Texas Intermediate Crude oil futures for July added $0.39 or 0.4 percent at $110.28 a barrel.Closer to home, Singapore will see April data for consumer prices later today; in March, overall inflation was up 1.2 percent on month and 5.4 percent on year, while core CPI rose an annual 2.9 percent.","news_type":1},"isVote":1,"tweetType":1,"viewCount":95,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9043865529,"gmtCreate":1655906508561,"gmtModify":1676535729416,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NU\">$Nu Holdings Ltd.(NU)$</a>Sell at $4.20...Can earn abit","listText":"<a href=\"https://ttm.financial/S/NU\">$Nu Holdings Ltd.(NU)$</a>Sell at $4.20...Can earn abit","text":"$Nu Holdings Ltd.(NU)$Sell at $4.20...Can earn abit","images":[{"img":"https://community-static.tradeup.com/news/0a20ee8cab8ae486ec694c72e6bcfe59","width":"1242","height":"2208"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9043865529","isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9021249261,"gmtCreate":1653064384353,"gmtModify":1676535217732,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Nice to know this..I will survey and follow this 3 stocks until soaring back.Hope yo heard good news from this stocks.Thanks for sharing.","listText":"Nice to know this..I will survey and follow this 3 stocks until soaring back.Hope yo heard good news from this stocks.Thanks for sharing.","text":"Nice to know this..I will survey and follow this 3 stocks until soaring back.Hope yo heard good news from this stocks.Thanks for sharing.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9021249261","repostId":"2236009402","repostType":4,"repost":{"id":"2236009402","kind":"highlight","pubTimestamp":1653059008,"share":"https://ttm.financial/m/news/2236009402?lang=&edition=fundamental","pubTime":"2022-05-20 23:03","market":"us","language":"en","title":"3 Growth Stocks Wall Street Thinks Could Rise 70% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2236009402","media":"Motley Fool","summary":"Find out why the pros on Wall Street expect great things from these beaten-down growth stocks.","content":"<html><head></head><body><p>This has been an absolutely rotten year to be a growth stock investor. The <b><a href=\"https://laohu8.com/S/EEME\">iShares</a> S&amp;P 500 Growth <a href=\"https://laohu8.com/S/PSFF\">Pacer Swan SOS Fund of Funds ETF|ETF</a></b> has fallen a staggering 26% this year.</p><p>But the dark clouds hanging over the market are lined with silver for patient investors who stick with terrific businesses like <b>Roku</b>, <b>SoFi Technologies</b>, and <b>Matterport</b>. That&#39;s because a stock market scorned for growth stocks in general has driven shares of these former market darlings down to prices they can easily bounce back from.</p><h2>Roku</h2><p>Roku shares are down about 80% from the peak they reached last summer. Analysts on Wall Street who follow the company expect a swift rebound. The average price target for Roku represents a 70% premium over recent prices.</p><p>Now that the stay-at-home orders meant to blunt the spread of the coronavirus are no longer in play, Roku stock has lost a lot of its luster. The stock&#39;s dive isn&#39;t due to poor performance. First-quarter revenue soared 28% year over year. That&#39;s especially impressive because at the beginning of the previous-year period, hardly anyone had been vaccinated yet.</p><p>Roku added 1.1 million accounts in the first quarter and ended March with 61.3 million in total. As more advertisers shift their budgets away from linear broadcasting and toward ad-supported video-on-demand (AVOD), those accounts are becoming more valuable. On a trailing-12-month basis, average revenue soared 34% year over year to $42.91 per user.</p><p>You need a streaming stick or a Roku-enabled television to be an active user, so the company tries to encourage their uptake by keeping these devices relatively inexpensive. Supply chain shortages are leading to losses from the manufacturing side of Roku&#39;s operation, but this is most likely a temporary problem.</p><p>As a practice, targeted advertising on connected televisions is still in its early days. The investments Roku is making to gain a leading share of the AVOD market could pay off many times over for patient shareholders.</p><h2>SoFi Technologies</h2><p>SoFi shares rocketed higher after the company&#39;s stock market debut in late 2020. Unfortunately, it has fallen about 70% from last year&#39;s high-water mark.</p><p>Analysts who keep tabs on SoFi think the up-and-coming consumer-focused bank can regain some of those losses. The consensus price target for SoFi represents a 64% premium over its price now.</p><p>Like many fintech stocks, SoFi has been under an unusual amount of pressure because nobody really knows if the company can succeed in a rising interest rate environment. Investors are also concerned about the ongoing student loan moratorium because SoFi cut its teeth refinancing student loans and this is still part of the company&#39;s overall operation.</p><p>Thanks to the rapid growth and diversification of SoFi&#39;s revenue sources, the persistent student loan moratorium hardly makes a dent. In the first quarter, SoFi&#39;s total customer base shot up by 408,000 members to reach 3.9 million.</p><p>The integrated application keeps encouraging customers to engage with multiple products including mortgages, credit cards, and retirement accounts. SoFi customers began using 689,000 new products in the first quarter, bringing the total up to 5.9 million.</p><p>In addition to an expanding customer base, SoFi owns Galileo, which provides the financial industry&#39;s most popular tools for setting up new accounts and implementing payment systems. With multiple growth engines pushing it forward, investors who hold this stock could come out miles ahead over the long run.</p><h2>Matterport</h2><p>Matterport shares are down 84% from the high-water mark they set last fall. Wall Street analysts expect a rebound up ahead. The consensus target for this metaverse stock is 76% above recent prices.</p><p>Matterport helps individuals and organizations create digital twins of real-world spaces, and its popularity is surging. The company finished the first quarter with 562,000 subscribers, which was 70% more than it had a year earlier.</p><p>Matterport allows its lowest-tier subscribers to use their smartphones to make basic maps of their homes and offices for free. Now the company has 7.3 million spaces under management, which is many times more than all of its competitors combined.</p><p>In the first quarter, Matterport signed a deal with Midland Holdings. This is a giant residential real estate broker in China that intends to create virtual 3D experiences for its entire portfolio of properties. It&#39;s probably just a matter of time before digital twins are a standard feature of real estate listings everywhere. With a commanding lead in this burgeoning industry, this stock has a chance to explode higher in the years to come.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks Wall Street Thinks Could Rise 70% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks Wall Street Thinks Could Rise 70% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-20 23:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/20/3-growth-stocks-wall-street-thinks-could-rise-64-o/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This has been an absolutely rotten year to be a growth stock investor. The iShares S&P 500 Growth Pacer Swan SOS Fund of Funds ETF|ETF has fallen a staggering 26% this year.But the dark clouds hanging...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/20/3-growth-stocks-wall-street-thinks-could-rise-64-o/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SOFI":"SoFi Technologies Inc.","ROKU":"Roku Inc","MTTR":"Matterport, Inc."},"source_url":"https://www.fool.com/investing/2022/05/20/3-growth-stocks-wall-street-thinks-could-rise-64-o/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2236009402","content_text":"This has been an absolutely rotten year to be a growth stock investor. The iShares S&P 500 Growth Pacer Swan SOS Fund of Funds ETF|ETF has fallen a staggering 26% this year.But the dark clouds hanging over the market are lined with silver for patient investors who stick with terrific businesses like Roku, SoFi Technologies, and Matterport. That's because a stock market scorned for growth stocks in general has driven shares of these former market darlings down to prices they can easily bounce back from.RokuRoku shares are down about 80% from the peak they reached last summer. Analysts on Wall Street who follow the company expect a swift rebound. The average price target for Roku represents a 70% premium over recent prices.Now that the stay-at-home orders meant to blunt the spread of the coronavirus are no longer in play, Roku stock has lost a lot of its luster. The stock's dive isn't due to poor performance. First-quarter revenue soared 28% year over year. That's especially impressive because at the beginning of the previous-year period, hardly anyone had been vaccinated yet.Roku added 1.1 million accounts in the first quarter and ended March with 61.3 million in total. As more advertisers shift their budgets away from linear broadcasting and toward ad-supported video-on-demand (AVOD), those accounts are becoming more valuable. On a trailing-12-month basis, average revenue soared 34% year over year to $42.91 per user.You need a streaming stick or a Roku-enabled television to be an active user, so the company tries to encourage their uptake by keeping these devices relatively inexpensive. Supply chain shortages are leading to losses from the manufacturing side of Roku's operation, but this is most likely a temporary problem.As a practice, targeted advertising on connected televisions is still in its early days. The investments Roku is making to gain a leading share of the AVOD market could pay off many times over for patient shareholders.SoFi TechnologiesSoFi shares rocketed higher after the company's stock market debut in late 2020. Unfortunately, it has fallen about 70% from last year's high-water mark.Analysts who keep tabs on SoFi think the up-and-coming consumer-focused bank can regain some of those losses. The consensus price target for SoFi represents a 64% premium over its price now.Like many fintech stocks, SoFi has been under an unusual amount of pressure because nobody really knows if the company can succeed in a rising interest rate environment. Investors are also concerned about the ongoing student loan moratorium because SoFi cut its teeth refinancing student loans and this is still part of the company's overall operation.Thanks to the rapid growth and diversification of SoFi's revenue sources, the persistent student loan moratorium hardly makes a dent. In the first quarter, SoFi's total customer base shot up by 408,000 members to reach 3.9 million.The integrated application keeps encouraging customers to engage with multiple products including mortgages, credit cards, and retirement accounts. SoFi customers began using 689,000 new products in the first quarter, bringing the total up to 5.9 million.In addition to an expanding customer base, SoFi owns Galileo, which provides the financial industry's most popular tools for setting up new accounts and implementing payment systems. With multiple growth engines pushing it forward, investors who hold this stock could come out miles ahead over the long run.MatterportMatterport shares are down 84% from the high-water mark they set last fall. Wall Street analysts expect a rebound up ahead. The consensus target for this metaverse stock is 76% above recent prices.Matterport helps individuals and organizations create digital twins of real-world spaces, and its popularity is surging. The company finished the first quarter with 562,000 subscribers, which was 70% more than it had a year earlier.Matterport allows its lowest-tier subscribers to use their smartphones to make basic maps of their homes and offices for free. Now the company has 7.3 million spaces under management, which is many times more than all of its competitors combined.In the first quarter, Matterport signed a deal with Midland Holdings. This is a giant residential real estate broker in China that intends to create virtual 3D experiences for its entire portfolio of properties. It's probably just a matter of time before digital twins are a standard feature of real estate listings everywhere. With a commanding lead in this burgeoning industry, this stock has a chance to explode higher in the years to come.","news_type":1},"isVote":1,"tweetType":1,"viewCount":15,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9049257413,"gmtCreate":1655807311632,"gmtModify":1676535708667,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9049257413","repostId":"1142598857","repostType":4,"repost":{"id":"1142598857","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1655801843,"share":"https://ttm.financial/m/news/1142598857?lang=&edition=fundamental","pubTime":"2022-06-21 16:57","market":"us","language":"en","title":"Valneva Shares Soared 91% in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1142598857","media":"Tiger Newspress","summary":"U.S. healthcare giant Pfizer has agreed to invest 90.5 million euros ($95.24 million) to buy an 8.1%","content":"<html><head></head><body><p>U.S. healthcare giant Pfizer has agreed to invest 90.5 million euros ($95.24 million) to buy an 8.1% percent stake in French vaccines company, as the companies announced developments in their partnership to tackle the Lyme disease.</p><p>Pfizer will buy the stake in Valneva, which is also working on its COVID-19 vaccine, at a price of 9.49 euros per share, via a reserved capital increase.</p><p>Shares in Valneva rose sharply, surging by 91% in premarket trading Tuesday.</p><p><img src=\"https://static.tigerbbs.com/02b28b1054ed9e3a5a3a4a77c92db6e9\" tg-width=\"874\" tg-height=\"619\" referrerpolicy=\"no-referrer\"/></p><p>Valneva will use the proceeds from Pfizer’s equity investment to support its Phase 3 development contribution to the Lyme disease program.</p><p>Valneva and Pfizer also updated the terms of their collaboration and license agreement which they announced on April 30, 2020 for the Lyme disease vaccine candidate VLA15.</p><p>&#34;Pfizer&#39;s investment in Valneva highlights the quality of the work that we’ve done together over the past two years and is a strong recognition of Valneva&#39;s vaccine expertise,&#34; said Valneva chief executive Thomas Lingelbach.</p><p>As previously announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study of VLA15 in the third quarter of 2022, they added.</p><p>Under the revised deal, Valneva will now fund 40% of the remaining shared development costs compared to 30% before.</p><p>Pfizer will pay Valneva tiered royalties ranging from 14% to 22%. In addition, the royalties will be complemented by up to $100 million in milestones payable to Valneva based on cumulative sales, added the companies.</p><p>($1 = 0.9502 euros)</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Valneva Shares Soared 91% in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValneva Shares Soared 91% in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-06-21 16:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>U.S. healthcare giant Pfizer has agreed to invest 90.5 million euros ($95.24 million) to buy an 8.1% percent stake in French vaccines company, as the companies announced developments in their partnership to tackle the Lyme disease.</p><p>Pfizer will buy the stake in Valneva, which is also working on its COVID-19 vaccine, at a price of 9.49 euros per share, via a reserved capital increase.</p><p>Shares in Valneva rose sharply, surging by 91% in premarket trading Tuesday.</p><p><img src=\"https://static.tigerbbs.com/02b28b1054ed9e3a5a3a4a77c92db6e9\" tg-width=\"874\" tg-height=\"619\" referrerpolicy=\"no-referrer\"/></p><p>Valneva will use the proceeds from Pfizer’s equity investment to support its Phase 3 development contribution to the Lyme disease program.</p><p>Valneva and Pfizer also updated the terms of their collaboration and license agreement which they announced on April 30, 2020 for the Lyme disease vaccine candidate VLA15.</p><p>&#34;Pfizer&#39;s investment in Valneva highlights the quality of the work that we’ve done together over the past two years and is a strong recognition of Valneva&#39;s vaccine expertise,&#34; said Valneva chief executive Thomas Lingelbach.</p><p>As previously announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study of VLA15 in the third quarter of 2022, they added.</p><p>Under the revised deal, Valneva will now fund 40% of the remaining shared development costs compared to 30% before.</p><p>Pfizer will pay Valneva tiered royalties ranging from 14% to 22%. In addition, the royalties will be complemented by up to $100 million in milestones payable to Valneva based on cumulative sales, added the companies.</p><p>($1 = 0.9502 euros)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VALN":"Valneva SE"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142598857","content_text":"U.S. healthcare giant Pfizer has agreed to invest 90.5 million euros ($95.24 million) to buy an 8.1% percent stake in French vaccines company, as the companies announced developments in their partnership to tackle the Lyme disease.Pfizer will buy the stake in Valneva, which is also working on its COVID-19 vaccine, at a price of 9.49 euros per share, via a reserved capital increase.Shares in Valneva rose sharply, surging by 91% in premarket trading Tuesday.Valneva will use the proceeds from Pfizer’s equity investment to support its Phase 3 development contribution to the Lyme disease program.Valneva and Pfizer also updated the terms of their collaboration and license agreement which they announced on April 30, 2020 for the Lyme disease vaccine candidate VLA15.\"Pfizer's investment in Valneva highlights the quality of the work that we’ve done together over the past two years and is a strong recognition of Valneva's vaccine expertise,\" said Valneva chief executive Thomas Lingelbach.As previously announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study of VLA15 in the third quarter of 2022, they added.Under the revised deal, Valneva will now fund 40% of the remaining shared development costs compared to 30% before.Pfizer will pay Valneva tiered royalties ranging from 14% to 22%. In addition, the royalties will be complemented by up to $100 million in milestones payable to Valneva based on cumulative sales, added the companies.($1 = 0.9502 euros)","news_type":1},"isVote":1,"tweetType":1,"viewCount":70,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9055918563,"gmtCreate":1655223691552,"gmtModify":1676535589169,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Lol...she got luck today and only today","listText":"Lol...she got luck today and only today","text":"Lol...she got luck today and only today","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9055918563","repostId":"2243484620","repostType":4,"repost":{"id":"2243484620","kind":"highlight","pubTimestamp":1655218797,"share":"https://ttm.financial/m/news/2243484620?lang=&edition=fundamental","pubTime":"2022-06-14 22:59","market":"us","language":"en","title":"Cathie Wood Goes Shopping: 3 Beaten-Down Growth Stocks She Just Bought","url":"https://stock-news.laohu8.com/highlight/detail?id=2243484620","media":"Motley Fool","summary":"As the markets continue to burn, Ark Invest's lead stock picker is charging into the inferno to scoop up more shares of these underappreciated gems.","content":"<html><head></head><body><p>Cathie Wood, the CEO of Ark Invest, made her name by embracing innovative businesses in the early stages of their life cycle. If you&#39;ve been paying attention to the stock market lately, you know that up-and-coming technology stocks have been under a lot of pressure.</p><p>Despite prices that are sinking in the present, Wood thinks there could be big gains down the road for savvy tech stock investors who wait out the storm. Here are three stocks that are more than 77% below the peak prices they reached last year. Here&#39;s why Wood&#39;s convinced they can outperform over time.</p><h2><a href=\"https://laohu8.com/S/PATH\">UiPath</a></h2><p>Wood has been a big fan of <b>UiPath</b> since its stock market debut in April of 2021. Unfortunately, shares of this enterprise automation business have been hammered down around 78% from their post-IPO peak.</p><p>Ark Invest&#39;s exchange-traded funds (<a href=\"https://laohu8.com/S/PSFF\">Pacer Swan SOS Fund of Funds ETF|ETF</a>s) have been buying up more shares of UiPath stock at beaten-down prices. Now, it&#39;s the seventh largest holding in the flagship <b>Ark Innovation ETF</b>.</p><p>By emulating human clicks and keystrokes, UiPath&#39;s robotic process automation (RPA) platform brings the benefits of automation to office employees, even if they lack programming skills. For example, corrections departments in the Netherlands use UiPath&#39;s robots to fill out forms so employees have more time to actually rehabilitate the convicted.</p><p>Businesses eager to retain talented employees are beating a path to UiPath&#39;s door. During its fiscal first quarter ended April 30, revenue rose 32% year over year to $254 million.</p><p>Information technology professionals enjoy using UiPath but you don&#39;t need to be a programmer to put the platform to good use. This is a big advantage UiPath has over its competitors in the RPA industry. With the leading platform for people who can&#39;t program their way out of a wet paper bag, investors can look forward to a rapidly expanding customer base for the foreseeable future.</p><h2>Roblox</h2><p>Wood was eager to buy up shares of <b>Roblox</b> late last year when it was trading near its all-time high. The stock has tumbled 79% from its peak, but that hasn&#39;t stopped Ark Invest from buying more shares of this metaverse stock with confidence.</p><p>Roblox is all about individual gamers creating their own games, which is a lot more popular than you might expect. There were 54.1 million daily active users on Roblox in the first quarter which was 28% more than the previous year&#39;s period.</p><p>The stock has been tanking because not as many parents are scrambling to find ways to keep their children entertained all day while they try to work from home. The important thing to remember here is that those kids will eventually get their own jobs.</p><p>As the age range of Roblox&#39;s customer base expands, opportunities for monetization also improve. For example, this March, <b>Sony</b>, and Roblox teamed up to host a live concert with 24kGoldn, a multi-platinum artist who grew up with Roblox. Concert sizes are traditionally limited by venue sizes and geography. These aren&#39;t constraints in a virtual setting. Expect more artists who are eager to sell virtual merchandise to millions of fans at a single event to start holding virtual concerts on Roblox in the future.</p><h2>Roku</h2><p><b>Roku</b> has tanked about 83% from the high water mark it set in 2021. The dramatic losses haven&#39;t darkened Wood&#39;s expectations for this streaming stock and its long-term future.</p><p>Now that we&#39;re spending less time in our homes, usage of Roku-enabled devices isn&#39;t growing quite as quickly as it did a year earlier. Despite the challenges, Roku&#39;s still growing pretty fast. The company racked up 20.9 million streaming hours in the first quarter, which was 14% more than it recorded in the previous year period.</p><p>More hours of engagement mean more revenue and serving targeted advertisements to connected televisions is an increasingly lucrative business. Average annual revenue per user soared 34% year over year to $42.91 in the first quarter.</p><p>Big brand advertisers are still shifting their budgets away from broadcast television and toward ad-supported streaming platforms. As America&#39;s largest streaming platform by hours viewed, Roku is in the right place at the right time and Wood knows it.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Goes Shopping: 3 Beaten-Down Growth Stocks She Just Bought</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Goes Shopping: 3 Beaten-Down Growth Stocks She Just Bought\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-14 22:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/06/14/cathie-wood-goes-shopping-3-beaten-down-growth-sto/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cathie Wood, the CEO of Ark Invest, made her name by embracing innovative businesses in the early stages of their life cycle. If you've been paying attention to the stock market lately, you know that ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/06/14/cathie-wood-goes-shopping-3-beaten-down-growth-sto/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RBLX":"Roblox Corporation","PATH":"UiPath","ROKU":"Roku Inc"},"source_url":"https://www.fool.com/investing/2022/06/14/cathie-wood-goes-shopping-3-beaten-down-growth-sto/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2243484620","content_text":"Cathie Wood, the CEO of Ark Invest, made her name by embracing innovative businesses in the early stages of their life cycle. If you've been paying attention to the stock market lately, you know that up-and-coming technology stocks have been under a lot of pressure.Despite prices that are sinking in the present, Wood thinks there could be big gains down the road for savvy tech stock investors who wait out the storm. Here are three stocks that are more than 77% below the peak prices they reached last year. Here's why Wood's convinced they can outperform over time.UiPathWood has been a big fan of UiPath since its stock market debut in April of 2021. Unfortunately, shares of this enterprise automation business have been hammered down around 78% from their post-IPO peak.Ark Invest's exchange-traded funds (Pacer Swan SOS Fund of Funds ETF|ETFs) have been buying up more shares of UiPath stock at beaten-down prices. Now, it's the seventh largest holding in the flagship Ark Innovation ETF.By emulating human clicks and keystrokes, UiPath's robotic process automation (RPA) platform brings the benefits of automation to office employees, even if they lack programming skills. For example, corrections departments in the Netherlands use UiPath's robots to fill out forms so employees have more time to actually rehabilitate the convicted.Businesses eager to retain talented employees are beating a path to UiPath's door. During its fiscal first quarter ended April 30, revenue rose 32% year over year to $254 million.Information technology professionals enjoy using UiPath but you don't need to be a programmer to put the platform to good use. This is a big advantage UiPath has over its competitors in the RPA industry. With the leading platform for people who can't program their way out of a wet paper bag, investors can look forward to a rapidly expanding customer base for the foreseeable future.RobloxWood was eager to buy up shares of Roblox late last year when it was trading near its all-time high. The stock has tumbled 79% from its peak, but that hasn't stopped Ark Invest from buying more shares of this metaverse stock with confidence.Roblox is all about individual gamers creating their own games, which is a lot more popular than you might expect. There were 54.1 million daily active users on Roblox in the first quarter which was 28% more than the previous year's period.The stock has been tanking because not as many parents are scrambling to find ways to keep their children entertained all day while they try to work from home. The important thing to remember here is that those kids will eventually get their own jobs.As the age range of Roblox's customer base expands, opportunities for monetization also improve. For example, this March, Sony, and Roblox teamed up to host a live concert with 24kGoldn, a multi-platinum artist who grew up with Roblox. Concert sizes are traditionally limited by venue sizes and geography. These aren't constraints in a virtual setting. Expect more artists who are eager to sell virtual merchandise to millions of fans at a single event to start holding virtual concerts on Roblox in the future.RokuRoku has tanked about 83% from the high water mark it set in 2021. The dramatic losses haven't darkened Wood's expectations for this streaming stock and its long-term future.Now that we're spending less time in our homes, usage of Roku-enabled devices isn't growing quite as quickly as it did a year earlier. Despite the challenges, Roku's still growing pretty fast. The company racked up 20.9 million streaming hours in the first quarter, which was 14% more than it recorded in the previous year period.More hours of engagement mean more revenue and serving targeted advertisements to connected televisions is an increasingly lucrative business. Average annual revenue per user soared 34% year over year to $42.91 in the first quarter.Big brand advertisers are still shifting their budgets away from broadcast television and toward ad-supported streaming platforms. As America's largest streaming platform by hours viewed, Roku is in the right place at the right time and Wood knows it.","news_type":1},"isVote":1,"tweetType":1,"viewCount":40,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9051742416,"gmtCreate":1654744824835,"gmtModify":1676535503655,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Jack Ma👍🏽","listText":"Jack Ma👍🏽","text":"Jack Ma👍🏽","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9051742416","repostId":"2242298847","repostType":2,"repost":{"id":"2242298847","kind":"highlight","pubTimestamp":1654731734,"share":"https://ttm.financial/m/news/2242298847?lang=&edition=fundamental","pubTime":"2022-06-09 07:42","market":"hk","language":"en","title":"Why Did Alibaba Shares Rise Almost 15% Wednesday? It's All in the Games","url":"https://stock-news.laohu8.com/highlight/detail?id=2242298847","media":"seekingalpha","summary":"Alibaba (NYSE:BABA) shares climbed almost 15% Wednesday as the Chinese Internet giant benefitted fro","content":"<html><head></head><body><p></p><p><img src=\"https://static.tigerbbs.com/c734479100befddea1e6e6d9d50f31a2\" tg-width=\"750\" tg-height=\"496\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/>Alibaba (NYSE:BABA) shares climbed almost 15% Wednesday as the Chinese Internet giant benefitted from signs that the Beijing government is taking new steps to support its tech sector.</p><p>Early Wednesday, Chinese authorities approved another license for domestic video games, which gave investors enthusiasm about the business prospects for many of China&#39;s leading tech companies. It was the second round of new licenses this week, and came after China put a halt on such licenses last year in and effort to curtail the amount of time minors in the country were spending online.</p><p>With Wednesday&#39;s gains, Alibaba (BABA) shares ended the day at $119.62, their best close since February.</p><p>Along with Alibaba (BABA) other Chinese stocks flexed their muscles, with JD.com (JD) rising almost 8%, PinDuoDuo (PDD) climbing nearly 10%, Baidu (BIDU) and ride-sharing leader DiDi Global (DIDI) rising more than 12% on the day.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did Alibaba Shares Rise Almost 15% Wednesday? It's All in the Games</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did Alibaba Shares Rise Almost 15% Wednesday? It's All in the Games\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-09 07:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3846903-why-did-alibaba-shares-rose-almost-15-wednesday-its-all-in-the-games><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alibaba (NYSE:BABA) shares climbed almost 15% Wednesday as the Chinese Internet giant benefitted from signs that the Beijing government is taking new steps to support its tech sector.Early Wednesday, ...</p>\n\n<a href=\"https://seekingalpha.com/news/3846903-why-did-alibaba-shares-rose-almost-15-wednesday-its-all-in-the-games\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4514":"搜索引擎","BK4565":"NFT概念","BK4539":"次新股","BK4554":"元宇宙及AR概念","09618":"京东集团-SW","09988":"阿里巴巴-W","BK4553":"喜马拉雅资本持仓","BK4531":"中概回港概念","BK4534":"瑞士信贷持仓","PDD":"拼多多","BK4533":"AQR资本管理(全球第二大对冲基金)","BABA":"阿里巴巴","BK4575":"芯片概念","BK4558":"双十一","BK4509":"腾讯概念","BK4535":"淡马锡持仓","BK4524":"宅经济概念","DIDIY":"DiDi Global Inc.","BK4527":"明星科技股","BK4538":"云计算","BK4501":"段永平概念","BK4077":"互动媒体与服务","BK4526":"热门中概股","BIDU":"百度","BK4579":"人工智能","DIDI":"滴滴(已退市)","BK4552":"Archegos爆仓风波概念","BK4122":"互联网与直销零售","BK4503":"景林资产持仓","JD":"京东","BK4574":"无人驾驶","BK4551":"寇图资本持仓","BK4022":"陆运","BK4502":"阿里概念","BK4561":"索罗斯持仓","BK4505":"高瓴资本持仓","QNETCN":"纳斯达克中美互联网老虎指数","BK4581":"高盛持仓","BK4504":"桥水持仓"},"source_url":"https://seekingalpha.com/news/3846903-why-did-alibaba-shares-rose-almost-15-wednesday-its-all-in-the-games","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2242298847","content_text":"Alibaba (NYSE:BABA) shares climbed almost 15% Wednesday as the Chinese Internet giant benefitted from signs that the Beijing government is taking new steps to support its tech sector.Early Wednesday, Chinese authorities approved another license for domestic video games, which gave investors enthusiasm about the business prospects for many of China's leading tech companies. It was the second round of new licenses this week, and came after China put a halt on such licenses last year in and effort to curtail the amount of time minors in the country were spending online.With Wednesday's gains, Alibaba (BABA) shares ended the day at $119.62, their best close since February.Along with Alibaba (BABA) other Chinese stocks flexed their muscles, with JD.com (JD) rising almost 8%, PinDuoDuo (PDD) climbing nearly 10%, Baidu (BIDU) and ride-sharing leader DiDi Global (DIDI) rising more than 12% on the day.","news_type":1},"isVote":1,"tweetType":1,"viewCount":264,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9022437790,"gmtCreate":1653567318410,"gmtModify":1676535304861,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"All the market price too high...Price lower is goodfor investor.","listText":"All the market price too high...Price lower is goodfor investor.","text":"All the market price too high...Price lower is goodfor investor.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9022437790","repostId":"1122775308","repostType":4,"repost":{"id":"1122775308","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1653566259,"share":"https://ttm.financial/m/news/1122775308?lang=&edition=fundamental","pubTime":"2022-05-26 19:57","market":"us","language":"en","title":"Jefferies Cut Tesla to $1,050; Deutsche Bank Reduced Nvidia to $190｜Price Target Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=1122775308","media":"Benzinga","summary":"UBS cut The Kraft Heinz Company price target from $40 to $34. Kraft Heinz shares fell 3.1% to $38.66","content":"<html><head></head><body><ul><li>UBS cut <b>The Kraft Heinz Company</b> price target from $40 to $34. Kraft Heinz shares fell 3.1% to $38.66 in pre-market trading.</li><li>Deutsche Bank reduced <b>NVIDIA Corporation</b> price target from $255 to $190. NVIDIA shares dropped 4.2% to $162.61 in pre-market trading.</li><li>Barclays lowered the price target for <b>Urban Outfitters, Inc.</b> from $29 to $21. Urban Outfitters shares fell 0.1% to $20.75 in pre-market trading.</li><li>Citigroup cut the price target for <b>Snowflake Inc.</b> from $232 to $175. 4. Snowflake shares fell 12.8% to $115.84 in pre-market trading.</li><li>B of A Securities reduced <b>Nutanix, Inc.</b> price target from $54 to $22. Nutanix shares fell 37.2% to $13.46 in pre-market trading.</li></ul><ul><li>Jefferies cut <b>Tesla, Inc.</b> price target from $1,250 to $1,050. Tesla shares rose 1.8% to $671.04 in pre-market trading.</li><li>Wolfe Research lowered the price target on <b>Comerica Incorporated</b> from $124 to $85. Comerica shares rose 0.6% to $79.60 in pre-market trading.</li><li>Needham cut the price target on <b>Splunk Inc.</b> from $145 to $118. Splunk shares rose 6.5% to $99.20 in pre-market trading.</li><li>Baird cut the price target on <b>DICK&#39;S Sporting Goods, Inc.</b> from $115 to $85. Dick&#39;s Sporting shares rose 1.4% to $79.24 in pre-market trading.</li><li>Morgan Stanley lowered <b>Lululemon Athletica Inc.</b> price target from $339 to $303. Lululemon shares rose 6% to $276.23 in pre-market trading.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jefferies Cut Tesla to $1,050; Deutsche Bank Reduced Nvidia to $190｜Price Target Changes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJefferies Cut Tesla to $1,050; Deutsche Bank Reduced Nvidia to $190｜Price Target Changes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-05-26 19:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><ul><li>UBS cut <b>The Kraft Heinz Company</b> price target from $40 to $34. Kraft Heinz shares fell 3.1% to $38.66 in pre-market trading.</li><li>Deutsche Bank reduced <b>NVIDIA Corporation</b> price target from $255 to $190. NVIDIA shares dropped 4.2% to $162.61 in pre-market trading.</li><li>Barclays lowered the price target for <b>Urban Outfitters, Inc.</b> from $29 to $21. Urban Outfitters shares fell 0.1% to $20.75 in pre-market trading.</li><li>Citigroup cut the price target for <b>Snowflake Inc.</b> from $232 to $175. 4. Snowflake shares fell 12.8% to $115.84 in pre-market trading.</li><li>B of A Securities reduced <b>Nutanix, Inc.</b> price target from $54 to $22. Nutanix shares fell 37.2% to $13.46 in pre-market trading.</li></ul><ul><li>Jefferies cut <b>Tesla, Inc.</b> price target from $1,250 to $1,050. Tesla shares rose 1.8% to $671.04 in pre-market trading.</li><li>Wolfe Research lowered the price target on <b>Comerica Incorporated</b> from $124 to $85. Comerica shares rose 0.6% to $79.60 in pre-market trading.</li><li>Needham cut the price target on <b>Splunk Inc.</b> from $145 to $118. Splunk shares rose 6.5% to $99.20 in pre-market trading.</li><li>Baird cut the price target on <b>DICK&#39;S Sporting Goods, Inc.</b> from $115 to $85. Dick&#39;s Sporting shares rose 1.4% to $79.24 in pre-market trading.</li><li>Morgan Stanley lowered <b>Lululemon Athletica Inc.</b> price target from $339 to $303. Lululemon shares rose 6% to $276.23 in pre-market trading.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","DKS":"迪克体育用品","KHC":"卡夫亨氏","NVDA":"英伟达","LULU":"lululemon athletica","SPLK":"Splunk Inc","SNOW":"Snowflake","CMA":"联信银行","URBN":"都市服饰","NTNX":"Nutanix Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122775308","content_text":"UBS cut The Kraft Heinz Company price target from $40 to $34. Kraft Heinz shares fell 3.1% to $38.66 in pre-market trading.Deutsche Bank reduced NVIDIA Corporation price target from $255 to $190. NVIDIA shares dropped 4.2% to $162.61 in pre-market trading.Barclays lowered the price target for Urban Outfitters, Inc. from $29 to $21. Urban Outfitters shares fell 0.1% to $20.75 in pre-market trading.Citigroup cut the price target for Snowflake Inc. from $232 to $175. 4. Snowflake shares fell 12.8% to $115.84 in pre-market trading.B of A Securities reduced Nutanix, Inc. price target from $54 to $22. Nutanix shares fell 37.2% to $13.46 in pre-market trading.Jefferies cut Tesla, Inc. price target from $1,250 to $1,050. Tesla shares rose 1.8% to $671.04 in pre-market trading.Wolfe Research lowered the price target on Comerica Incorporated from $124 to $85. Comerica shares rose 0.6% to $79.60 in pre-market trading.Needham cut the price target on Splunk Inc. from $145 to $118. Splunk shares rose 6.5% to $99.20 in pre-market trading.Baird cut the price target on DICK'S Sporting Goods, Inc. from $115 to $85. Dick's Sporting shares rose 1.4% to $79.24 in pre-market trading.Morgan Stanley lowered Lululemon Athletica Inc. price target from $339 to $303. Lululemon shares rose 6% to $276.23 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":77,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9022147579,"gmtCreate":1653507268291,"gmtModify":1676535292870,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Wow!!!","listText":"Wow!!!","text":"Wow!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9022147579","repostId":"1149593751","repostType":4,"repost":{"id":"1149593751","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1653501924,"share":"https://ttm.financial/m/news/1149593751?lang=&edition=fundamental","pubTime":"2022-05-26 02:05","market":"us","language":"en","title":"Fed Minutes Point to More Rate Hikes Quicker Than the Market Anticipates","url":"https://stock-news.laohu8.com/highlight/detail?id=1149593751","media":"Tiger Newspress","summary":"Fed minutes released Wednesday indicated that officials are prepared to move ahead with multiple 50 ","content":"<html><head></head><body><ul><li>Fed minutes released Wednesday indicated that officials are prepared to move ahead with multiple 50 basis points interest rate increases.</li><li>In addition, the Federal Open Market Committee said policy may have to move past “neutral” and into “restrictive” territory.</li><li>The minutes indicate that members are hopeful they can bring down inflation, but also concerned about financial stability risks.</li></ul><p>Federal Reserve officials earlier this month stressed the need to raise interest rates quickly and possibly more than markets anticipate to tackle a burgeoning inflation problem, meeting minutes released Wednesday showed.</p><p>Not only did policymakers see the need to raise benchmark borrowing rates by 50 points, but they also said similar hikes likely would be necessary at the next several meetings.</p><p>They further noted that policy may have to move past a “neutral” stance where it is neither supportive nor restrictive of growth, an important consideration for central bankers that could echo through the economy.</p><p>“Most participants judged that 50 basis point increases in the target range would likely be appropriate at the next couple of meetings,” the minutes stated. In addition, Federal Open Market Committee members indicated that “a restrictive stance of policy may well become appropriate depending on the evolving economic outlook and the risks to the outlook.”</p><p>The May 3-4 session saw the rate-setting FOMC approve the half percentage point cut and lay out a plan, starting in June, to reduce the central bank’s $9 trillion balance sheet consisting mostly of Treasurys and mortgage-backed securities.</p><p>That was the biggest rate increase in 22 years and came as the Fed is trying to pull down inflation running at a 40-year high.</p><p>Market pricing currently sees the Fed moving to a policy rate around 2.5%-2.75% by the end of the year, which would be consistent with where many central bankers view a neutral rate. Statements in the minutes, though, indicate that the committee is prepared to go beyond there.</p><p>“All participants reaffirmed their strong commitment and determination to take the measures necessary to restore price stability,” the meeting summary stated.</p><p>“To this end, participants agreed that the Committee should expeditiously move the stance of monetary policy toward a neutral posture, through both increases in the target range for the federal funds rate and reductions in the size of the Federal Reserve’s balance sheet,” it continued.</p><p>On the balance sheet issue, the plan will be to allow a capped level of proceeds to roll off each month, a number that will reach $95 billion by August, including $60 billion Treasurys and $35 billion for mortgages. The minutes further indicate that outright sale of MBS is possible, with notice of that happening well in advance.</p><p>The minutes mentioned inflation 60 times, with members expressing concern about rising prices even amid confidence that Fed policy and the easing of several contributing factors, such as supply-chain problems, combined with tighter monetary policy would help the situation. On the other hand, officials noted that the war in Ukraine and the Covid-associated lockdowns in China would exacerbate inflation.</p><p>At his post-meeting news conference, Fed Chairman Jerome Powell took the unusual step of addressing the American public directly to stress the central bank’s commitment to taming inflation. Last week, Powell said in a Wall Street Journal interview that it would take “clear and convincing evidence” that inflation was coming down to the Fed’s 2% target before the rate increases would stop.</p><p>Along with their resolve to bring down inflation came concerns about financial stability.</p><p>Officials expressed concern that tighter policy could cause instability in both the Treasury and commodities market. Specifically, the minutes cautioned about “the trading and risk-management practices of some key participants in commodities markets [that] were not fully visible to regulatory authorities.”</p><p>Risk-management issues “could give rise to significant liquidity demands for large banks, broker-dealers, and their clients.”</p><p>Still, officials remained committed to raising rates and reducing the balance sheet. The minutes stated that doing so would leave the Fed “well positioned later this year” to reevaluate the effect policy was having on inflation.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fed Minutes Point to More Rate Hikes Quicker Than the Market Anticipates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFed Minutes Point to More Rate Hikes Quicker Than the Market Anticipates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-05-26 02:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><ul><li>Fed minutes released Wednesday indicated that officials are prepared to move ahead with multiple 50 basis points interest rate increases.</li><li>In addition, the Federal Open Market Committee said policy may have to move past “neutral” and into “restrictive” territory.</li><li>The minutes indicate that members are hopeful they can bring down inflation, but also concerned about financial stability risks.</li></ul><p>Federal Reserve officials earlier this month stressed the need to raise interest rates quickly and possibly more than markets anticipate to tackle a burgeoning inflation problem, meeting minutes released Wednesday showed.</p><p>Not only did policymakers see the need to raise benchmark borrowing rates by 50 points, but they also said similar hikes likely would be necessary at the next several meetings.</p><p>They further noted that policy may have to move past a “neutral” stance where it is neither supportive nor restrictive of growth, an important consideration for central bankers that could echo through the economy.</p><p>“Most participants judged that 50 basis point increases in the target range would likely be appropriate at the next couple of meetings,” the minutes stated. In addition, Federal Open Market Committee members indicated that “a restrictive stance of policy may well become appropriate depending on the evolving economic outlook and the risks to the outlook.”</p><p>The May 3-4 session saw the rate-setting FOMC approve the half percentage point cut and lay out a plan, starting in June, to reduce the central bank’s $9 trillion balance sheet consisting mostly of Treasurys and mortgage-backed securities.</p><p>That was the biggest rate increase in 22 years and came as the Fed is trying to pull down inflation running at a 40-year high.</p><p>Market pricing currently sees the Fed moving to a policy rate around 2.5%-2.75% by the end of the year, which would be consistent with where many central bankers view a neutral rate. Statements in the minutes, though, indicate that the committee is prepared to go beyond there.</p><p>“All participants reaffirmed their strong commitment and determination to take the measures necessary to restore price stability,” the meeting summary stated.</p><p>“To this end, participants agreed that the Committee should expeditiously move the stance of monetary policy toward a neutral posture, through both increases in the target range for the federal funds rate and reductions in the size of the Federal Reserve’s balance sheet,” it continued.</p><p>On the balance sheet issue, the plan will be to allow a capped level of proceeds to roll off each month, a number that will reach $95 billion by August, including $60 billion Treasurys and $35 billion for mortgages. The minutes further indicate that outright sale of MBS is possible, with notice of that happening well in advance.</p><p>The minutes mentioned inflation 60 times, with members expressing concern about rising prices even amid confidence that Fed policy and the easing of several contributing factors, such as supply-chain problems, combined with tighter monetary policy would help the situation. On the other hand, officials noted that the war in Ukraine and the Covid-associated lockdowns in China would exacerbate inflation.</p><p>At his post-meeting news conference, Fed Chairman Jerome Powell took the unusual step of addressing the American public directly to stress the central bank’s commitment to taming inflation. Last week, Powell said in a Wall Street Journal interview that it would take “clear and convincing evidence” that inflation was coming down to the Fed’s 2% target before the rate increases would stop.</p><p>Along with their resolve to bring down inflation came concerns about financial stability.</p><p>Officials expressed concern that tighter policy could cause instability in both the Treasury and commodities market. Specifically, the minutes cautioned about “the trading and risk-management practices of some key participants in commodities markets [that] were not fully visible to regulatory authorities.”</p><p>Risk-management issues “could give rise to significant liquidity demands for large banks, broker-dealers, and their clients.”</p><p>Still, officials remained committed to raising rates and reducing the balance sheet. The minutes stated that doing so would leave the Fed “well positioned later this year” to reevaluate the effect policy was having on inflation.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149593751","content_text":"Fed minutes released Wednesday indicated that officials are prepared to move ahead with multiple 50 basis points interest rate increases.In addition, the Federal Open Market Committee said policy may have to move past “neutral” and into “restrictive” territory.The minutes indicate that members are hopeful they can bring down inflation, but also concerned about financial stability risks.Federal Reserve officials earlier this month stressed the need to raise interest rates quickly and possibly more than markets anticipate to tackle a burgeoning inflation problem, meeting minutes released Wednesday showed.Not only did policymakers see the need to raise benchmark borrowing rates by 50 points, but they also said similar hikes likely would be necessary at the next several meetings.They further noted that policy may have to move past a “neutral” stance where it is neither supportive nor restrictive of growth, an important consideration for central bankers that could echo through the economy.“Most participants judged that 50 basis point increases in the target range would likely be appropriate at the next couple of meetings,” the minutes stated. In addition, Federal Open Market Committee members indicated that “a restrictive stance of policy may well become appropriate depending on the evolving economic outlook and the risks to the outlook.”The May 3-4 session saw the rate-setting FOMC approve the half percentage point cut and lay out a plan, starting in June, to reduce the central bank’s $9 trillion balance sheet consisting mostly of Treasurys and mortgage-backed securities.That was the biggest rate increase in 22 years and came as the Fed is trying to pull down inflation running at a 40-year high.Market pricing currently sees the Fed moving to a policy rate around 2.5%-2.75% by the end of the year, which would be consistent with where many central bankers view a neutral rate. Statements in the minutes, though, indicate that the committee is prepared to go beyond there.“All participants reaffirmed their strong commitment and determination to take the measures necessary to restore price stability,” the meeting summary stated.“To this end, participants agreed that the Committee should expeditiously move the stance of monetary policy toward a neutral posture, through both increases in the target range for the federal funds rate and reductions in the size of the Federal Reserve’s balance sheet,” it continued.On the balance sheet issue, the plan will be to allow a capped level of proceeds to roll off each month, a number that will reach $95 billion by August, including $60 billion Treasurys and $35 billion for mortgages. The minutes further indicate that outright sale of MBS is possible, with notice of that happening well in advance.The minutes mentioned inflation 60 times, with members expressing concern about rising prices even amid confidence that Fed policy and the easing of several contributing factors, such as supply-chain problems, combined with tighter monetary policy would help the situation. On the other hand, officials noted that the war in Ukraine and the Covid-associated lockdowns in China would exacerbate inflation.At his post-meeting news conference, Fed Chairman Jerome Powell took the unusual step of addressing the American public directly to stress the central bank’s commitment to taming inflation. Last week, Powell said in a Wall Street Journal interview that it would take “clear and convincing evidence” that inflation was coming down to the Fed’s 2% target before the rate increases would stop.Along with their resolve to bring down inflation came concerns about financial stability.Officials expressed concern that tighter policy could cause instability in both the Treasury and commodities market. Specifically, the minutes cautioned about “the trading and risk-management practices of some key participants in commodities markets [that] were not fully visible to regulatory authorities.”Risk-management issues “could give rise to significant liquidity demands for large banks, broker-dealers, and their clients.”Still, officials remained committed to raising rates and reducing the balance sheet. The minutes stated that doing so would leave the Fed “well positioned later this year” to reevaluate the effect policy was having on inflation.","news_type":1},"isVote":1,"tweetType":1,"viewCount":75,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9029012385,"gmtCreate":1652701484447,"gmtModify":1676535144377,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"This got potential..Can try","listText":"This got potential..Can try","text":"This got potential..Can try","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9029012385","repostId":"2235749858","repostType":4,"repost":{"id":"2235749858","kind":"highlight","pubTimestamp":1652688018,"share":"https://ttm.financial/m/news/2235749858?lang=&edition=fundamental","pubTime":"2022-05-16 16:00","market":"us","language":"en","title":"3 High-Yield Dividend Stocks That Can Turn $300,000 Into $1 Million by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2235749858","media":"Motley Fool","summary":"These passive income powerhouses, with yields ranging from 4.4% to 11.9%, can generate some serious wealth for patient investors.","content":"<html><head></head><body><p>There are a lot of ways to make money on Wall Street, but few have proved more fruitful over the long run than buying dividend stocks.</p><p>Back in 2013, J.P. Morgan Asset Management unveiled a report examining the performance of dividend stocks to non-payers over a four-decade time frame (1972-2012). During this period, income stocks averaged an annual return of 9.5%, which meant that investors were doubling their money, on average, every 7.6 years. By comparison, the companies that didn&#39;t pay a dividend clawed their way to a meager average annual return of 1.6%.</p><p>Even if we didn&#39;t know the magnitude of difference between the average annual return of dividend stocks and non-dividend payers, these results aren&#39;t surprising. Businesses that pay a regular dividend are often profitable, time-tested, and can provide transparent long-term outlooks. In other words, they should increase in value over time.</p><p>With market volatility picking up big time, dividend stocks might be the perfect way to position your portfolio for success throughout the remainder of the decade. The following three high-yield stocks (i.e., yields 4% and above) all have the tools and intangibles needed to turn a $300,000 initial investment into $1 million, including dividends paid, by 2030.</p><h2><a href=\"https://laohu8.com/S/WBA\">Walgreens Boots Alliance</a>: 4.41% yield</h2><p>The first high-yield income stock that can help investors generate a 233% total return in eight years is pharmacy chain <b>Walgreens Boots Alliance</b> . Walgreens is currently paying out a 4.41% yield and has raised its base annual payout in each of the past 46 years.</p><p>Generally, healthcare stocks are a relatively safe investment no matter how well or poorly the U.S. economy is performing. Since we have no control over when we get sick or what ailment(s) we develop, there&#39;s a steady demand for prescription drugs, medical devices, and healthcare services.</p><p>However, Walgreens and its pharmacy peers found out the hard way that there are exceptions to the rule. Since pharmacies rely heavily on foot traffic, they were adversely affected by the COVID-19 pandemic. Walgreens saw weakness in its front-end retail sales, as well as its clinic revenue. But the good news is that this temporary weakness is allowing investors to buy a highly profitable company on the cheap.</p><p>Walgreens Boots Alliance is in the midst of executing a multipoint turnaround plan that&#39;s geared at boosting its operating margins, lifting organic growth, and promoting repeat visits and engagement. To improve operating margins, the company is trimming the fat, so to speak. When its fiscal 2021 year ended Aug. 31, 2021, Walgreens announced it had reduced its annual operating expenses by north of $2 billion a full year ahead of schedule.</p><p>Yet, while the company is cutting costs, it&#39;s also emphasizing digitization initiatives designed to promote convenience. Even though Walgreens&#39; brick-and-mortar locations will continue to generate the bulk of its revenue, encouraging consumers to purchase online should provide a nice sales boost.</p><p>There&#39;s also Walgreens&#39; partnership with and majority investment in VillageMD. The duo have opened over 100 co-located clinics thus far, with a goal of reaching 1,000 clinics in more than 30 U.S. markets by 2027.  The differentiating factor with these clinics is that they&#39;re physician-staffed. Being able to handle more than just a sniffle should encourage repeat visits and bolster consumer engagement with the Walgreens brand.</p><h2>Antero Midstream: 9.16% yield</h2><p>A second high-yield dividend stock with the ability to turn $300,000 into a cool $1 million by 2030 is energy middleman <b>Antero Midstream</b>. Antero is yielding 9.16% at the time of this writing, which means its passive income alone, when reinvested, can double your money by 2030.</p><p>For some folks, the thought of putting their money to work in oil and gas stocks is enough to make them cringe. Let&#39;s not forget that crude oil demand fell off a cliff 25 months ago during the initial stage of the pandemic. Ultimately, oil futures briefly traded as low as negative $40 a barrel.</p><p>As you can imagine, companies involved in oil and natural gas drilling were clobbered by this historic demand drawdown. However, midstream companies like Antero were in far better shape. Midstream businesses operate the infrastructure that helps move, transport, and sometimes refine, oil, natural gas, and natural gas liquids. In Antero Midstream&#39;s case, it provides gathering, compression, processing, and water delivery for parent company <b>Antero Resources</b>. The latter is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the largest producers of natural gas in the United States.</p><p>There are three factors that make Antero such a rock-solid investment over the next eight years. First, there&#39;s the structuring of Antero Midstream&#39;s contracts with its parent company. Midstream providers typically rely on volume-based or fixed-fee contracts to ensure a highly predictable level of operating cash flow each year. This means that even if the price of natural gas whipsaws, Antero Midstream will have clarity on its annual operating cash flow.</p><p>Secondly, Antero Resources is stepping up drilling on Antero Midstream&#39;s acreage. Although the latter did reduce its quarterly distribution by 27% in 2021 (again, still yielding 9.16%), this move was made so additional capital can be allocated for future infrastructure projects. Management expects $400 million in added incremental free cash flow by the midpoint of the decade.</p><p>And third, a big rebound in the price of natural gas, coupled with Antero Resources desire to boost production, has allowed Antero Midstream to improve its balance sheet. After ending 2020 with a leverage ratio of 3.1, the company anticipates this leverage ratio dipping below 1 by the end of the year.</p><h2><a href=\"https://laohu8.com/S/AGNCO\">AGNC Investment Corp.</a>: 11.86% yield</h2><p>The third and final high-yield income stock that can allow patient investors to turn $300,000 into $1 million by 2030 is mortgage real estate investment trust (REIT) <b><a href=\"https://laohu8.com/S/AGNCM\">AGNC Investment Corp</a>.</b>. AGNC has averaged a double-digit yield in 12 of the past 13 years. Reinvesting these payouts at an 11.86% yield would net more than a 150% return from the initial investment by the end of 2030.</p><p>Although the securities AGNC buys can be a bit complicated, the company&#39;s operating model is pretty easy to understand. Mortgage REITs are typically looking to borrow money at low short-term rates, then use this capital to acquire higher-yielding long-term assets, such as a mortgage-backed securities (MBS). The bigger the difference (known as net interest margin) between the average yield on owned assets minus the average borrowing rate, often the more profitable the mortgage REIT.</p><p>Over the past couple of months, things couldn&#39;t have gone any worse for mortgage REITs. Historically high inflation has encouraged the Fed to get aggressive with interest rates, which means short-term borrowing costs are rising. At the same time, the interest rate yield curve flattened. The yield curve describes the difference between short-and-long-term U.S. Treasury bond yields. When the yield curve flattens, net interest margin and book values for mortgage REITs usually decline.</p><p>However, when things look their bleakest is historically when it&#39;s the best time to buy into the mortgage REIT industry. For instance, even though rising interest rates are weighing on the industry in the short-term, higher rates should also increase the yields on the MBSs that AGNC is purchasing. Over time, this is a recipe for net interest margin expansion.</p><p>Another really important piece of the puzzle is the makeup of AGNC&#39;s investment portfolio. The company ended March with a $68.6 billion investment portfolio, 97.5% of which were agency assets.  An &#34;agency&#34; security is backed by the federal government in the event of default. While investing in these safe securities does lower the yield AGNC receives on the MBSs it buys, it also allows the company to deploy leverage in order to increase its profits.</p><p>Over the next eight years, there&#39;s a good chance AGNC&#39;s book value will increase and its share price will follow. When coupled with its mammoth monthly dividend, there exists a recipe for substantial wealth creation.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 High-Yield Dividend Stocks That Can Turn $300,000 Into $1 Million by 2030</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 High-Yield Dividend Stocks That Can Turn $300,000 Into $1 Million by 2030\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-16 16:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/05/15/3-high-yield-dividend-stocks-300000-into-1-million/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There are a lot of ways to make money on Wall Street, but few have proved more fruitful over the long run than buying dividend stocks.Back in 2013, J.P. Morgan Asset Management unveiled a report ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/05/15/3-high-yield-dividend-stocks-300000-into-1-million/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WBA":"沃尔格林联合博姿","AM":"Antero Midstream Corporation","AGNCO":"AGNC Investment Corp."},"source_url":"https://www.fool.com/investing/2022/05/15/3-high-yield-dividend-stocks-300000-into-1-million/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2235749858","content_text":"There are a lot of ways to make money on Wall Street, but few have proved more fruitful over the long run than buying dividend stocks.Back in 2013, J.P. Morgan Asset Management unveiled a report examining the performance of dividend stocks to non-payers over a four-decade time frame (1972-2012). During this period, income stocks averaged an annual return of 9.5%, which meant that investors were doubling their money, on average, every 7.6 years. By comparison, the companies that didn't pay a dividend clawed their way to a meager average annual return of 1.6%.Even if we didn't know the magnitude of difference between the average annual return of dividend stocks and non-dividend payers, these results aren't surprising. Businesses that pay a regular dividend are often profitable, time-tested, and can provide transparent long-term outlooks. In other words, they should increase in value over time.With market volatility picking up big time, dividend stocks might be the perfect way to position your portfolio for success throughout the remainder of the decade. The following three high-yield stocks (i.e., yields 4% and above) all have the tools and intangibles needed to turn a $300,000 initial investment into $1 million, including dividends paid, by 2030.Walgreens Boots Alliance: 4.41% yieldThe first high-yield income stock that can help investors generate a 233% total return in eight years is pharmacy chain Walgreens Boots Alliance . Walgreens is currently paying out a 4.41% yield and has raised its base annual payout in each of the past 46 years.Generally, healthcare stocks are a relatively safe investment no matter how well or poorly the U.S. economy is performing. Since we have no control over when we get sick or what ailment(s) we develop, there's a steady demand for prescription drugs, medical devices, and healthcare services.However, Walgreens and its pharmacy peers found out the hard way that there are exceptions to the rule. Since pharmacies rely heavily on foot traffic, they were adversely affected by the COVID-19 pandemic. Walgreens saw weakness in its front-end retail sales, as well as its clinic revenue. But the good news is that this temporary weakness is allowing investors to buy a highly profitable company on the cheap.Walgreens Boots Alliance is in the midst of executing a multipoint turnaround plan that's geared at boosting its operating margins, lifting organic growth, and promoting repeat visits and engagement. To improve operating margins, the company is trimming the fat, so to speak. When its fiscal 2021 year ended Aug. 31, 2021, Walgreens announced it had reduced its annual operating expenses by north of $2 billion a full year ahead of schedule.Yet, while the company is cutting costs, it's also emphasizing digitization initiatives designed to promote convenience. Even though Walgreens' brick-and-mortar locations will continue to generate the bulk of its revenue, encouraging consumers to purchase online should provide a nice sales boost.There's also Walgreens' partnership with and majority investment in VillageMD. The duo have opened over 100 co-located clinics thus far, with a goal of reaching 1,000 clinics in more than 30 U.S. markets by 2027.  The differentiating factor with these clinics is that they're physician-staffed. Being able to handle more than just a sniffle should encourage repeat visits and bolster consumer engagement with the Walgreens brand.Antero Midstream: 9.16% yieldA second high-yield dividend stock with the ability to turn $300,000 into a cool $1 million by 2030 is energy middleman Antero Midstream. Antero is yielding 9.16% at the time of this writing, which means its passive income alone, when reinvested, can double your money by 2030.For some folks, the thought of putting their money to work in oil and gas stocks is enough to make them cringe. Let's not forget that crude oil demand fell off a cliff 25 months ago during the initial stage of the pandemic. Ultimately, oil futures briefly traded as low as negative $40 a barrel.As you can imagine, companies involved in oil and natural gas drilling were clobbered by this historic demand drawdown. However, midstream companies like Antero were in far better shape. Midstream businesses operate the infrastructure that helps move, transport, and sometimes refine, oil, natural gas, and natural gas liquids. In Antero Midstream's case, it provides gathering, compression, processing, and water delivery for parent company Antero Resources. The latter is one of the largest producers of natural gas in the United States.There are three factors that make Antero such a rock-solid investment over the next eight years. First, there's the structuring of Antero Midstream's contracts with its parent company. Midstream providers typically rely on volume-based or fixed-fee contracts to ensure a highly predictable level of operating cash flow each year. This means that even if the price of natural gas whipsaws, Antero Midstream will have clarity on its annual operating cash flow.Secondly, Antero Resources is stepping up drilling on Antero Midstream's acreage. Although the latter did reduce its quarterly distribution by 27% in 2021 (again, still yielding 9.16%), this move was made so additional capital can be allocated for future infrastructure projects. Management expects $400 million in added incremental free cash flow by the midpoint of the decade.And third, a big rebound in the price of natural gas, coupled with Antero Resources desire to boost production, has allowed Antero Midstream to improve its balance sheet. After ending 2020 with a leverage ratio of 3.1, the company anticipates this leverage ratio dipping below 1 by the end of the year.AGNC Investment Corp.: 11.86% yieldThe third and final high-yield income stock that can allow patient investors to turn $300,000 into $1 million by 2030 is mortgage real estate investment trust (REIT) AGNC Investment Corp.. AGNC has averaged a double-digit yield in 12 of the past 13 years. Reinvesting these payouts at an 11.86% yield would net more than a 150% return from the initial investment by the end of 2030.Although the securities AGNC buys can be a bit complicated, the company's operating model is pretty easy to understand. Mortgage REITs are typically looking to borrow money at low short-term rates, then use this capital to acquire higher-yielding long-term assets, such as a mortgage-backed securities (MBS). The bigger the difference (known as net interest margin) between the average yield on owned assets minus the average borrowing rate, often the more profitable the mortgage REIT.Over the past couple of months, things couldn't have gone any worse for mortgage REITs. Historically high inflation has encouraged the Fed to get aggressive with interest rates, which means short-term borrowing costs are rising. At the same time, the interest rate yield curve flattened. The yield curve describes the difference between short-and-long-term U.S. Treasury bond yields. When the yield curve flattens, net interest margin and book values for mortgage REITs usually decline.However, when things look their bleakest is historically when it's the best time to buy into the mortgage REIT industry. For instance, even though rising interest rates are weighing on the industry in the short-term, higher rates should also increase the yields on the MBSs that AGNC is purchasing. Over time, this is a recipe for net interest margin expansion.Another really important piece of the puzzle is the makeup of AGNC's investment portfolio. The company ended March with a $68.6 billion investment portfolio, 97.5% of which were agency assets.  An \"agency\" security is backed by the federal government in the event of default. While investing in these safe securities does lower the yield AGNC receives on the MBSs it buys, it also allows the company to deploy leverage in order to increase its profits.Over the next eight years, there's a good chance AGNC's book value will increase and its share price will follow. When coupled with its mammoth monthly dividend, there exists a recipe for substantial wealth creation.","news_type":1},"isVote":1,"tweetType":1,"viewCount":40,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9045174255,"gmtCreate":1656588138377,"gmtModify":1676535858645,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"All in pfizer.....Stock of the year💪🏼👏🏼👏🏼👏🏼👏🏼🚀","listText":"All in pfizer.....Stock of the year💪🏼👏🏼👏🏼👏🏼👏🏼🚀","text":"All in pfizer.....Stock of the year💪🏼👏🏼👏🏼👏🏼👏🏼🚀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9045174255","repostId":"2247475886","repostType":2,"repost":{"id":"2247475886","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1656587274,"share":"https://ttm.financial/m/news/2247475886?lang=&edition=fundamental","pubTime":"2022-06-30 19:07","market":"us","language":"en","title":"Pfizer Files for Full FDA Approval for COVID-19 Antiviral","url":"https://stock-news.laohu8.com/highlight/detail?id=2247475886","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 tr","content":"<html><head></head><body><p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.</p><p>PAXLOVID has previously been granted Emergency Use Authorization <a href=\"https://laohu8.com/S/EUA.UK\">$(EUA.UK)$</a> for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.</p><p>&#34;Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,&#34; said Pfizer Chief Executive Albert Bourla.</p><p>The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&amp;P 500  has climbed 19.9%.</p><p><img src=\"https://static.tigerbbs.com/5f5463ed1aa0fa37ef029aec1dd2eea6\" tg-width=\"842\" tg-height=\"830\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Files for Full FDA Approval for COVID-19 Antiviral</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Files for Full FDA Approval for COVID-19 Antiviral\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-06-30 19:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.</p><p>PAXLOVID has previously been granted Emergency Use Authorization <a href=\"https://laohu8.com/S/EUA.UK\">$(EUA.UK)$</a> for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.</p><p>&#34;Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,&#34; said Pfizer Chief Executive Albert Bourla.</p><p>The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&amp;P 500  has climbed 19.9%.</p><p><img src=\"https://static.tigerbbs.com/5f5463ed1aa0fa37ef029aec1dd2eea6\" tg-width=\"842\" tg-height=\"830\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4570":"地缘局势概念股","BK4017":"黄金","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4550":"红杉资本持仓","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4581":"高盛持仓","BK4007":"制药","PFE":"辉瑞","BNTX":"BioNTech SE","NGD":"New Gold"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2247475886","content_text":"Pfizer Inc. $(PFE)$ said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.PAXLOVID has previously been granted Emergency Use Authorization $(EUA.UK)$ for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.\"Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,\" said Pfizer Chief Executive Albert Bourla.The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&P 500  has climbed 19.9%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":560,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9045174898,"gmtCreate":1656588093914,"gmtModify":1676535858644,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"Gogo pfizer...","listText":"Gogo pfizer...","text":"Gogo pfizer...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9045174898","repostId":"2247475886","repostType":2,"repost":{"id":"2247475886","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1656587274,"share":"https://ttm.financial/m/news/2247475886?lang=&edition=fundamental","pubTime":"2022-06-30 19:07","market":"us","language":"en","title":"Pfizer Files for Full FDA Approval for COVID-19 Antiviral","url":"https://stock-news.laohu8.com/highlight/detail?id=2247475886","media":"Dow Jones","summary":"Pfizer Inc. $(PFE)$ said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 tr","content":"<html><head></head><body><p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.</p><p>PAXLOVID has previously been granted Emergency Use Authorization <a href=\"https://laohu8.com/S/EUA.UK\">$(EUA.UK)$</a> for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.</p><p>&#34;Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,&#34; said Pfizer Chief Executive Albert Bourla.</p><p>The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&amp;P 500  has climbed 19.9%.</p><p><img src=\"https://static.tigerbbs.com/5f5463ed1aa0fa37ef029aec1dd2eea6\" tg-width=\"842\" tg-height=\"830\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Files for Full FDA Approval for COVID-19 Antiviral</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Files for Full FDA Approval for COVID-19 Antiviral\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2022-06-30 19:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Pfizer Inc. <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.</p><p>PAXLOVID has previously been granted Emergency Use Authorization <a href=\"https://laohu8.com/S/EUA.UK\">$(EUA.UK)$</a> for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.</p><p>&#34;Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,&#34; said Pfizer Chief Executive Albert Bourla.</p><p>The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&amp;P 500  has climbed 19.9%.</p><p><img src=\"https://static.tigerbbs.com/5f5463ed1aa0fa37ef029aec1dd2eea6\" tg-width=\"842\" tg-height=\"830\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4570":"地缘局势概念股","BK4017":"黄金","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4550":"红杉资本持仓","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4581":"高盛持仓","BK4007":"制药","PFE":"辉瑞","BNTX":"BioNTech SE","NGD":"New Gold"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2247475886","content_text":"Pfizer Inc. $(PFE)$ said Thursday that it has submitted a New Drug Application (NDA) for COVID-19 treatment pills PAXLOVID for patients at high risk for progression to severe illness.PAXLOVID has previously been granted Emergency Use Authorization $(EUA.UK)$ for treatment of mild-to-moderate COVID-19. The drug maker said the NDA submission provides longer-term follow-up data needed for potential approval.\"Data from our clinical development program, coupled with the more than 1.7 million patients around the world who have been prescribed our oral treatment to date, reinforce PAXLOVID as an important treatment option for mild-to-moderate COVID-19 in patients at greater risk of progression to severe symptoms, regardless of vaccination status,\" said Pfizer Chief Executive Albert Bourla.The stock, which slipped 0.5% in premarket trading, has lost 13.7% year to date through Wednesday, while the S&P 500  has climbed 19.9%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9041901609,"gmtCreate":1655990937901,"gmtModify":1676535746021,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NU\">$Nu Holdings Ltd.(NU)$</a>Hope tonite can go $4.20","listText":"<a href=\"https://ttm.financial/S/NU\">$Nu Holdings Ltd.(NU)$</a>Hope tonite can go $4.20","text":"$Nu Holdings Ltd.(NU)$Hope tonite can go $4.20","images":[{"img":"https://community-static.tradeup.com/news/2eafdb7a96c4dc18b781854ef03d7996","width":"1242","height":"2208"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9041901609","isVote":1,"tweetType":1,"viewCount":133,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9051500053,"gmtCreate":1654708418272,"gmtModify":1676535495954,"author":{"id":"3574635585550746","authorId":"3574635585550746","name":"Skyzero9285","avatar":"https://community-static.tradeup.com/news/ce3deda4c45dd13f062919df2394e86b","crmLevel":1,"crmLevelSwitch":1,"followedFlag":false,"idStr":"3574635585550746","authorIdStr":"3574635585550746"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GRAB\">$Grab Holdings(GRAB)$</a>Gogo","listText":"<a href=\"https://ttm.financial/S/GRAB\">$Grab Holdings(GRAB)$</a>Gogo","text":"$Grab Holdings(GRAB)$Gogo","images":[{"img":"https://community-static.tradeup.com/news/bd7e310fc84354d37b808d1806057e7a","width":"1242","height":"2699"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9051500053","isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}